日本臨牀　81/増刊2　膵癌・胆道癌　2023　上　膵癌編

出版社： 日本臨牀社
発行日： 2023-02-28
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 膵癌・胆道癌　2023　上　膵癌編
電子書籍版： 2023-02-28 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

24,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

24,200 円(税込)

購入する

目次

  • 特集　膵癌・胆道癌　202(3)上　膵癌編

    序　 文：本書の発刊にあたってー膵癌の現状について

    I．総　論
    　1．基礎編
    　　（1）膵癌発症の分子異常
    　　（2）膵癌の浸潤・転移機序
    　　（3）膵癌の腫瘍微小環境（TME)
    　　（4）膵癌の動物モデル
    　2．臨床編
    　　（1）膵癌の疫学
    　　（2）膵腫瘍の病理学的分類
    　　（3）膵腫瘍のバイオマーカー
    　　（4）膵腫瘍の画像診断
    　　　　1）膵腫瘍の超音波画像診断
    　　　　2）膵癌の画像診断CT/MRI
    　　　　3）ERCP
    　　　　4）EUS
    　　　　5）PET
    　　（5）膵腫瘍の組織診断
    　　　　1）膵液細胞診
    　　　　2）膵腫瘍の組織診断（EUS-TA）
    　　　　3）術前補助療法後膵癌における組織学的治療効果判定と標準化への取り組み

    II．各　論
    　1．上皮性腫瘍
    　　（1）浸潤性膵管癌
    　　　　1）浸潤性膵管癌の疫学
    　　　　2）危険因子
    　　　　3）臨床病理学的分類と特徴
    　　　　4）症状・所見・血液検査
    　　　　5）診　断
    　　　　　　(1)浸潤性膵管癌の診断・検査のアルゴリズム
    　　　　　　(2)切除可能性分類
    　　　　6）鑑別診断
    　　　　7）治　療
    　　　　　　(1)治療のアルゴリズム
    　　　　　　(2)外科的切除
    　　　　　　　　a.　標準的切除
    　　　　　　　　　　(a)　開腹手術
    　　　　　　　　　　(b)　膵癌に対する腹腔鏡下手術
    　　　　　　　　b.　血管合併切除術
    　　　　　　 　c.　浸潤性膵管癌に対する膵全摘術
    　　　　　　(3)化学療法
    　　　　　　　　a.　術後補助化学療法
    　　　　　　　　b.　切除不能膵癌の薬物療法
    　　　　　　　　c. 切除可能膵癌に対する術前治療の現状と課題
    　　　　　　　　d.　切除不能膵癌のConversion surgery
    　　　　　　(4)放射線療法
    　　　　　　　　a.　術前化学放射線療法
    　　　　　　　　b.　膵癌の転移巣への放射線治療
    　　　　　　(5)支持療法
    　　　　　　　　a. 内視鏡的ステント(胆道,十二指腸)
    　　　　　　　　b. 外科的バイパス術
    　　　　8）予　後
    　　　　　　(1)膵癌の治療成績(日本と欧米の比較)
    　　　　　　(2)長期生存に関する予後因子
    　　　　9）特殊な組織型(臨床病理学的特徴)
    　　　　　　(1)膵腺扁平上皮癌
    　　　　　　(2)粘液癌
    　　　　　　(3)退形成癌
    　　　　　　(4)腺房細胞癌
    　　（2）嚢胞性膵腫瘍
    　　　　1）膵管内乳頭粘液性腫瘍(IPMN)
    　　　　　　(1)IPMNの疫学
    　　　　　　(2)悪性・再発の危険因子
    　　　　　　(3)IPMNの臨床病理学的分類
    　　　　　　(4)症状・血液検査
    　　　　　　(5)診　断
    　　　　　　　　a.　悪性度診断・進展度診断
    　　　　　　　　b.　由来癌と併存癌
    　　　　　　(6) 鑑別診断
    　　　　　　(7) 治　療
    　　　　　　　　a.　膵管内乳頭粘液性腫瘍（IPMN）の手術適応
    　　　　　　　　b.　外科的切除
    　　　　　　　　　　(a)　膵管内乳頭粘液性腫瘍（IPMN）に対する術式
    　　　　　　　　　　(b)　膵管内乳頭粘液性腫瘍（IPMN）に対する膵縮小手術
    　　　　　　　　　　(c) 術後経過観察法
    　　　　2）膵管内管状乳頭腫瘍
    　　　　3）膵粘液性嚢胞腫瘍(MCN)
    　　　　　　(1)MCNの疫学
    　　　　　　(2)MCNの発生学的機序
    　　　　　　(3)Mucinous cystic neoplasm (MCN)の臨床病理学的特徴
    　　　　　　(4)MCNの外科治療
    　　　　　　(5)MCNの予後
    　　　　4）膵漿液性嚢胞腫瘍(SCN)
    　　　　5）Solid-pseudopapillary neoplasm (SPN)
    　　　　6）その他の嚢胞性膵腫瘍
    　　（3）神経内分泌腫瘍(NET)
    　　　　1）膵内分泌腫瘍全国疫学調査；概論
    　　　　2）PNET(膵神経内分泌腫瘍)のWHO分類：概論
    　　　　3）多発性内分泌腫瘍症(MEN)；概論
    　　　　4）機能性内分泌腫瘍
    　　　　　　(1)インスリノーマ
    　　　　　　(2)グルカゴノーマ
    　　　　　　(3)ガストリノーマ
    　　　　　　(4)セロトニン産生性膵神経内分泌腫瘍
    　　　　5）非機能性膵内分泌腫瘍（非機能性PNET）
    　　　　6）NETに対する治療
    　　　　　　(1)外科治療
    　　　　　　(2)薬物療法
    　　　　　　(3)PRRT
    　　（4）転移性膵腫瘍
    　　（5）その他の膵腫瘍(膵芽腫，類肝細胞癌，髄様癌)
    　2．非上皮性腫瘍
    　　（1）膵悪性リンパ腫

    III．特　論
    　1．膵癌診療ガイドライン2022の概要
    　2．IPMN国際診療ガイドライン2017年の概要
    　3．膵・消化管神経内分泌腫瘍診療ガイドライン2019の概要
    　4．膵癌治療の進歩
    　　（1）薬物療法（分子標的薬・免疫チェックポイント阻害剤など）
    　　（2）免疫療法（ペプチドワクチンを含む）
    　　（3）膵癌のがんゲノム医療
    　　（4）膵癌の粒子線療法（重粒子線、陽子線）
    　5．家族性膵癌と登録制度
    　6．生活習慣と膵癌
    　7．膵癌の早期発見と病診連携
    　8．膵癌の緩和医療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文 本書の発刊にあたって - 膵癌の現状について

P.7 掲載の参考文献
1) 日本臨牀 73 (増刊 : 膵癌・胆道癌-基礎と臨床の最新研究動向), 2015.
 
2) 膵癌取扱い規約 [第7版] (日本膵臓学会編), 金原出版, 2016.
 
3) Isaji S, Mizuno S, Windsor JA, et al : International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18 : 2-11, 2018.
PubMed
4) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
5) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed

I 総論

P.15 掲載の参考文献
1) Hruban RH, Wilentz RE, Kern SE : Genetic progression in the pancreatic ducts. Am J Pathol 156 : 1821-1825, 2000.
PubMed
2) Gill AJ, Klimstra DS, Lam AK, et al : Tumours of the pancreas. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p295-372, IARC, Lyon, 2019.
 
3) Basturk O, Hong SM, Wood LD, et al : A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol 39 : 1730-1741, 2015.
PubMed
4) Notta F, Chan-Seng-Yue M, Lemire M, et al : A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538 : 378-382, 2016.
PubMed
5) Real FX : A "catastrophic hypothesis" for pancreas cancer progression. Gastroenterology 124 : 1958-1964, 2003.
PubMed
6) Strickler JH, Satake H, Hollebecque A, et al : First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation : A phase I/II study evaluating efficacy and safety. J Clin Oncol 40 (36 Suppl) : 360490, 2022.
 
7) Iacobuzio-Donahue CA, Fu B, Yachida S, et al : DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27 : 1806-1813, 2009.
PubMed
8) Collisson EA, Sadanandam A, Olson P, et al : Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17 : 500-503, 2011.
PubMed
9) Moffitt RA, Marayati R, Flate EL, et al : Virtual microdissection identifies distinct tumor- and stromaspecific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47 : 1168-1178, 2015.
PubMed
10) Bailey P, Chang DK, Nones K, et al : Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 : 47-52, 2016.
PubMed
11) Collisson EA, Bailey P, Chang DK, et al : Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 16 : 207-220, 2019.
PubMed
12) Waddell N, Pajic M, Patch AM, et al : Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518 : 495-501, 2015.
PubMed
13) Furukawa T : Mechanisms of development and progression of pancreatic neoplasms. Pathol Int 72 : 529-540, 2022.
PubMed
14) Miyai Y, Esaki N, Takahashi M, et al : Cancer-associated fibroblasts that restrain cancer progression : Hypotheses and perspectives. Cancer Sci 111 : 1047-1057, 2020.
PubMed
15) Liu Y, Li F, Gao F, et al : Role of microenvironmental periostin in pancreatic cancer progression. Oncotarget 8 : 89552-89565, 2017.
 
P.20 掲載の参考文献
1) がん研究振興財団 : がんの統計 2021. [https://ganjoho.jp/public/qa_links/report/statistics/2021_jp.html] (2022年9月閲覧)
 
2) がん研究振興財団 : がんの統計 2022. [https://ganjoho.jp/public/qa_links/report/statistics/2022_jp.html] (2022年9月閲覧)
 
3) 佐藤賢一 : 膵癌 : 発生・進展の分子機構. 日本消化器病学会雑誌 110 : 2042-2050, 2013.
Medical*Online
4) 佐藤賢一 : 膵癌の浸潤・転移機序. 日本臨牀 73 (増刊 : 膵癌・胆道癌) : 16-21, 2015
 
5) 佐藤賢一 : 膵癌の浸潤・転移研究のup-to-date. 胆と膵 36 : 1109-1115, 2015.
Medical*Online
6) Huber MA, Kraut N, Beug H : Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17 : 548-558, 2005.
PubMed
7) Ellenrieder V, Hendler SF, Boeck W, et al : Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61 : 4222-4228, 2001.
 
8) Yang AD, Camp ER, Fan F, et al : Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66 : 46-51, 2006.
PubMed
9) Hamada S, Satoh K, Hirota M, et al : Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J Cell Physiol 213 : 768-774, 2007.
PubMed
10) Satoh K, Hamada S, Kimura K, et al : Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol 172 : 926-939, 2008.
PubMed
11) Fukui K, Nomura M, Kishimoto K, et al : PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. Cancer Sci 113 : 1613-1624, 2022.
PubMed
12) von Burstin J, Eser S, Paul MC, et al : E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137 : 361-371, 371.e1-5, 2009.
 
13) Simeonov KP, Byrns CN, Clark ML, et al : Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39 : 1150-1162.e9, 2021.
 
14) Rhim AD, Mirek ET, Aiello NM, et al : EMT and dissemination precede pancreatic tumor formation. Cell 148 : 349-361, 2012.
PubMed
15) Carstens JL, Yang S, Correa de Sampaio P, et al : Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. Cell Rep 35 : 108990, 2021.
PubMed
16) Gregory PA, Bert AG, Paterson EL, et al : The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10 : 593-601, 2008.
PubMed
17) Li Y, VandenBoom TG, Kong D, et al : Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69 : 6704-6712, 2009.
 
18) Hamada S, Satoh K, Fujibuchi W, et al : MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 10 : 3-10, 2012.
PubMed
19) Hamada S, Satoh K, Miura S, et al : miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 228 : 1255-1263, 2013.
PubMed
20) Takahashi K, Taniue K, Ono Y, et al : Long Non-Coding RNAs in Epithelial-Mesenchymal Transition of Pancreatic Cancer. Front Mol Biosci 8 : 717890, 2021.
PubMed
21) Yachida S, Jones S, Bozic I, et al : Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 : 1114-1117, 2010.
PubMed
22) Notta F, Chan-Seng-Yue M, Lemire M, et al : A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538 : 378-382, 2016.
PubMed
23) Makohon-Moore AP, Matsukuma K, Zhang M, et al : Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561 : 201-205, 2018.
PubMed
24) Kanno A, Satoh K, Masamune A, et al : Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer 122 : 2707-2718, 2008.
PubMed
25) Satoh K, Ohtani H, Shimosegawa T, et al : Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas. Gastroenterology 107 : 1488-1495, 1994.
PubMed
26) Kikuta K, Masamune A, Watanabe T, et al : Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 403 : 380-384, 2010.
PubMed
27) Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al : Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 : 719-734, 2014.
PubMed
28) Rhim AD, Oberstein PE, Thomas DH, et al : Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 : 735-747, 2014.
PubMed
29) Ohlund D, Handly-Santana A, Biffi G, et al : Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214 : 579-596, 2017.
PubMed
30) Mizutani Y, Kobayashi H, Iida T, et al : Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis. Cancer Res 79 : 5367-5381, 2019.
PubMed
31) Chen Y, Yang S, Tavormina J, et al : Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell 40 : 818-834.e9, 2022.
 
P.28 掲載の参考文献
1) Yachida S, Jones S, Bozic I, et al : Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 : 1114-1117, 2010.
PubMed
2) Erkan M, Adler G, Apte MV, et al : StellaTUM : current consensus and discussion on pancreatic stellate cell research. Gut 61 : 172-178, 2012.
PubMed
3) Hamada S, Masamune A, Yoshida N, et al : IL-6/STAT3 Plays a Regulatory Role in the Interaction Between Pancreatic Stellate Cells and Cancer Cells. Dig Dis Sci 61 : 1561-1571, 2016.
 
4) Hamada S, Masamune A, Takikawa T, et al : Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Biochem Biophys Res Commun 421 : 349-354, 2012.
PubMed
5) Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al : Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 : 719-734, 2014.
PubMed
6) Mizutani Y, Kobayashi H, Iida T, et al : Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis. Cancer Res 79 : 5367-5381, 2019.
PubMed
7) Kitajima Y, Ide T, Ohtsuka T, et al : Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci 99 : 1341-1347, 2008.
PubMed
8) Cao XP, Cao Y, Li WJ, et al : P4HA1/HIF1α feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer. Biochem Biophys Res Commun 516 : 606-612, 2019.
 
9) Takikawa T, Masamune A, Hamada S, et al : miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem Biophys Res Commun 437 : 433-439, 2013.
PubMed
10) Masamune A, Kikuta K, Watanabe T, et al : Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 295 : G709-G717, 2008.
PubMed
11) Sada M, Ohuchida K, Horioka K, et al : Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Cancer Lett 372 : 210-218, 2016.
PubMed
12) Taguchi K, Yamamoto M : The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment. Cancers (Basel) 13 : 46, 2020.
PubMed
13) Hamada S, Taguchi K, Masamune A, et al : Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis. Carcinogenesis 38 : 661-670, 2017.
PubMed
14) Masamune A, Watanabe T, Kikuta K, et al : NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 294 : G99-G108, 2008.
 
15) Tanaka Y, Hamada S, Matsumoto R, et al : Nrf2 expression in pancreatic stellate cells promotes progression of cancer. Am J Physiol Gastrointest Liver Physiol 321 : G378-G388, 2021.
PubMed
P.35 掲載の参考文献
1) Hingorani SR, Petricoin EF, Maitra A, et al : Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 : 437-450, 2003.
PubMed
2) Aguirre AJ, Bardeesy N, Sinha M, et al : Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17 : 3112-3126, 2003.
PubMed
3) Hingorani SR, Wang L, Multani AS, et al : Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 : 469-483, 2005.
PubMed
4) Bardeesy N, Aguirre AJ, Chu GC, et al : Both p16 (Ink4a) and the p19 (Arf) -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103 : 5947-5952, 2006.
PubMed
5) Ijichi H, Chytil A, Gorska AE, et al : Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20 : 3147-3160, 2006.
PubMed
6) Bardeesy N, Cheng KH, Berger JH, et al : Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20 : 3130-3146, 2006.
PubMed
7) Guerra C, Schuhmacher AJ, Canamero M, et al : Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11 : 291-302, 2007.
 
8) Habbe N, Shi G, Meguid RA, et al : Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A 105 : 18913-18918, 2008.
PubMed
9) Gidekel Friedlander SY, Chu GC, Snyder EL, et al : Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16 : 379-389, 2009.
PubMed
10) Ray KC, Bell KM, Yan J, et al : Epithelial tissues have varying degrees of susceptibility to Kras (G12D) -initiated tumorigenesis in a mouse model. PLoS One 6 : e16786, 2011.
 
11) Kopp JL, von Figura G, Mayes E, et al : Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22 : 737-750, 2012.
PubMed
12) Ying H, Kimmelman AC, Lyssiotis CA, et al : Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 : 656-670, 2012.
PubMed
13) Schonhuber N, Seidler B, Schuck K, et al : A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nat Med 20 : 1340-1347, 2014.
PubMed
14) Taki K, Ohmuraya M, Tanji E, et al : GNAS (R201H) and Kras (G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm. Oncogene 35 : 2407-2412, 2016.
PubMed
15) von Figura G, Fukuda A, Roy N, et al : The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol 16 : 255-267, 2014.
PubMed
16) Boj SF, Hwang CI, Baker LA, et al : Organoid models of human and mouse ductal pancreatic cancer. Cell 160 : 324-338, 2015.
PubMed
17) Miyabayashi K, Baker LA, Deschenes A, et al : Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Cancer Discov 10 : 1566-1589, 2020.
PubMed
18) Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al : Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 : 719-734, 2014.
PubMed
19) Ohlund D, Handly-Santana A, Biffi G, et al : Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214 : 579-596, 2017.
PubMed
20) Biffi G, Oni TE, Spielman B, et al : IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov 9 : 282-301, 2019.
 
21) Elyada E, Bolisetty M, Laise P, et al : Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov 9 : 1102-1123, 2019.
PubMed
22) Flowers BM, Xu H, Mulligan AS, et al : Cell of Origin Influences Pancreatic Cancer Subtype. Cancer Discov 11 : 660-677, 2021.
PubMed
P.42 掲載の参考文献
1) 国立がん研究センター : 人口動態統計 (厚生労働省大臣官房統計情報部). がん情報サービス「がん統計」 (人口動態統計).
 
2) 国立がん研究センター : 全国がん罹患データ (2016年～2019年). がん情報サービス「がん統計」 (全国がん登録).
 
3) 令和元年「国民健康・栄養調査」の結果. [https://www.mhlw.go.jp/bunya/kenkou/kenkou_eiyou_chousa.html] (2022年11月閲覧)
 
4) Koyanagi YN, Matsuo K, Ito H, et al : Body-Mass Index and Pancreatic Cancer Incidence : A Pooled Analysis of Nine Population-Based Cohort Studies With More Than 340,000 Japanese Subjects. J Epidemiol 28 : 245-252, 2018.
PubMed
5) Carreras-Torres R, Johansson M, Gaborieau V, et al : The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer : A Mendelian Randomization Study. J Natl Cancer Inst 109 : 2017.
PubMed
6) Cancer Genome Atlas Research Network. Electronic address : andrew_aguirre@dfci.harvard.edu ; Cancer Genome Atlas Research Network : Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32 : 185-203.e13, 2017.
 
7) Amundadottir LT : Pancreatic Cancer Genetics. Int J Biol Sci 12 : 314-325, 2016.
PubMed
8) Low SK, Kuchiba A, Zembutsu H, et al : Genome-wide association study of pancreatic cancer in Japanese population. PLoS One 5 : e11824, 2010.
PubMed
9) Lin Y, Nakatochi M, Hosono Y, et al : Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Nat Commun 11 : 3175, 2020.
PubMed
10) Khera AV, Chaffin M, Aragam KG, et al : Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50 : 1219-1224, 2018.
PubMed
11) Sharma S, Tapper WJ, Collins A, et al : Predicting Pancreatic Cancer in the UK Biobank Cohort Using Polygenic Risk Scores and Diabetes Mellitus. Gastroenterology 162 : 1665-1674.e2, 2022.
 
12) Nakatochi M, Lin Y, Ito H, et al : Prediction model for pancreatic cancer risk in the general Japanese population. PLoS One 13 : e0203386, 2018.
PubMed
13) Rahib L, Wehner MR, Matrisian LM, et al : Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open 4 : e214708, 2021.
PubMed
14) Katanoda K, Ito Y, Sobue T : International comparison of trends in cancer mortality : Japan has fallen behind in screening-related cancers. Jpn J Clin Oncol 51 : 1680-1686, 2021.
PubMed
P.47 掲載の参考文献
1) Gill AJ, Klimstra DS, Lam AK, et al : Tumours of the pancreas. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p295-372, IARC, Lyon, 2019.
 
2) 膵癌取扱い規約 [第7版] (日本膵臓学会編), 金原出版, 2016.
 
3) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
4) Mattiolo P, Hong SM, Paolino G, et al : CD117 Is a Specific Marker of Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas, Oncocytic Subtype. Int J Mol Sci 21 : 5794, 2020.
PubMed
5) 菊山正隆, 花田敬士, 植木敏晴 : 膵体部高度脂肪化をCTにて確認した膵上皮内癌の3例. 膵臓 30 : 626-632, 2015.
Medical*Online
P.53 掲載の参考文献
1) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
2) Goonetilleke KS, Siriwardena AK : Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33 : 266-270, 2007.
PubMed
3) Sunagawa Y, Yamada S, Sato Y, et al : Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Ann Surg Oncol 27 : 2081-2089, 2020.
PubMed
4) Omiya K, Oba A, Inoue Y, et al : Serum DUPAN-2 could be an alternative biological marker for CA19-9 non-secretors with pancreatic cancer. Ann Surg, 2022. (DOI : 10.1097/SLA.0000000000005395)
 
5) Qi ZH, Xu HX, Zhang SR, et al : The Significance of Liquid Biopsy in Pancreatic Cancer. J Cancer 9 : 3417-3426, 2018.
PubMed
6) Sturm N, Ettrich TJ, Perkhofer L : The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers (Basel) 14 : 217, 2022.
PubMed
7) Wang Y, Yu X, Hartmann D, et al : Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role : a systematic review and meta-analysis. HPB (Oxford) 22 : 660-669, 2020.
 
8) Melo SA, Luecke LB, Kahlert C, et al : Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523 : 177-182, 2015.
PubMed
9) Lai X, Wang M, McElyea SD, et al : A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett 393 : 86-93, 2017.
PubMed
10) Zhu Y, Zhang H, Chen N, et al : Diagnostic value of various liquid biopsy methods for pancreatic cancer : A systematic review and meta-analysis. Medicine (Baltimore) 99 : e18581, 2020.
PubMed
11) 高橋賢治, 北野陽平, 水上裕輔, ほか : 膵癌におけるエクソソームを用いた診断・治療への応用. 胆と膵 42 : 717-724, 2021.
Medical*Online
12) Mayerle J, Kalthoff H, Reszka R, et al : Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut 67 : 128-137, 2018.
PubMed
13) Mukherjee S, Patra A, Khasawneh H, et al : Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diagnosis. Gastroenterology 163 : 1435-1446.e3, 2022.
 
14) 三木正美 : 膵神経内分泌腫瘍 (pancreatic neuroendocrine tumor : PNET) におけるバイオマーカーの潮流. 胆と膵 43 : 123-126, 2022.
Medical*Online
15) Modlin IM, Drozdov I, Kidd M : The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One 8 : e63364, 2013.
PubMed
P.59 掲載の参考文献
1) 国立がん研究センターがん情報サービス : がん種別統計情報膵臓. [https://ganjoho.jp/reg_stat/statistics/stat/cancer/10_pancreas.html] (2022年11月閲覧)
 
2) Toft J, Hadden WJ, Laurence JM, et al : Imaging modalities in the diagnosis of pancreatic adenocarcinoma : A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol 92 : 17-23, 2017.
PubMed
3) Yamashita Y, Shimokawa T, Ashida R, et al : Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer : A Meta-analysis. Ultrasound Med Biol 47 : 3315-3322, 2021.
PubMed
4) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
5) Kamata K, Kitano M, Kudo M, et al : Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 46 : 22-29, 2014.
PubMed
6) Miyasaka Y, Ohtsuka T, Tamura K, et al : Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm. Ann Surg 263 : 1180-1187, 2016.
PubMed
7) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
8) 木村理, 森谷敏幸, 花田敬士, ほか : 膵漿液性嚢胞腫瘍 (Serous cystic neoplasm) の全国症例調査-日本膵臓学会膵嚢胞性腫瘍委員会-. 膵臓 27 : 572-583, 2012.
Medical*Online
9) Luchtrath H, Schriefers KH : [A pancreatic cyst with features of a so-called branchiogenic cyst]. Pathologe 6 : 217-219, 1985.
PubMed
10) Adsay NV, Hasteh F, Cheng JD, et al : Squamous-lined cysts of the pancreas : lymphoepithelial cysts, dermoid cysts (teratomas), and accessory-splenic epidermoid cysts. Semin Diagn Pathol 17 : 56-65, 2000.
PubMed
P.68 掲載の参考文献
1) Gill AJ, Klimstra DS, Lam AK, et al : Tumours of the pancreas. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p295-372, IARC, Lyon, 2019.
 
2) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
3) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 41 : 985-992, 2012.
PubMed
4) NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) : Pancreatic Adenocarcinoma, Version 1. 2022, National Comprehensive Cancer Network (NCCN), 2022.
 
5) Ichikawa T, Erturk SM, Sou H, et al : MDCT of pancreatic adenocarcinoma : optimal imaging phases and multiplanar reformatted imaging. AJR Am J Roentgenol 187 : 1513-1520, 2006.
PubMed
6) Fukukura Y, Kumagae Y, Fujisaki Y, et al : Adding Delayed Phase Images to Dual-Phase Contrast-Enhanced CT Increases Sensitivity for Small Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol 217 : 888-897, 2021.
PubMed
7) Nagayama Y, Tanoue S, Inoue T, et al : Dual-layer spectral CT improves image quality of multiphasic pancreas CT in patients with pancreatic ductal adenocarcinoma. Eur Radiol 30 : 394-403, 2020.
PubMed
8) 画像診断ガイドライン [2021年版] (日本医学放射線学会編), p222-305, 金原出版, 2021.
 
9) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), p113-116, 金原出版, 2022.
 
10) Koelblinger C, Ba-Ssalamah A, Goetzinger P, et al : Gadobenate dimeglumine-enhanced 3.0-T MR imaging versus multiphasic 64-detector row CT : prospective evaluation in patients suspected of having pancreatic cancer. Radiology 259 : 757-766, 2011.
 
11) Park HS, Lee JM, Choi HK, et al : Preoperative evaluation of pancreatic cancer : comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 30 : 586-595, 2009.
PubMed
12) Gabata T, Matsui O, Kadoya M, et al : Small pancreatic adenocarcinomas : efficacy of MR imaging with fat suppression and gadolinium enhancement. Radiology 193 : 683-688, 1994.
PubMed
13) Park MJ, Kim YK, Choi SY, et al : Preoperative detection of small pancreatic carcinoma : value of adding diffusion-weighted imaging to conventional MR imaging for improving confidence level. Radiology 273 : 433-443, 2014.
PubMed
14) Fukukura Y, Shindo T, Hakamada H, et al : Diffusion-weighted MR imaging of the pancreas : optimizing b-value for visualization of pancreatic adenocarcinoma. Eur Radiol 26 : 3419-3427, 2016.
PubMed
15) Motosugi U, Ichikawa T, Morisaka H, et al : Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging : comparison with contrast-enhanced multi-detector row CT. Radiology 260 : 446-453, 2011.
PubMed
P.76 掲載の参考文献
1) Mine T, Morizane T, Kawaguchi Y, et al : Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol 52 : 1013-1022, 2017.
PubMed
2) Kobayashi G, Fujita N, Noda Y, et al : Lateral spread along the main pancreatic duct in branch-duct intraductal papillary-mucinous neoplasms of the pancreas : usefulness of intraductal ultrasonography for its evaluation. Dig Endosc 23 : 62-68, 2011.
PubMed
3) Banafea O, Mghanga FP, Zhao J, et al : Endoscopic ultrasonography with fine-needle aspiration for histological diagnosis of solid pancreatic masses : A meta-analysis of diagnostic accuracy studies. BMC Gastroenterol 16 : 108, 2016.
PubMed
4) Haba S, Yamao K, Bhatia V, et al : Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions : Japanese large single center experience. J Gastroenterol 48 : 973-981, 2013.
PubMed
5) Kitano M, Yoshida M, Ashida R, et al : Needle tract seeding after endoscopic ultrasound-guided tissue acquisition of pancreatic tumors : Nationwide survey in Japan. Dig Endosc 34 : 1442-1455, 2022.
 
6) Yane K, Kuwatani M, Yoshida M, et al : Non-negligible rate of needle tract seeding after endoscopic ultrasound-guided fine-needle aspiration for patients undergoing distal pancreatectomy for pancreatic cancer. Dig Endosc 32 : 801-811, 2020.
PubMed
7) Suzuki R, Thosani N, Annangi S, et al : Diagnostic yield of endoscopic retrograde cholangiopancreatography-based cytology for distinguishing malignant and benign intraductal papillary mucinous neoplasm : systematic review and meta-analysis. Dig Endosc 26 : 586-593, 2014.
PubMed
8) 日本膵臓学会・厚生労働省IgG4 関連疾患の診断基準並びに治療指針を目指す研究班 : 自己免疫性膵炎診療ガイドライン 2020. 膵臓 35 : 465-550, 2020.
Medical*Online
9) Ohtsuka T, Nakamura M, Hijioka S, et al : Prediction of the Probability of Malignancy in Mucinous Cystic Neoplasm of the Pancreas With Ovarian-Type Stroma : A Nationwide Multicenter Study in Japan. Pancreas 49 : 181-186, 2020.
PubMed
10) Kanno A, Masamune A, Hanada K, et al : Multicenter study of early pancreatic cancer in Japan. Pancreatology 18 : 61-67, 2018.
PubMed
11) Nakahodo J, Kikuyama M, Nojiri S, et al : Focal parenchymal atrophy of pancreas : An important sign of underlying high-grade pancreatic intraepithelial neoplasia without invasive carcinoma, i.e., carcinoma in situ. Pancreatology 20 : 1689-1697, 2020.
 
12) Hanada K, Shimizu A, Kurihara K, et al : Endoscopic approach in the diagnosis of high-grade pancreatic intraepithelial neoplasia. Dig Endosc 34 : 927-937, 2022.
PubMed
13) Kusunose H, Koshita S, Kanno Y, et al : Pancreatic duct lavage cytology combined with a cell-block method for patients with possible pancreatic ductal adenocarcinomas, including pancreatic carcinoma in situ. Clin Endosc, 2022. (DOI : https://doi.org/10.5946/ce.2022.021)
 
14) Koshita S, Noda Y, Ito K, et al : Pancreatic juice cytology with immunohistochemistry to detect malignancy and histologic subtypes in patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Gastrointest Endosc 85 : 1036-1046, 2017.
PubMed
15) Koshita S, Noda Y, Kanno Y, et al : Value of repeated cytology for intraductal papillary mucinous neoplasms of the pancreas with high risk potential of malignancy : Is it a promising method for monitoring a malignant transformation? Pancreatology 20 : 1164-1174, 2020.
PubMed
P.82 掲載の参考文献
1) Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine : Ultrasonographic diagnostic criteria for pancreatic cancer. J Med Ultrasonics 40 : 497-504, 2013.
 
2) Yamashita Y, Kitano M : Endoscopic ultrasonography for pancreatic solid lesions. J Med Ultrason 47 : 377-387, 2020.
 
3) Kataoka K, Ishikawa T, Ohno E, et al : Differentiation Between Solid Pseudopapillary Neoplasm of the Pancreas and Nonfunctional Pancreatic Neuroendocrine Neoplasm Using Endoscopic Ultrasound. Pancreas 51 : 106-111, 2022.
PubMed
4) Ohno E, Hirooka Y, Kawashima H, et al : Endoscopic ultrasonography for the evaluation of pancreatic cystic neoplasms. J Med Ultrason 47 : 401-411, 2020.
 
5) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
6) Yamao K, Yanagisawa A, Takahashi K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
7) Kimura W, Moriya T, Hirai I, et al : Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas 41 : 380-387, 2012.
PubMed
8) Kitano M, Yamashita Y, Kamata K, et al : The Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Guidelines for Contrast-Enhanced Endoscopic Ultrasound. Ultrasound Med Biol 47 : 1433-1447, 2021.
PubMed
9) Matsubara H, Itoh A, Kawashima H, et al : Dynamic quantitative evaluation of contrast-enhanced endoscopic ultrasonography in the diagnosis of pancreatic diseases. Pancreas 40 : 1073-1079, 2011.
PubMed
10) Ishikawa T, Hirooka Y, Kawashima H, et al : Multiphase evaluation of contrast-enhanced endoscopic ultrasonography in the diagnosis of pancreatic solid lesions. Pancreatology 18 : 291-297, 2018.
PubMed
11) Ishikawa R, Kamata K, Hara A, et al : Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms. Dig Endosc 33 : 829-839, 2021.
PubMed
12) Hirooka Y, Kuwahara T, Irisawa A, et al : JSUM ultrasound elastography practice guidelines : pancreas. J Med Ultrason 42 : 151-174, 2015.
 
13) Saftoiu A, Gilja OH, Sidhu PS, et al : The EFSUMB Guidelines and Recommendations for the Clinical Practice of Elastography in Non-Hepatic Applications : Update 2018. Ultraschall Med 40 : 425-453, 2019.
PubMed
14) Kataoka K, Ishikawa T, Ohno E, et al : Endoscopic ultrasound elastography for small solid pancreatic lesions with or without main pancreatic duct dilatation. Pancreatology 21 : 451-458, 2021.
PubMed
15) Ohno E, Kawashima H, Ishikawa T, et al : Diagnostic performance of endoscopic ultrasonography-guided elastography for solid pancreatic lesions : Shear-wave measurements versus strain elastography with histogram analysis. Dig Endosc 33 : 629-638, 2021.
PubMed
P.87 掲載の参考文献
1) Takeshita K, Kutomi K, Haruyama T, et al : Imaging of early pancreatic cancer on multidetector row helical computed tomography. Br J Radiol 83 : 823-830, 2010.
PubMed
2) Zubarik R, Gordon SR, Lidofsky SD, et al : Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS : a feasibility study. Gastrointest Endosc 74 : 87-95, 2011.
 
3) Okano K, Kakinoki K, Akamoto S, et al : 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 17 : 231-235, 2011.
PubMed
4) 山本立真, 杉浦禎一, 岡村行泰, ほか : FDG-PET陰性膵癌の特徴. 胆と膵 33 : 407-412, 2012.
Medical*Online
5) Rijkers AP, Valkema R, Duivenvoorden HJ, et al : Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer : a meta-analysis. Eur J Surg Oncol 40 : 794-804, 2014.
PubMed
6) Tang S, Huang G, Liu J, et al : Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma : a meta-analysis. Eur J Radiol 78 : 142-150, 2011.
PubMed
7) Wang Z, Chen JQ, Liu JL, et al : FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma : a meta-analysis. World J Gastroenterol 19 : 4808-4817, 2013.
 
8) Izuishi K, Yamamoto Y, Sano T, et al : Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 14 : 1151-1158, 2010.
PubMed
9) Kauhanen SP, Komar G, Seppanen MP, et al : A prospective diagnostic accuracy study of 18Ffluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250 : 957-963, 2009.
PubMed
10) Sato A, Masui T, Yogo A, et al : Usefulness of 18 F-FDG-PET/CT in the diagnosis and prediction of recurrence of pancreatic neuroendocrine neoplasms. J Hepatobiliary Pancreat Sci 27 : 414-420, 2020.
PubMed
11) Utsunomiya T, Ogawa K, Funamizu N, et al : The tumor-to-liver ratio of the standardized uptake value is a useful FDG-PET/CT parameter for predicting malignant intraductal papillary mucinous neoplasm of the pancreas. Ann Gastroenterol Surg 6 : 695-703, 2022.
PubMed
12) Ruf J, Lopez Hanninen E, Oettle H, et al : Detection of recurrent pancreatic cancer : comparison of FDG-PET with CT/MRI. Pancreatology 5 : 266-272, 2005.
PubMed
13) Daamen LA, Groot VP, Goense L, et al : The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer : a systematic review and meta-analysis. Eur J Radiol 106 : 128-136, 2018.
PubMed
14) Wakabayashi H, Nishiyama Y, Otani T, et al : Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 14 : 64-69, 2008.
 
15) Yamamoto T, Sugiura T, Mizuno T, et al : Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Ann Surg Oncol 22 : 677-684, 2015.
 
16) Maemura K, Takao S, Shinchi H, et al : Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 13 : 435-441, 2006.
PubMed
17) Suto H, Okano K, Oshima M, et al : Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Pancreas 51 : 269-277, 2022.
PubMed
18) Mellon EA, Jin WH, Frakes JM, et al : Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol 56 : 391-397, 2017.
PubMed
19) Okano K, Suto H, Oshima M, et al : 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Jpn J Clin Oncol 48 : 434-441, 2018.
PubMed
P.93 掲載の参考文献
1) Papanicolaou GN, Traut HF : The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 42 : 193-206, 1941.
 
2) 小松京子 : 細胞検査の基礎. 細胞検査技術教本 (日本臨床衛生検査技師会監), p2-4, 丸善出版, 2018.
 
3) 広岡保明, 中泉明彦, 岡輝明, ほか : 胆汁細胞診の採取・判定方法に関する研究 (第1報) -貯留胆汁細胞診の細胞判定基準-. 日本臨床細胞学会雑誌 49 : 7-14, 2010.
Medical*Online
4) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
5) 平林健一, 才荷翼, 加戸伸明, ほか : 膵液・膵管擦過細胞診と超音波内視鏡下穿刺吸引細胞診・生検の現状. 膵臓 35 : 293-301, 2020.
Medical*Online
6) 南智之, 花田敬士, 平野巨通, ほか : 膵上皮内癌の診断. 膵臓 32 : 50-55, 2017.
Medical*Online
7) 木村公一, 古川善也, 山崎総一郎, ほか : ENPDチューブ留置での連続膵液採取による細胞診の小膵癌診断への有用性の検討. 日本消化器病学会雑誌 108 : 928-936, 2011.
Medical*Online
P.97 掲載の参考文献
1) Vilmann P, Jacobsen GK, Henriksen FW, et al : Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. Gastrointest Endosc 38 : 172-173, 1992.
PubMed
2) Banafea O, Mghanga FP, Zhao J, et al : Endoscopic ultrasonography with fine-needle aspiration for histological diagnosis of solid pancreatic masses : a meta-analysis of diagnostic accuracy studies. BMC Gastroenterol 16 : 108, 2016.
PubMed
3) Puli SR, Bechtold ML, Buxbaum JL, et al : How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass? : A meta-analysis and systematic review. Pancreas 42 : 20-26, 2013.
 
4) Yang Y, Li L, Qu C, et al : Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions : a systematic review and Meta-Analysis. Sci Rep 6 : 22978, 2016.
 
5) Kanno A, Yasuda I, Irisawa A, et al : Adverse events of endoscopic ultrasound-guided fine-needle aspiration for histologic diagnosis in Japanese tertiary centers : Multicenter retrospective study. Dig Endosc 33 : 1146-1157, 2021.
PubMed
6) Motoi F, Kosuge T, Ueno H, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upgront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49 : 190-194, 2019.
PubMed
7) 藤本一眞, 藤城光弘, 加藤元嗣, ほか : 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消化器内視鏡学会雑誌 54 : 2073-2102, 2012.
 
8) Yane K, Kuwatani M, Yoshida M, et al : Non-negligible rate of needle tract seeding after endoscopic ultrasound-guided fine-needle aspiration for patients undergoing distal pancreatectomy for pancreatic cancer. Dig Endosc 32 : 801-811, 2020.
PubMed
9) Varadarajulu S, Ginnetti L, Peetermans J, et al : Meta-analysis comparing rates of complications between the standard 19G and 22G/25G needles for EUS-guided FNA of pancreatic lesions. Gastrointest Endosc 77 : AB405, 2013.
 
10) Kovacevic B, Vilmann P : EUS tissue acquisition : From A to B. Endosc Ultrasound 9 : 225-231, 2020.
 
11) van Riet PA, Erler NS, Bruno MJ, et al : Comparison of fine-needle aspiration and fine-needle biopsy devices for endoscopic ultrasound-guided sampling of solid lesions : a systemic review and meta-analysis. Endoscopy 53 : 411-423, 2021.
PubMed
12) Park JK, Lee JH, Noh DH, et al : Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Gut Liver 14 : 387-394, 2020.
PubMed
13) Ikeda G, Hijioka S, Nagashio Y, et al : Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancreatic cancer. Dig Endosc, 2022. (DOI : 10.1111/den.14423)
 
14) Crino SF, Di Mitri R, Nguyen NQ, et al : Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions : A Randomized Controlled Non-Inferiority Trial. Gastroenterology 161 : 899-909.e5, 2021.
 
15) Iwashita T, Yasuda I, Mukai T, et al : Macroscopic on-site quality evaluation of biopsy specimens to improve the diagnostic accuracy during EUS-guided FNA using a 19-gauge needle for solid lesions : a single-center prospective pilot study (MOSE study). Gastrointest Endosc 81 : 177-185, 2015.
PubMed
P.103 掲載の参考文献
1) Motoi F, Kosuge T, Ueno H, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). Jpn J Clin Oncol 49 : 190-194, 2019.
PubMed
2) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), p193-196, 金原出版, 2022.
 
3) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127 : 1335-1339, 1992.
PubMed
4) 膵癌取扱い規約 [第7版] (日本膵臓学会編), p119-125, 金原出版, 2016.
 
5) Zhao Q, Rashid A, Gong Y, et al : Pathologic Complete Response to Neoadjuvant Therapy in Patients with Pancreatic Ductal Adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 16 : 29-37, 2012.
PubMed
6) Protocol for the Examination of Specimens From Patients With Carcinoma of the Pancreas Version : 4.2.0.2. College of American Pathologists 2021. [http://www.cap.org/web/home]
 
7) Matsuda Y, Ohkubo S, Nakano-Narusawa Y, et al : Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma : comparison of multiple tumor regression grading systems. Sci Rep 10 : 18278, 2020.
PubMed
8) White RR, Xie HB, Gottfried MR, et al : Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 12 : 214-221, 2005.
PubMed
9) Janssen BV, Tutucu F, van Roessel S, et al : Amsterdam International Consensus Meeting : tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod Pathol 34 : 4-12, 2021.
PubMed
10) Redegalli M, Schiavo Lena M, Cangi MG, et al : Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). Ann Surg Oncol 29 : 3492-3502, 2022.
PubMed
11) Janssen BV, van Roessel S, van Dieren S, et al : Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy : international interobserver study (ISGPP-1). Br J Surg, 2022. (DOI : 10.1093/bjs/znac350)
 
12) Murata Y, Mizuno S, Kishiwada M, et al : Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma. Pancreatology 21 : 1482-1490, 2021.
PubMed
13) Carcinoma of the Exocrine Pancreas Histopathology Reporting Guide, International Collaboration on Cancer Reporting. [http://www.iccr-cancer.org/datasets/published-datasets/digestive-tract/pancreas]
 

II 各論

P.111 掲載の参考文献
1) 国立がん研究センター : がん情報サービス「がん統計」 (全国がん登録). [https://ganjoho.jp/reg_stat/statistics/data/dl/index.html] (2022年11月閲覧)
 
2) 国立がん研究センター : がん情報サービス「がん統計」 (グラフデータベース). [https://gdb.ganjoho.jp/graph_db/gdb1] (2022年11月閲覧)
 
3) 厚生労働省 : 厚生労働統計一覧人口動態調査. [https://www.mhlw.go.jp/toukei/list/81-1.html]
 
4) 国立がん研究センター : がん情報サービス「がん統計」 (全国がん罹患モニタリング集計 (MCIJ)). [https://ganjoho.jp/reg_stat/statistics/data/dl/index.html] (2022年11月閲覧)
 
5) Katanoda K, Hori M, Saito E, et al : Updated Trends in Cancer in Japan : Incidence in 1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence. J Epidemiol 31 : 426-450, 2021.
PubMed
6) 膵癌取扱い規約 [第7版] (日本膵臓学会編), 金原出版, 2016.
 
7) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e1-427, 2007.
 
8) 膵癌取扱い規約 [第5版] (日本膵臓学会編), 金原出版, 2002.
 
9) 江川新一 : 膵癌登録された1 cm以下の小膵癌の解析. 胆と膵 30 : 311-316, 2009.
Medical*Online
10) 水間正道, 海野倫明, 五十嵐久人, ほか : 膵癌の疫学膵癌登録におけるT1 膵癌の解析. 胆と膵 39 : 763-767, 2018.
 
11) 膵癌登録NCD実装後7年の総括的年次統計と膵腫瘍の生存分析. [https://www.med.tohoku.ac.jp/doc/2021-1-312.pdf] (2022年11月閲覧)
 
P.116 掲載の参考文献
1) 国立がん研究センターがん情報サービス : がん登録・統計 : 最新がん統計. [https://ganjoho.jp/reg_stat/statistics/stat/summary.html] (2022年11月閲覧)
 
2) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
3) Rebours V, Boutron-Ruault MC, Schnee M, et al : Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis : a national exhaustive series. Am J Gastroenterol 103 : 111-119, 2008.
PubMed
4) Matsubayashi H : Familial pancreatic cancer and hereditary syndromes : screening strategy for high-risk individuals. J Gastroenterol 46 : 1249-1259, 2011.
PubMed
5) Klein AP, Brune KA, Petersen GM, et al : Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64 : 2634-2638, 2004.
PubMed
6) Brune KA, Lau B, Palmisano E, et al : Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 102 : 119-126, 2010.
PubMed
7) McFaul CD, Greenhalf W, Earl J, et al : Anticipation in familial pancreatic cancer. Gut 55 : 252-258, 2006.
PubMed
8) 北野雅之, 森実千種, 肱岡範, ほか : 家族性膵癌高危険群のサーベイランス法 (エキスパート・コンセンサス) -日本膵臓学会家族性膵癌レジストリ委員会・家族性膵癌に関する小班会議-. 膵臓 35 : 322-330, 2020.
Medical*Online
9) Batabyal P, Vander Hoorn S, Christophi C, et al : Association of diabetes mellitus and pancreatic adenocarcinoma : a meta-analysis of 88 studies. Ann Surg Oncol 21 : 2453-2462, 2014.
PubMed
10) Chari ST, Leibson CL, Rabe KG, et al : Pancreatic cancer-associated diabetes mellitus : prevalence and temporal association with diagnosis of cancer. Gastroenterology 134 : 95-101, 2008.
PubMed
11) Tada M, Kawabe T, Arizumi M, et al : Pancreatic cancer in patients with pancreatic cystic lesions : a prospective study in 197 patients. Clin Gastroenterol Hepatol 4 : 1265-1270, 2006.
PubMed
12) Yamaguchi K, Kanemitsu S, Hatori T, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 : 571-580, 2011.
PubMed
13) Oyama H, Tada M, Takagi K, et al : Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. Gastroenterology 158 : 226-237.e5, 2020.
 
14) Tanaka S, Nakao M, Ioka T, et al : Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer : a prospective study. Radiology 254 : 965-972, 2010.
PubMed
15) Kanno A, Masamune A, Hanada K, et al : Multicenter study of early pancreatic cancer in Japan. Pancreatology 18 : 61-67, 2018.
PubMed
P.122 掲載の参考文献
1) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
2) Gill AJ, Klimstra DS, Lam AK, et al : Tumours of the pancreas. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p295-372, IARC, Lyon, 2019.
 
3) 永田耕治 : 膵胆道癌の腫瘍進展因子の評価とその問題点. 病理と臨床 31 : 376-382, 2013.
Medical*Online
4) 古川徹 : 膵管内乳頭粘液性腫瘍 (IPMN) 由来癌 vs 通常型膵癌 vs 併存癌. 腫瘍病理鑑別診断アトラス胆道癌・膵癌 (鬼島宏, 福嶋敬宜編, 腫瘍病理鑑別診断アトラス刊行委員会監), p225-229, 文光堂, 2015.
 
5) Stelow EB, Pambuccian SE, Bauer TW, et al : Mucus rupture (extrusion) and duct expansion/expansive growth are not diagnostic of minimal invasion when seen with intraductal papillary mucinous neoplasms. Am J Surg Pathol 33 : 320-321 ; author reply 321-322, 2009.
PubMed
P.126 掲載の参考文献
1) Kanno A, Masamune A, Hanada K, et al : Multicenter study of early pancreatic cancer in Japan. Pancreatology 18 : 61-67, 2018.
PubMed
2) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
3) Dobbins M, Decorby K, Choi BCK : The Association between Obesity and Cancer Risk : A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Prev Med 2013 : 680536, 2013.
 
4) Stolzenberg-Solomon RZ, Adams K, Leitzmann M, et al : Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. Am J Epidemiol 167 : 586-597, 2008.
PubMed
5) Koyanagi YN, Matsuo K, Ito H, et al : Body-Mass Index and Pancreatic Cancer Incidence : A Pooled Analysis of Nine Population-Based Cohort Studies With More Than 340,000 Japanese Subjects. J Epidemiol 28 : 245-252, 2018.
PubMed
6) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e1-427, 2007.
 
7) Liu J, Gao J, Du Y, et al : Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131 : 683-691, 2012.
PubMed
8) Shimizu T, Asakuma M, Tomioka A, et al : Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy. Am Surg 84 : 109-113, 2018.
PubMed
9) Singh S, Singh PP, Singh AG, et al : Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus : a systematic review and meta-analysis. Am J Gastroenterol 108 : 510-519 ; quiz 520, 2013.
PubMed
10) Ben Q, Xu M, Ning X, et al : Diabetes mellitus and risk of pancreatic cancer : A meta-analysis of cohort studies. Eur J Cancer 47 : 1928-1937, 2011.
PubMed
P.131 掲載の参考文献
1) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
2) 赤尾潤一, 清水京子 : 膵癌の早期診断 : 腫瘍マーカー. 胆と膵 39 : 769-772, 2018.
Medical*Online
3) Klein AP, Brune KA, Petersen GM, et al : Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64 : 2634-2638, 2004.
PubMed
4) Goggins M, Overbeek KA, Brand R, et al : Management of patients with increased risk for familial pancreatic cancer : updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69 : 7-17, 2020.
PubMed
5) Matsuo K, Ito H, Wakai K, et al : Cigarette smoking and pancreas cancer risk : an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Jpn J Clin Oncol 41 : 1292-1302, 2011.
PubMed
6) Wang YT, Gou YW, Jin WW, et al : Association between alcohol intake and the risk of pancreatic cancer : a dose-response meta-analysis of cohort studies. BMC Cancer 16 : 212, 2016.
PubMed
7) Ben Q, Xu M, Ning X, et al : Diabetes mellitus and risk of pancreatic cancer : A meta-analysis of cohort studies. Eur J Cancer 47 : 1928-1937, 2011.
PubMed
8) Kirkegard J, Mortensen FV, Cronin-Fenton D : Chronic Pancreatitis and Pancreatic Cancer Risk : A Systematic Review and Meta-analysis. Am J Gastroenterol 112 : 1366-1372, 2017.
 
9) Tada M, Kawabe T, Arizumi M, et al : Pancreatic cancer in patients with pancreatic cystic lesions : a prospective study in 197 patients. Clin Gastroenterol Hepatol 4 : 1265-1270, 2006.
PubMed
10) Tanaka S, Nakao M, Ioka T, et al : Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer : a prospective study. Radiology 254 : 965-972, 2010.
PubMed
11) Alabousi M, McInnes MD, Salameh JP, et al : MRI vs. CT for the Detection of Liver Metastases in Patients With Pancreatic Carcinoma : A Comparative Diagnostic Test Accuracy Systematic Review and Meta-Analysis. J Magn Reson Imaging 53 : 38-48, 2021.
PubMed
12) Dietrich CF, Sahai AV, D'Onofrio M, et al : Differential diagnosis of small solid pancreatic lesions. Gastrointest Endosc 84 : 933-940, 2016.
PubMed
13) Ikeda S, Maeshiro K, Ryu S, et al : Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography : an analysis of 29 patients. Pancreas 38 : e102-e113, 2009.
PubMed
14) Ikemoto J, Serikawa M, Hanada K, et al : Clinical Analysis of Early-Stage Pancreatic Cancer and Proposal for a New Diagnostic Algorithm : A Multicenter Observational Study. Diagnostics (Basel) 11 : 287, 2021.
PubMed
15) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
P.138 掲載の参考文献
1) 膵癌取扱い規約 [第7版] (日本膵臓学会編), p48-53, 金原出版, 2016.
 
2) International Union Against Cancer (UICC) : TNM Classification of Malignant Tumours, 8th ed (ed by Brierley JD, Gospodarowicz MK, Wittekind C), Wiley-Blackwell, Oxford, 2016.
 
3) 膵癌診療ガイドライン [2016年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2016.
 
4) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
5) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e1-427, 2007.
 
6) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 41 : 985-992, 2012.
PubMed
7) Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 7 : e1000267, 2010.
PubMed
8) 科学的根拠に基づく膵癌診療ガイドライン [2013年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2013.
 
9) 岸和田昌之, 伊佐地秀司 : Borderline resectable 膵癌. 日本臨牀73 (増刊 : 膵癌・胆道癌) : 428-432, 2015.
 
10) Callery MP, Chang KJ, Fishman EK, et al : Pretreatment assessment of resectable and borderline resectable pancreatic cancer : expert consensus statement. Ann Surg Oncol 16 : 1727-1733, 2009.
PubMed
11) Varadhachary GR, Tamm EP, Abbruzzese JL, et al : Borderline resectable pancreatic cancer : definitions, management, and role of preoperative therapy. Ann Surg Oncol 13 : 1035-1046, 2006.
PubMed
12) Katz MHG, Shi Q, Ahmad SA, et al : Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer : Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 151 : e161137, 2016.
PubMed
13) NCCN Guidelines Version 2.2022, Pancreatic Adenocarcinoma. [https://www.nccn.org/guidelines/category_2]
 
14) Isaji S, Mizuno S, Windsor JA, et al : International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18 : 2-11, 2018.
PubMed
15) Oba A, Del Chiaro M, Satoi S, et al : New criteria of resectability for pancreatic cancer : A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci 29 : 725-731, 2022.
PubMed
P.143 掲載の参考文献
1) 膵癌取扱い規約 [第7版] (日本膵臓学会編), 金原出版, 2016.
 
2) Chandarana H, Babb J, Macari M : Signal characteristic and enhancement patterns of pancreatic adenocarcinoma : evaluation with dynamic gadolinium enhanced MRI. Clin Radiol 62 : 876-883, 2007.
PubMed
3) Ishii S, Kobayashi G, Fujita N, et al : Undifferentiated carcinoma of the pancreas involving intraductal pedunculated polypoid growth. Intern Med 51 : 3373-3377, 2012.
PubMed
4) Sahani DV, Bonaffini PA, Fernandez-Del Castillo C, et al : Gastroenteropancreatic neuroendocrine tumors : role of imaging in diagnosis and management. Radiology 266 : 38-61, 2013.
PubMed
5) Tatli S, Mortele KJ, Levy AD, et al : CT and MRI features of pure acinar cell carcinoma of the pancreas in adults. AJR Am J Roentgenol 184 : 511-519, 2005.
PubMed
6) Yu MH, Lee JY, Kim MA, et al : MR imaging features of small solid pseudopapillary tumors : retrospective differentiation from other small solid pancreatic tumors. AJR Am J Roentgenol 195 : 1324-1332, 2010.
PubMed
7) Kanno Y, Noda Y, Koshita S, et al : Surgically resected pancreatic metastasis from nasal malignant melanoma : case report and literature review. Clin J Gastroenterol 12 : 372-381, 2019.
PubMed
8) Kobayashi G, Fujita N, Noda Y, et al : Lymphoplasmacytic sclerosing pancreatitis forming a localized mass : a variant form of autoimmune pancreatitis. J Gastroenterol 42 : 650-656, 2007.
 
9) Koshita S, Ito K, Fujita N, et al : Localized autoimmune pancreatitis, 9 mm in size, without strictures of the main pancreatic duct. Gastrointest Endosc 75 : 920-922, 2012.
PubMed
10) Ichikawa T, Sou H, Araki T, et al : Duct-penetrating sign at MRCP : usefulness for differentiating inflammatory pancreatic mass from pancreatic carcinomas. Radiology 221 : 107-116, 2001.
PubMed
11) Irie H, Honda H, Kuroiwa T, et al : MRI of groove pancreatitis. J Comput Assist Tomogr 22 : 651-655, 1998.
PubMed
12) Kim SH, Lee JM, Han JK, et al : MDCT and superparamagnetic iron oxide (SPIO) -enhanced MR findings of intrapancreatic accessory spleen in seven patients. Eur Radiol 16 : 1887-1897, 2006.
PubMed
P.149 掲載の参考文献
1) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
2) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
3) Unno M, Motoi F, Matsuyama Y, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). J Clin Oncol 37 (Suppl 4) : abstract 189, 2019.
 
4) Satoi S, Unno M, Motoi F : The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial ; Prep-02/JSAP-05). J Clin Oncol 37 : abstract 4126, 2019.
 
5) Versteijne E, van Dam JL, Suker M, et al : Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 40 : 1220-1230, 2022.
 
6) National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) : Pancreatic Adenocarcinoma (Version 1.2021). [https://www2.tri-kobe.org/nccn/guideline/pancreas/english/pancreatic.pdf]
 
7) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19 : 230-241, 2012.
 
8) Jang JY, Kang MJ, Heo JS, et al : A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 259 : 656-664, 2014.
PubMed
9) Tsuchida H, Fujii T, Mizuma M, et al : Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy : A nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery 166 : 997-1003, 2019.
 
10) Uesaka K, Boku N, Fukutomi A, et al : Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 : 248-257, 2016.
PubMed
11) Yamaguchi J, Yokoyama Y, Fujii T, et al : Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Ann Surg 275 : 1043-1049, 2022.
PubMed
12) Takahashi S, Ohno I, Ikeda M, et al : Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer : A Phase II Open-label Multicenter Prospective Trial (JASPAC05). Ann Surg 276 : e510-e517, 2022.
PubMed
P.155 掲載の参考文献
1) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
2) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19 : 230-241, 2012.
 
3) Demir IE, Jager C, Schlitter AM, et al : R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Ann Surg 268 : 1058-1068, 2018.
PubMed
4) Murata Y, Mizuno S, Kishiwada M, et al : Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Pancreas 41 : 130-136, 2012.
 
5) Murata Y, Mizuno S, Kishiwada M, et al : Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma. Pancreatology 21 : 1482-1490, 2021.
PubMed
6) Sanjay P, Takaori K, Govil S, et al : 'Artery-first' approaches to pancreatoduodenectomy. Br J Surg 99 : 1027-1035, 2012.
PubMed
7) Nakao A, Takagi H : Isolated pancreatectomy for pancreatic head carcinoma using catheter bypass of the portal vein. Hepatogastroenterology 40 : 426-429, 1993.
PubMed
8) 伊佐地秀司, 櫻井洋至, 臼井正信, ほか : 下部胆管癌・乳頭部癌に対する幽門輪温存膵頭十二指腸切除-前方到達法による膵頭側切除術-. 手術 61 : 821-827, 2007.
 
9) 水野修吾, 種村彰洋, 早崎碧泉, ほか : 膵癌に対するSMA神経叢郭清を伴う膵頭十二指腸切除. 消化器外科 44 : 1735-1745, 2021.
 
10) Mizuno S, Isaji S, Tanemura A, et al : Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma. J Gastrointest Surg 18 : 1209-1215, 2014.
 
11) Azumi Y, Isaji S, Kato H, et al : A standardized technique for safe pancreaticojejunostomy : Pair-Watch suturing technique. World J Gastrointest Surg 2 : 260-264, 2010.
PubMed
12) Strasberg SM, Linehan DC, Hawkins WG : Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas : ability to obtain negative tangential margins. J Am Coll Surg 204 : 244-249, 2007.
PubMed
P.161 掲載の参考文献
1) Ohtsuka T, Ban D, Nakamura Y, et al : Difficulty scoring system in laparoscopic distal pancreatectomy. J Hepatobiliary Pancreat Sci 25 : 489-497, 2018.
PubMed
2) de Rooij T, van Hilst J, van Santvoort H, et al : Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD) : A Multicenter Patient-blinded Randomized Controlled Trial. Ann Surg 269 : 2-9, 2019.
 
3) Bjornsson B, Larsson AL, Hjalmarsson C, et al : Comparison of the duration of hospital stay after laparoscopic or open distal pancreatectomy : randomized controlled trial. Br J Surg 107 : 1281-1288, 2020.
PubMed
4) Korrel M, Vissers FL, van Hilst J, et al : Minimally invasive versus open distal pancreatectomy : an individual patient data meta-analysis of two randomized controlled trials. HPB (Oxford) 23 : 323-330, 2021.
PubMed
5) Nakamura M, Wakabayashi G, Miyasaka Y, et al : Multicenter comparative study of laparoscopic and open distal pancreatectomy using propensity score-matching. J Hepatobiliary Pancreat Sci 22 : 731-736, 2015.
PubMed
6) van Hilst J, de Rooij T, Klompmaker S, et al : Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA) : A Pan-European Propensity Score Matched Study. Ann Surg 269 : 10-17, 2019.
PubMed
7) Watson MD, Baimas-George MR, Thompson KJ, et al : Improved oncologic outcomes for minimally invasive left pancreatectomy : Propensity-score matched analysis of the National Cancer Database. J Surg Oncol 122 : 1383-1392, 2020.
PubMed
8) Ohtsuka T, Nagakawa Y, Toyama H, et al : A multicenter prospective registration study on laparoscopic pancreatectomy in Japan : report on the assessment of 1,429 patients. J Hepatobiliary Pancreat Sci 27 : 47-55, 2020.
 
9) Poves I, Burdio F, Morato O, et al : Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy : The PADULAP Randomized Controlled Trial. Ann Surg 268 : 731-739, 2018.
PubMed
10) Wang M, Li D, Chen R, et al : Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours : a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 6 : 438-447, 2021.
PubMed
11) Palanivelu C, Senthilnathan P, Sabnis SC, et al : Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. Br J Surg 104 : 1443-1450, 2017.
PubMed
12) van Hilst J, de Rooij T, Bosscha K, et al : Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2) : a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol 4 : 199-207, 2019.
 
13) Feng Q, Liao W, Xin Z, et al : Laparoscopic Pancreaticoduodenectomy Versus Conventional Open Approach for Patients With Pancreatic Duct Adenocarcinoma : An Up-to-Date Systematic Review and Meta-Analysis. Front Oncol 11 : 749140, 2021.
PubMed
14) Nakata K, Yamamoto H, Miyata H, et al : Comparison of outcomes between laparoscopic and open pancreaticoduodenectomy without radical lymphadenectomy : Results of coarsened exact matching analysis using national database systems. Asian J Endosc Surg 15 : 15-21, 2022.
PubMed
15) Beane JD, Borrebach JD, Zureikat AH, et al : Optimal Pancreatic Surgery : Are We Making Progress in North America? Ann Surg 274 : e355-e363, 2021.
PubMed
P.169 掲載の参考文献
1) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
2) Satoi S, Yamaue H, Kato K, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 : 590-600, 2013.
PubMed
3) Nakao A, Kanzaki A, Fujii T, et al : Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg 255 : 103-108, 2012.
PubMed
4) Fujii T, Nakao A, Yamada S, et al : Vein resections > 3 cm during pancreatectomy are associated with poor 1-year patency rates. Surgery 157 : 708-715, 2015.
PubMed
5) Zhang J, Qian HG, Leng JH, et al : Long mesentericoportal vein resection and end-to-end anastomosis without graft in pancreaticoduodenectomy. J Gastrointest Surg 13 : 1524-1528, 2009.
PubMed
6) Kitagawa H, Tajima H, Nakagawara H, et al : En bloc vascular resection for the treatment of borderline resectable pancreatic head carcinoma. Mol Clin Oncol 2 : 369-374, 2014.
PubMed
7) Nakao A, Takagi H : Isolated pancreatectomy for pancreatic head carcinoma using catheter bypass of the portal vein. Hepatogastroenterology 40 : 426-429, 1993.
PubMed
8) Mizuno S, Kato H, Yamaue H, et al : Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic Cancer : A Project Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Ann Surg 274 : e36-e44, 2021.
PubMed
9) Gyoten K, Mizuno S, Nagata M, et al : Significance of Simultaneous Splenic Artery Resection in Left-Sided Portal Hypertension After Pancreaticoduodenectomy with Combined Portal Vein Resection. World J Surg 41 : 2111-2120, 2017.
PubMed
10) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
11) Hirano S, Kondo S, Hara T, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer long-term results. Ann Surg 246 : 46-51, 2007.
PubMed
12) Okada K, Kawai M, Tani M, et al : Preservation of the left gastric artery on the basis of anatomical features in patients undergoing distal pancreatectomy with celiac axis en-bloc resection (DP-CAR). World J Surg 38 : 2980-2985, 2014.
PubMed
13) Sato T, Inoue Y, Takahashi Y, et al : Distal Pancreatectomy with Celiac Axis Resection Combined with Reconstruction of the Left Gastric Artery. J Gastrointest Surg 21 : 910-917, 2017.
PubMed
14) Ishikawa M, Yamagami T, Kakizawa H, et al : Preoperative Coil Embolization in Patients With a Replaced Hepatic Artery Scheduled for Pancreatectomy With Splanchnic Artery Resection Helps to Prevent Ischemic Organ Injury. J Comput Assist Tomogr 40 : 172-176, 2016.
PubMed
15) Ueda A, Sakai N, Yoshitomi H, et al : Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? World J Surg Oncol 17 : 124, 2019.
PubMed
P.173 掲載の参考文献
1) 膵癌診療ガイドライン [2019年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2019.
 
2) Lygidakis NJ, Singh G, Bardaxoglou E, et al : Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study. Hepatogastroenterology 51 : 427-433, 2004.
PubMed
3) Muller MW, Friess H, Kleeff J, et al : Is there still a role for total pancreatectomy? Ann Surg 246 : 966-975, 2007.
 
4) Schmidt CM, Glant J, Winter JM, et al : Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 142 : 572-580, 2007.
PubMed
5) Reddy S, Wolfgang CL, Cameron JL, et al : Total pancreatectomy for pancreatic adenocarcinoma : evaluation of morbidity and long-term survival. Ann Surg 250 : 282-287, 2009.
PubMed
6) Nakagawa Y, Kato H, Maeda K, et al : Proximal subtotal pancreatectomy as an alternative to total pancreatectomy for malnourished patients. Surg Today 51 : 1619-1629, 2021.
PubMed
7) Miyazaki M, Yoshitomi H, Shimizu H, et al : Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy : is it worthwhile? Surgery 155 : 58-66, 2014.
PubMed
8) Choi M, Kim NW, Hwang HK, et al : Repeated Pancreatectomy for Isolated Local Recurrence in the Remnant Pancreas Following Radical Pancreatectomy for Pancreatic Ductal Adenocarcinoma : A Pooled Analysis. J Clin Med 9 : 3945, 2020.
PubMed
9) Hiyoshi M, Kai K, Hamada T, et al : Curative remnant total pancreatectomy for recurrent pancreatic acinar cell carcinoma : A case report. Int J Surg Case Rep 94 : 107091, 2022.
PubMed
10) 加藤宏之, 水野修吾, 岸和田昌之, ほか : 膵切除後の消化吸収障害と低栄養, 脂肪肝について. 膵臓 34 : 157-165, 2019.
Medical*Online
11) Kato H, Isaji S, Azumi Y, et al : Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy : proposal of a postoperative NAFLD scoring system. J Hepatobiliary Pancreat Sci 17 : 296-304, 2010.
PubMed
12) Miura H, Ijichi M, Ando Y, et al : A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy. Clin J Gastroenterol 6 : 470-475, 2013.
PubMed
13) Murata Y, Mizuno S, Kato H, et al : Nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy : association of pancreatic exocrine deficiency and infection. Clin J Gastroenterol 4 : 242-248, 2011.
PubMed
14) Kato H, Kamei K, Suto H, et al : Incidence and risk factors of nonalcoholic fatty liver disease after total pancreatectomy : A first multicenter prospective study in Japan. J Hepatobiliary Pancreat Sci 29 : 428-438, 2022.
PubMed
15) Roberts KJ, Schrem H, Hodson J, et al : Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. HPB (Oxford) 19 : 859-867, 2017.
 
16) Roberts KJ, Bannister CA, Schrem H : Enzyme replacement improves survival among patients with pancreatic cancer : Results of a population based study. Pancreatology 19 : 114-121, 2019.
 
P.179 掲載の参考文献
1) Vincent A, Herman J, Schulick R, et al : Pancreatic cancer. Lancet 378 : 607-620, 2011.
PubMed
2) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
3) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 297 : 267-277, 2007.
PubMed
4) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 310 : 1473-1481, 2013.
PubMed
5) Ueno H, Kosuge T, Matsuyama Y, et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101 : 908-915, 2009.
 
6) Uesaka K, Boku N, Fukutomi A, et al : Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 : 248-257, 2016.
PubMed
7) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 31 : 1640-1648, 2013.
PubMed
8) Neoptolemos JP, Palmer DH, Ghaneh P, et al : Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial. Lancet 389 : 1011-1024, 2017.
PubMed
9) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
10) Conroy T, Hammel P, Hebbar M, et al : FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 379 : 2395-2406, 2018.
 
11) Tempero MA, Reni M, Riess H, et al : APACT : phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol 37 (15 Suppl) : 4000, 2019.
 
12) Chuah B, Goh BC, Lee SC, et al : Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 102 : 478-483, 2011.
 
13) Unno M, Motoi F, Matsuyama Y, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05) [ASCO 2019 Gastrointestinal Cancers Symposium, 2019 Jan17-19, San Francisco]. J Clin Oncol 37 (4 Suppl) : 189, 2019.
 
14) Versteijne E, Suker M, Groothuis K, et al : Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 38 : 1763-1773, 2020.
 
P.184 掲載の参考文献
1) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 15 : 2403-2413, 1997.
 
2) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 31 : 1640-1648, 2013.
PubMed
3) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 : 1960-1966, 2007.
 
4) Okusaka T, Furuse J, Funakoshi A, et al : Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102 : 425-431, 2011.
PubMed
5) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
6) Okusaka T, Ikeda M, Fukutomi A, et al : Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci 105 : 1321-1326, 2014.
PubMed
7) Ozaka M, Ishii H, Sato T, et al : A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81 : 1017-1023, 2018.
 
8) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
9) Ueno H, Ikeda M, Ueno M, et al : Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77 : 595-603, 2016.
PubMed
10) Ozaka M, Ueno M, Ishii H, et al : Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). J Clin Oncol 39 (15 Suppl) : 4017, 2021.
 
11) Wang-Gillam A, Li CP, Bodoky G, et al : Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) : a global, randomised, open-label, phase 3 trial. Lancet 387 : 545-557, 2016.
PubMed
12) Ueno M, Nakamori S, Sugimori K, et al : nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer : Randomized phase 2 trial in Japanese patients. Cancer Med 9 : 9396-9408, 2020.
PubMed
13) Sokol ES, Pavlick D, Khiabanian H, et al : Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precis Oncol 4 : 442-465, 2020.
PubMed
14) Golan T, Hammel P, Reni M, et al : Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381 : 317-327, 2019.
PubMed
P.192 掲載の参考文献
1) Siegel RL, Miller KD, Fuchs HE, et al : Cancer statistics, 2022. CA Cancer J Clin 72 : 7-33, 2022.
PubMed
2) Uesaka K, Boku N, Fukutomi A, et al : Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 : 248-257, 2016.
PubMed
3) Unno M, Motoi F, Matsuyama Y, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol 37 (4 Suppl) : Abstract 189, 2019.
 
4) Golcher H, Brunner TB, Witzigmann H, et al : Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer : results of the first prospective randomized phase II trial. Strahlenther Onkol 191 : 7-16, 2015.
PubMed
5) Casadei R, Di Marco M, Ricci C, et al : Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer : A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. J Gastrointest Surg 19 : 1802-1812, 2015.
 
6) Reni M, Balzano G, Zanon S, et al : Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15) : a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol 3 : 413-423, 2018.
PubMed
7) Versteijne E, Suker M, Groothuis K, et al : Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 38 : 1763-1773, 2020.
 
8) Mokdad AA, Minter RM, Zhu H, et al : Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer : A Propensity Score Matched Analysis. J Clin Oncol 35 : 515-522, 2017.
PubMed
9) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multiinstitutional phase 2 trial. Ann Surg Oncol 20 : 3794-3801, 2013.
PubMed
10) Motoi F, Kosuge T, Ueno H, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49 : 190-194, 2019.
PubMed
11) Satoi S, Unno M, Motoi F, et al : The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial ; (Prep-02/JSAP-05). J Clin Oncol 37 (15 Suppl) : Abstract 4126, 2019.
 
12) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 21 : 148-158, 2014.
PubMed
13) Takahashi H, Ogawa H, Ohigashi H, et al : Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery 150 : 547-556, 2011.
PubMed
14) Sugiura T, Uesaka K, Kanemoto H, et al : Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg 16 : 977-985, 2012.
PubMed
15) Motoi F, Murakami Y, Okada KI, et al : Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World J Surg 43 : 634-641, 2019.
PubMed
16) Motoi F, Rikiyama T, Katayose Y, et al : Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol 18 : 371-379, 2011.
PubMed
17) Aoki S, Motoi F, Murakami Y, et al : Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma : a multicenter case-control study of 240 patients. BMC Cancer 19 : 252, 2019.
 
18) Su SB, Qin SY, Chen W, et al : Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 21 : 4323-4333, 2015.
PubMed
19) Huang Z, Liu F : Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer : a meta-analysis. Tumour Biol 35 : 7459-7465, 2014.
PubMed
20) Chen H, Tu H, Meng ZQ, et al : K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol 36 : 657-662, 2010.
 
21) Hata T, Mizuma M, Motoi F, et al : Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection. J Hepatobiliary Pancreat Sci, 2022. (DOI : 10.1002/jhbp.1282)
 
22) Groot VP, Mosier S, Javed AA, et al : Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clin Cancer Res 25 : 4973-4984, 2019.
PubMed
23) Nakano Y, Kitago M, Matsuda S, et al : KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker : a retrospective study. Br J Cancer 118 : 662-669, 2018.
 
24) Lee B, Lipton L, Cohen J, et al : Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol 30 : 1472-1478, 2019.
PubMed
25) Pietrasz D, Pecuchet N, Garlan F, et al : Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Clin Cancer Res 23 : 116-123, 2017.
PubMed
26) Tsuchida H, Fujii T, Mizuma M, et al : Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy : A nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery 166 : 997-1003, 2019.
 
27) Aoki S, Mizuma M, Hayashi H, et al : Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Pancreatology 20 : 1711-1717, 2020.
PubMed
28) Takadate T, Morikawa T, Ishida M, et al : Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Surg Today 51 : 686-694, 2021.
PubMed
29) Ariake K, Mizuma M, Motoi F, et al : Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery. Ann Surg Oncol 28 : 6246-6254, 2021.
PubMed
30) Boccaccio C, Comoglio PM : Invasive growth : a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6 : 637-645, 2006.
PubMed
31) Fujita-Sato S, Galeas J, Truitt M, et al : Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions. Cancer Res 75 : 2851-2862, 2015.
PubMed
32) Oba A, Del Chiaro M, Satoi S, et al : New criteria of resectability for pancreatic cancer : A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci 29 : 725-731, 2022.
PubMed
33) Conroy T, Castan F, Lopez A, et al : Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer : A Randomized Clinical Trial. JAMA Oncol 8 : 1571-1578, 2022.
PubMed
34) Janssen QP, van Dam JL, Bonsing BA, et al : Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial) : study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 21 : 300, 2021.
PubMed
P.199 掲載の参考文献
1) Ducreux M, Cuhna AS, Caramella C, et al : Cancer of the pancreas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 (Suppl 5) : v56-v68, 2015.
 
2) Siegel RL, Miller KD, Fuchs HE, et al : Cancer statistics, 2022. CA Cancer J Clin 72 : 7-33, 2022.
PubMed
3) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
4) Conroy T, Hammel P, Hebbar M, et al : FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 379 : 2395-2406, 2018.
 
5) 膵癌取扱い規約 [第7版] (日本膵臓学会編), 金原出版, 2016.
 
6) Satoi S, Yanagimoto H, Yamamoto T, et al : A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol 14 : 14, 2016.
 
7) Satoi S, Yamaue H, Kato K, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 : 590-600, 2013.
PubMed
8) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
9) Ikeda M, Ioka T, Ito Y, et al : A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 85 : 163-169, 2013.
 
10) Fiore M, Trodella L, Valeri S, et al : Prospective study of cetuximab and gemcitabine in combination with radiation therapy : feasibility and efficacy in locally advanced pancreatic head cancer. Radiat Oncol 10 : 255, 2015.
PubMed
11) Hurt CN, Falk S, Crosby T, et al : Long-term results and recurrence patterns from SCALOP : a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer 116 : 1264-1270, 2017.
PubMed
12) Gemenetzis G, Groot VP, Blair AB, et al : Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg 270 : 340-347, 2019.
PubMed
13) Napolitano F, Formisano L, Giardino A, et al : Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel : A Single-Center Experience and a Literature Review. Cancers (Basel) 11 : 981, 2019.
PubMed
14) Kimura Y, Nakamura T, Hayashi T, et al : Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging : Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01). Ann Gastroenterol Surg 3 : 523-533, 2019.
 
15) Lee M, Kang JS, Kim H, et al : Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci 30 : 111-121, 2023.
 
16) Ushida Y, Inoue Y, Oba A, et al : Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel : A Single-Center Retrospective Study. Ann Surg Oncol 29 : 5038-5050, 2022.
PubMed
17) Shinoto M, Yamada S, Terashima K, et al : Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 95 : 498-504, 2016.
PubMed
18) Shinoto M, Yamada S, Yasuda S, et al : Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 119 : 45-51, 2013.
PubMed
19) Shinoto M, Terashima K, Suefuji H, et al : A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. Radiother Oncol 129 : 333-339, 2018.
PubMed
20) 篠藤誠 : 膵癌に対する重粒子線治療の意義. 胆と膵 41 : 499-505, 2020.
Medical*Online
21) Chatterjee D, Katz MH, Rashid A, et al : Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma : a predictor for patient outcome. Cancer 118 : 3182-3190, 2012.
PubMed
22) Mackay TM, van Erning FN, van der Geest LGM, et al : Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome : A population-based analysis. Eur J Cancer 106 : 99-105, 2019.
PubMed
23) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 31 : 1640-1648, 2013.
PubMed
24) Crippa S, Bittoni A, Sebastiani E, et al : Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol 42 : 1533-1539, 2016.
 
25) Frigerio I, Regi P, Giardino A, et al : Downstaging in Stage IV Pancreatic Cancer : A New Population Eligible for Surgery? Ann Surg Oncol 24 : 2397-2403, 2017.
PubMed
26) Satoi S, Fujii T, Yanagimoto H, et al : Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Ann Surg 265 : 397-401, 2017.
 
27) Yamada S, Fujii T, Yamamoto T, et al : Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg 107 : 1811-1817, 2020.
PubMed
28) Yamamoto T, Satoi S, Yamaki S, et al : Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers (Basel) 14 : 2022.
PubMed
29) 腹膜播種診療ガイドライン [2021年版] (日本腹膜播種研究会編), 金原出版, 2021.
 
30) Tanaka M, Heckler M, Mihaljevic AL, et al : CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol 45 : 1453-1459, 2019.
PubMed
31) Okui M, Yamamichi T, Asakawa A, et al : Resection for Pancreatic Cancer Lung Metastases. Korean J Thorac Cardiovasc Surg 50 : 326-328, 2017.
PubMed
32) Ilmer M, Schiergens TS, Renz BW, et al : Oligometastatic pulmonary metastasis in pancreatic cancer patients : Safety and outcome of resection. Surg Oncol 31 : 16-21, 2019.
PubMed
33) Yanagimoto H, Satoi S, Yamamoto T, et al : Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 12 : 1428, 2020.
PubMed
34) Lee J, Lee JC, Gromski MA, et al : Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer : A single center experience. Medicine (Baltimore) 97 : e13592, 2018.
 
35) Wright GP, Poruk KE, Zenati MS, et al : Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases : a Bi-institutional Analysis. J Gastrointest Surg 20 : 1830-1835, 2016.
PubMed
36) De Rubis G, Rajeev Krishnan S, Bebawy M : Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci 40 : 172-186, 2019.
PubMed
37) Tanaka F, Yoneda K, Kondo N, et al : Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 15 : 6980-6986, 2009.
PubMed
38) Naito T, Tanaka F, Ono A, et al : Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol 7 : 512-519, 2012.
PubMed
39) Sparano J, O'Neill A, Alpaugh K, et al : Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer : A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 4 : 1700-1706, 2018.
PubMed
40) Lee JS, Rhee TM, Pietrasz D, et al : Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma : A systematic review and meta-analysis. Sci Rep 9 : 16971, 2019.
PubMed
41) Groot VP, Mosier S, Javed AA, et al : Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clin Cancer Res 25 : 4973-4984, 2019.
PubMed
42) Hata T, Mizuma M, Iseki M, et al : Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. J Hepatobiliary Pancreat Sci 28 : 648-658, 2021.
PubMed
43) Zill OA, Banks KC, Fairclough SR, et al : The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res 24 : 3528-3538, 2018.
PubMed
P.207 掲載の参考文献
1) 国立がん研究センターがん情報サービス : がん統計予測. [https://ganjoho.jp/reg_stat/statistics/stat/short_pred.html] (2022年11月閲覧)
 
2) Murata Y, Mizuno S, Kishiwada M, et al : Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma. Pancreatology 21 : 1482-1490, 2021.
PubMed
3) Lee SM, Katz MH, Liu L, et al : Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Am J Surg Pathol 40 : 1653-1660, 2016.
PubMed
4) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
5) Versteijne E, Suker M, Groothuis K, et al : Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 38 : 1763-1773, 2020.
 
6) Fujii T, Satoi S, Yamada S, et al : Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head : an observational study using inverse probability of treatment weighting. J Gastroenterol 52 : 81-93, 2017.
PubMed
7) Sho M, Akahori T, Tanaka T, et al : Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbecks Arch Surg 400 : 477-485, 2015.
PubMed
8) Eguchi H, Takeda Y, Takahashi H, et al : A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 26 : 4498-4505, 2019.
 
9) Katz MH, Shi Q, Ahmad SA, et al : Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer : Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 151 : e161137, 2016.
PubMed
10) Nagakawa Y, Hosokawa Y, Nakayama H, et al : A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. Cancer Chemother Pharmacol 79 : 951-957, 2017.
PubMed
11) Masui T, Takaori K, Anazawa T, et al : A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement. Anticancer Res 37 : 7023-7030, 2017.
 
12) Murphy JE, Wo JY, Ryan DP, et al : Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma : A Phase 2 Clinical Trial. JAMA Oncol 4 : 963-969, 2018.
PubMed
13) Hayashi T, Nakamura T, Kimura Y, et al : Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Int J Radiat Oncol Biol Phys 105 : 606-617, 2019.
PubMed
14) Tran NH, Sahai V, Griffith KA, et al : Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 106 : 124-133, 2020.
PubMed
15) Masui T, Nagai K, Anazawa T, et al : Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment ; a prospective, open-label, phase II study in a single institution. BMC Cancer 22 : 119, 2022.
 
16) Takahashi S, Ohno I, Ikeda M, et al : Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer : A Phase II Open-label Multicenter Prospective Trial (JASPAC05). Ann Surg 276 : e510-e517, 2022.
PubMed
17) Jang JY, Han Y, Lee H, et al : Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer : A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg 268 : 215-222, 2018.
 
18) Sultana A, Tudur Smith C, Cunningham D, et al : Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96 : 1183-1190, 2007.
PubMed
19) Yoshitomi H, Takano S, Furukawa K, et al : Conversion surgery for initially unresectable pancreatic cancer : current status and unresolved issues. Surg Today 49 : 894-906, 2019.
PubMed
20) Kato H, Kishiwada M, Hayasaki A, et al : Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma : CEA Level Before Operation is a Significant Prognostic Indicator in Patients With Locally Advanced Pancreatic Cancer Treated With Neoadjuvant Therapy Followed by Surgical Resection : A Retrospective Analysis. Ann Surg 275 : e698-e707, 2022.
PubMed
P.212 掲載の参考文献
1) Groot VP, Rezaee N, Wu W, et al : Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg 267 : 936-945, 2018.
PubMed
2) Sato H, Yoshida R, Yasui K, et al : Feasibility of local therapy for recurrent pancreatic cancer. Pancreatology 22 : 774-781, 2022.
PubMed
3) Habermehl D, Brecht IC, Bergmann F, et al : Chemoradiation in patients with isolated recurrent pancreatic cancer-therapeutical efficacy and probability of re-resection. Radiat Oncol 8 : 27, 2013.
PubMed
4) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
5) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
6) Sultana A, Tudur Smith C, Cunningham D, et al : Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96 : 1183-1190, 2007.
PubMed
7) Maemura K, Shinchi H, Noma H, et al : Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. Anticancer Res 28 : 2369-2372, 2008.
PubMed
8) Shinchi H, Maemura K, Mataki Y, et al : A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 19 : 152-158, 2012.
 
9) Iio S, Hozaka Y, Tanoue K, et al : Curative resection after chemotherapy and chemoradiotherapy for postoperative recurrence of pancreatic tail cancer in the abdominal wall : a case report. Surg Case Rep 8 : 101, 2022.
PubMed
10) Cha YJ, Kim MS, Jang WI, et al : Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors. Radiat Oncol J 35 : 172-179, 2017.
PubMed
11) Anstadt EJ, Shumway R, Colasanto J, et al : Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases. J Gastrointest Oncol 10 : 330-338, 2019.
PubMed
12) Ji X, Zhao Y, He C, et al : Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. Front Oncol 11 : 659987, 2021.
 
13) Hall WA, Straza MW, Chen X, et al : Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac. PLoS One 15 : e0236570, 2020.
PubMed
14) Makishima H, Yasuda S, Isozaki Y, et al : Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis : A dose escalation study. Cancer Sci 110 : 303-309, 2019.
PubMed
15) Liu Y, Dong Y, Kong L, et al : Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 11 : 104, 2018.
 
P.218 掲載の参考文献
1) Motoi F, Kosuge T, Ueno H, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49 : 190-194, 2019.
PubMed
2) van der Gaag NA, Rauws EA, van Eijck CH, et al : Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362 : 129-137, 2010.
PubMed
3) Frazzoni L, Fuccio L, Larghi A : EUS-guided biliary drainage versus ERCP for the primary treatment of malignant distal biliary obstruction : time for a large randomized study. Gastrointest Endosc 88 : 571-572, 2018.
PubMed
4) Crippa S, Cirocchi R, Partelli S, et al : Systematic review and meta-analysis of metal versus plastic stentsfor preoperative biliary drainage in resectable periampullary or pancreatic head tumors. Eur J Surg Oncol 42 : 1278-1285, 2016.
PubMed
5) Tamura T, Itonaga M, Ashida R, et al : Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline resectable pancreatic cancer : Prospective randomized study. Dig Endosc 33 : 1170-1178, 2021.
PubMed
6) Davids PH, Groen AK, Rauws EA, et al : Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 340 : 1488-1492, 1992.
PubMed
7) Katsinelos P, Paikos D, Kountouras J, et al : Tannenbaum and metal stents in the palliative treatment of malignant distal bile duct obstruction : a comparative study of patency and cost effectiveness. Surg Endosc 20 : 1587-1593, 2006.
PubMed
8) Moss AC, Morris E, Leyden J, et al : Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 19 : 1119-1124, 2007.
 
9) Artifon EL, Marson FP, Gaidhane M, et al : Hepaticogastrostomy or choledochoduodenostomy for distal malignant biliary obstruction after failed ERCP : is there any difference? Gastrointest Endosc 81 : 950-959, 2015.
PubMed
10) Ogura T, Kitano M, Takenaka M, et al : Multicenter prospective evaluation study of endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting (with video). Dig Endosc 30 : 252-259, 2018.
PubMed
11) Sharaiha RZ, Khan MA, Kamal F, et al : Efficacy and safety of EUS-guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails : a systematic review and meta-analysis. Gastrointest Endosc 85 : 904-914, 2017.
 
12) Jeurnink SM, Steyerberg EW, van Hooft JE, et al : Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study) : a multicenter randomized trial. Gastrointest Endosc 71 : 490-499, 2010.
 
13) Pan YM, Pan J, Guo LK, et al : Covered versus uncovered self-expandable metallic stents for palliation of malignant gastric outlet obstruction : a systematic review and meta-analysis. BMC Gastroenterol 14 : 170, 2014.
PubMed
14) Lee H, Min BH, Lee JH, et al : Covered metallic stents with an anti-migration design vs. uncovered stents for the palliation of malignant gastric outlet obstruction : a multicenter, randomized trial. Am J Gastroenterol 110 : 1440-1449, 2015.
 
15) Fabian A, Bor R, Gede N, et al : Double Stenting for Malignant Biliary and Duodenal Obstruction : A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol 11 : e00161, 2020.
PubMed
P.223 掲載の参考文献
1) Andtbacka RH, Evans DB, Pisters PW : Surgical and endoscopic palliation for pancreatic cancer. Minerva Chir 59 : 123-136, 2004.
PubMed
2) Lopera JE, Brazzini A, Gonzales A, et al : Gastroduodenal stent placement : current status. Radiographics 24 : 1561-1573, 2004.
PubMed
3) Shah A, Fehmi A, Savides TJ : Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management. Dig Dis Sci 59 : 2294-2298, 2014.
PubMed
4) Hong J, Chen Y, Li J, et al : Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction : An updated Systematic Review and Meta-analysis. Am J Surg 223 : 1067-1078, 2022.
 
5) Ly J, O'Grady G, Mittal A, et al : A systematic review of methods to palliate malignant gastric outlet obstruction. Surg Endosc 24 : 290-297, 2010.
 
6) Jeurnink SM, Steyerberg EW, van Hooft JE, et al : Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study) : a multicenter randomized trial. Gastrointest Endosc 71 : 490-499, 2010.
 
7) Giovannini M : EUS-guided hepaticogastrostomy. Endosc Ultrasound 8 : S35-S39, 2019.
PubMed
8) Ojima T, Nakamori M, Nakamura M, et al : Laparoscopic Gastrojejunostomy for Patients with Unresectable Gastric Cancer with Gastric Outlet Obstruction. J Gastrointest Surg 21 : 1220-1225, 2017.
PubMed
9) Mehta S, Hindmarsh A, Cheong E, et al : Prospective randomized trial of laparoscopic gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction. Surg Endosc 20 : 239-242, 2006.
PubMed
10) Kumagai K, Rouvelas I, Ernberg A, et al : A systematic review and meta-analysis comparing partial stomach partitioning gastrojejunostomy versus conventional gastrojejunostomy for malignant gastroduodenal obstruction. Langenbecks Arch Surg 401 : 777-785, 2016.
PubMed
P.228 掲載の参考文献
1) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
2) Conroy T, Hammel P, Hebbar M, et al : FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 379 : 2395-2406, 2018.
 
3) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 31 : 1640-1648, 2013.
PubMed
4) Unno M, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). J Clin Oncol 37 (4 Suppl) : 189, 2019.
 
5) Versteijne E, Suker M, Groothuis K, et al : Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 38 : 1763-1773, 2020.
 
6) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 310 : 1473-1481, 2013.
PubMed
7) Uesaka K, Boku N, Fukutomi A, et al : Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 : 248-257, 2016.
PubMed
8) Neoptolemos JP, Palmer DH, Ghaneh P, et al : Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial. Lancet 389 : 1011-1024, 2017.
PubMed
9) Gemenetzis G, Groot VP, Blair AB, et al : Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg 270 : 340-347, 2019.
PubMed
10) Yanagimoto H, Satoi S, Yamamoto T, et al : Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 12 : 1428, 2020.
PubMed
P.231 掲載の参考文献
1) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 41 : 985-992, 2012.
PubMed
2) 水間正道, 海野倫明, 隈丸拓, ほか : National Clinical Database (NCD) 膵癌登録の第1回予後調査. 第119回日本外科学会定期学術集会抄録集, 2019.
 
3) 国立がん研究センター : がん情報サービス最新がん統計. [https://ganjoho.jp/reg_stat/statistics/stat/summary.html] (2022年11月閲覧)
 
4) Bengtsson A, Andersson R, Ansari D : The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep 10 : 16425, 2020.
PubMed
5) Nakano Y, Kitago M, Shinoda M, et al : Clinical predictive factors of long-term survival after curative resection of pancreatic cancer : a retrospective study. Cancer Med 6 : 2278-2286, 2017.
PubMed
6) Picozzi VJ, Oh SY, Edwards A, et al : Five-Year Actual Overall Survival in Resected Pancreatic Cancer : A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Ann Surg Oncol 24 : 1722-1730, 2017.
PubMed
7) Nakagawa K, Akahori T, Nishiwada S, et al : Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 403 : 693-700, 2018.
PubMed
8) Kardosh A, Lichtensztajn DY, Gubens MA, et al : Long-Term Survivors of Pancreatic Cancer : A California Population-Based Study. Pancreas 47 : 958-966, 2018.
PubMed
9) Kasahara N, Noda H, Kakizawa N, et al : A lack of postoperative complications after pancreatectomy contributes to the long-term survival of patients with pancreatic cancer. Pancreatology 19 : 686-694, 2019.
 
10) Yoon SJ, Shin SH, Yoon SK, et al : Appraisal of 5-year recurrence-free survival after surgery in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 28 : 287-296, 2021.
PubMed
11) Dal Molin M, Zhang M, de Wilde RF, et al : Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes : Results of Whole-Exome Sequencing Analysis. Clin Cancer Res 21 : 1944-1950, 2015.
 
12) Balachandran VP, Luksza M, Zhao JN, et al : Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551 : 512-516, 2017.
PubMed
P.236 掲載の参考文献
1) 北川裕久, 中川原寿俊, 田島秀浩, ほか : 膵腺扁平上皮癌 ; 膵腫瘍. 膵癌. 別冊日本臨牀新領域別症候群シリーズ No.16 膵臓症候群 (第2版), p296-298, 日本臨牀社, 2011.
 
2) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e1-427, 2007.
 
3) Madura JA, Jarman BT, Doherty MG, et al : Adenosquamous carcinoma of the pancreas. Arch Surg 134 : 599-603, 1999.
PubMed
4) 膵癌取扱い規約 [第7版] (日本膵臓学会編), p70, 金原出版, 2016.
 
5) 大川伸一, 大池信之 : 膵腺扁平上皮癌. 日本臨牀73 (増刊 : 膵癌・胆道癌) : 186-189, 2015.
 
6) Boyd CA, Benarroch-Gampel J, Sheffield KM, et al : 415 patients with adenosquamous carcinoma of the pancreas : a population-based analysis of prognosis and survival. J Surg Res 174 : 12-19, 2012.
PubMed
7) 唐澤幸彦, 得丸重夫, 吉村昌記, ほか : 膵腺扁平上皮癌の2手術例. 胆と膵 38 : 599-604, 2017.
Medical*Online
8) 鬼澤俊輔, 羽鳥隆, 高崎健 : 膵腺扁平上皮癌. 肝胆膵 49 : 744-747, 2004.
Medical*Online
9) 石渡裕俊, 真口宏介, 高橋邦幸, ほか : 膵腺扁平上皮癌の画像所見の特徴. 膵臓 21 : 62-69, 2006.
Medical*Online
10) Imaoka H, Shimizu Y, Mizuno N, et al : Clinical characteristics of adenosquamous carcinoma of the pancreas : a matched case-control study. Pancreas 43 : 287-290, 2014.
PubMed
11) Wild AT, Dholakia AS, Fan KY, et al : Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J Gastrointest Oncol 6 : 115-125, 2015.
PubMed
12) Fang Y, Pu N, Zhang L, et al : Chemoradiotherapy is associated with improved survival for resected pancreatic adenosquamous carcinoma : a retrospective cohort study from the SEER database. Ann Transl Med 7 : 522, 2019.
PubMed
13) Yoshida Y, Kobayashi S, Ueno M, et al : Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma : A multicenter retrospective analysis. Pancreatology 22 : 1159-1166, 2022.
PubMed
P.239 掲載の参考文献
1) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
2) WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), IARC, Lyon, 2019.
 
3) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e26-253, 2007.
 
4) Yoon MA, Lee JM, Kim SH, et al : MRI features of pancreatic colloid carcinoma. AJR Am J Roentgenol 193 : W308-W313, 2009.
PubMed
5) 北田英貴, 一二三倫郎, 竹熊与志, ほか : 著明な石灰化をともなった膵粘液癌の1例. 日本消化器病学会雑誌 102 : 479-483, 2005.
Medical*Online
6) Adsay NV, Pierson C, Sarkar F, et al : Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 25 : 26-42, 2001.
PubMed
7) 島田和明, 岸庸二, 奈良聡, ほか : 膵粘液癌-まれな膵外分泌腫瘍. 胆と膵 33 : 685-690, 2012.
Medical*Online
8) 浦田孝広, 一二三倫郎, 竹熊与志, ほか : 急性膵炎を契機に発見された膵粘液癌の1例. 日本消化器病学会雑誌 106 : 233-239, 2009.
Medical*Online
9) Suda K, Nobukawa B, Yamasaki S, et al : Pre-existing histological type and developmental mechanism of mucinous noncystic carcinoma of pancreas. Pathol Oncol Res 6 : 125-129, 2000.
PubMed
10) Poultsides GA, Reddy S, Cameron JL, et al : Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 251 : 470-476, 2010.
PubMed
11) Seidel G, Zahurak M, Iacobuzio-Donahue C, et al : Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms : a study of 39 cases. Am J Surg Pathol 26 : 56-63, 2002.
PubMed
P.245 掲載の参考文献
1) Sommers SC, Meissner WA : Unusual carcinomas of the pancreas. AMA Arch Pathol 58 : 101-111, 1954.
PubMed
2) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), p71-79, 金原出版, 2020.
 
3) WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), IARC, Lyon, 2019.
 
4) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e1-e425, 2007.
 
5) Clark CJ, Graham RP, Arun JS, et al : Clinical outcomes for anaplastic pancreatic cancer : a population-based study. J Am Coll Surg 215 : 627-634, 2012.
PubMed
6) Hoshimoto S, Matsui J, Miyata R, et al : Anaplastic carcinoma of the pancreas : Case report and literature review of reported cases in Japan. World J Gastroenterol 22 : 8631-8637, 2016.
PubMed
7) Imaoka H, Ikeda M, Maehara K, et al : Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas : a retrospective multicenter cohort study. BMC Cancer 20 : 946, 2020.
PubMed
8) Strobel O, Hartwig W, Bergmann F, et al : Anaplastic pancreatic cancer : Presentation, surgical management, and outcome. Surgery 149 : 200-208, 2011.
PubMed
9) Paal E, Thompson LD, Frommelt RA, et al : A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol 5 : 129-140, 2001.
PubMed
P.250 掲載の参考文献
1) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
2) La Rosa S, Klimstra DS, Wood LD : Pancreatic acinar cell carcinoma. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p333-336, IARC, Lyon, 2019.
 
3) Garcia-Romero D, Vanaclocha F : Pancreatic panniculitis. Dermatol Clin 26 : 465-470, 2008.
PubMed
4) Mustafa S, Hruban RH, Ali SZ : Acinar cell carcinoma of the pancreas : a clinicopathologic and cytomorphologic review. J Am Soc Cytopathol 9 : 586-595, 2020.
PubMed
5) Klimstra DS, Heffess CS, Oertel JE, et al : Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 16 : 815-837, 1992.
PubMed
6) Holen KD, Klimstra DS, Hummer A, et al : Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 20 : 4673-4678, 2002.
PubMed
7) Kitagami H, Kondo S, Hirano S, et al : Acinar cell carcinoma of the pancreas : clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas 35 : 42-46, 2007.
PubMed
8) Thompson ED, Wood LD. Pancreatic neoplasms with acinar differentiation. A review of pathologic and molecular features. Arch Pathol Lab Med 144 : 808-815, 2019.
 
9) 岸川さつき, 福村由紀 : 腺房細胞癌 (ACC). 膵臓 を診る医師のための膵臓病理テキスト (中沼安二, 古川徹, 福村由紀編), p176-179, 南江堂, 2020.
 
10) Al-Hader A, Al-Rohil RN, Han H, et al : Pancreatic acinar cell carcinoma : A review on molecular profiling of patient tumors. World J Gastroenterol 23 : 7945-7951, 2017.
PubMed
11) Abraham SC, Wu TT, Hruban RH, et al : Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma : frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 160 : 953-962, 2002.0
 
12) Furukawa T, Sakamoto H, Takeuchi S, et al : Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. Sci Rep 5 : 8829, 2015.
PubMed
13) Jiao Y, Yonescu R, Offerhaus GJ, et al : Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 232 : 428-435, 2014.
PubMed
14) Chmielecki J, Hutchinson KE, Frampton GM, et al : Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes. Cancer Discov 4 : 1398-1405, 2014.
PubMed
15) Wood LD, Klimstra DS : Pathology and genetics of pancreatic neoplasms with acinar differentiation. Semin Diagn Pathol 31 : 491-497, 2014.
PubMed
16) La Rosa S, Bernasconi B, Vanoli A, et al : c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers. Virchows Arch 473 : 435-441, 2018.
 
P.253 掲載の参考文献
1) 大橋計彦, 村上義央, 丸山雅一, ほか : 粘液産生膵癌の4例-特異な十二指腸乳頭所見を中心として-. Progress of Digestive Endoscopy 20 : 348-351, 1982.
 
2) Suzuki Y, Atomi Y, Sugiyama M, et al : Cystic neoplasm of the pancreas : a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
3) Tanaka M, Chari S, Adsay V, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
4) Maguchi H, Tanno S, Mizuno N, et al : Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas : a multicenter study in Japan. Pancreas 40 : 364-370, 2011.
PubMed
5) Kobayashi G, Fujita N, Maguchi H, et al : Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules : a Japan Pancreas Society multicenter study. Pancreas 43 : 532-538, 2014.
PubMed
6) Yamaguchi K, Kanemitsu S, Hatori T, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 : 571-580, 2011.
PubMed
7) 丹野誠志, 真口宏介, 小山内学, ほか : IPMN症例における膵管癌の危険因子-北海道多施設調査1181例の検討-. 消化器内科 55 : 86-90, 2012.
 
8) Capurso G, Boccia S, Salvia R, et al : Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas : a multicentre case-control study. Am J Gastroenterol 108 : 1003-1009, 2013.
PubMed
9) Jang JY, Kim SW, Ahn YJ, et al : Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas : is it possible to predict the malignancy before surgery? Ann Surg Oncol 12 : 124-132, 2005.
PubMed
10) Kim TH, Woo YS, Chon HK, et al : Predictors of Malignancy in "Pure" Branch-Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas without Enhancing Mural Nodules on CT Imaging : A Nationwide Multicenter Study. Gut Liver 12 : 583-590, 2018.
 
11) Hwang DW, Jang JY, Lim CS, et al : Determination of malignant and invasive predictors in branch duct type intraductal papillary mucinous neoplasms of the pancreas : a suggested scoring formula. J Korean Med Sci 26 : 740-746, 2011.
PubMed
P.257 掲載の参考文献
1) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
2) Ideno N, Ohtsuka T, Kono H, et al : Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258 : 141-151, 2013.
PubMed
3) Correa-Gallego C, Do R, Lafemina J, et al : Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas : development of a preoperative nomogram. Ann Surg Oncol 20 : 4348-4355, 2013.
PubMed
4) Jang JY, Park T, Lee S, et al : Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg 101 : 686-692, 2014.
PubMed
5) Tanaka M, Chari S, Adsay V, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
6) Shimizu Y, Hijioka S, Hirono S, et al : New Model for Predicting Malignancy in Patients With Intraductal Papillary Mucinous Neoplasm. Ann Surg 272 : 155-162, 2020.
PubMed
7) 清水泰博, 肱岡範, 山上裕機, ほか : 悪性予測 (切除適応) ; 新しいIPMN 悪性予測モデルの作成. 胆と膵41 (臨時増刊特大号 : IPMN 大全) : 1313-1317, 2020.
 
8) Ohtsuka T, Matsunaga T, Kimura H, et al : Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012. World J Surg 38 : 2994-3001, 2014.
PubMed
9) Kwong WT, Lawson RD, Hunt G, et al : Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy. Dig Dis Sci 60 : 2800-2806, 2015.
PubMed
10) Fritz S, Hackert T, Hinz U, et al : Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 98 : 104-110, 2011.
PubMed
11) Oyama H, Tada M, Takagi K, et al : Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. Gastroenterology 158 : 226-237.e5, 2020.
 
12) Hirono S, Shimizu Y, Ohtsuka T, et al : Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas ; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol 55 : 86-99, 2020.
PubMed
13) Hirono S, Kawai M, Okada K, et al : Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery 160 : 306-317, 2016.
PubMed
14) Miyasaka Y, Ohtsuka T, Tamura K, et al : Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm. Ann Surg 263 : 1180-1187, 2016.
PubMed
15) He J, Cameron JL, Ahuja N, et al : Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg 216 : 657-665 ; discussion 665-667, 2013.
 
P.262 掲載の参考文献
1) Basturk O, Esposito I, Fukushima N, et al : Pancreatic intraductal papillary mucinous neoplasm. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p310-314, IARC, Lyon, 2019.
 
2) Furukawa T, Kloppel G, Volkan Adsay N, et al : Classification of types of intraductal papillary-mucinous neoplasm of the pancreas : a consensus study. Virchows Arch 447 : 794-799, 2005.
PubMed
3) 膵癌取扱い規約 [第7版] (日本膵臓学会編), 金原出版, 2016.
 
4) Furukawa T, Hatori T, Fujita I, et al : Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60 : 509-516, 2011.
PubMed
5) Monzen M, Shimizu K, Hatori T, et al : Usefulness of cell block cytology for preoperative grading and typing of intraductal papillary mucinous neoplasms. Pancreatology 13 : 369-378, 2013.
PubMed
6) Hara T, Ikebe D, Odaka A, et al : Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain. Ann Surg 257 : 1103-1111, 2013.
 
7) Kuboki Y, Shimizu K, Hatori T, et al : Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas. Pancreas 44 : 227-235, 2015.
PubMed
8) Furukawa T, Kuboki Y, Tanji E, et al : Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 1 : 161, 2011.
PubMed
9) Sakamoto H, Kuboki Y, Hatori T, et al : Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 28 : 261-267, 2015.
PubMed
10) Vyas M, Hechtman JF, Zhang Y, et al : DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Mod Pathol 33 : 648-656, 2020.
 
11) Singhi AD, Wood LD, Parks E, et al : Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct. Gastroenterology 158 : 573-582.e2, 2020.
 
12) Omori Y, Ono Y, Morikawa T, et al : Serine/threonine kinase 11 plays a canonical role in malignant progression of KRAS-mutant and GNAS-wild-type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 277 : e384-e395, 2023.
 
13) Kobayashi T, Omori Y, Ono Y, et al : Pathways for the development of multiple epithelial types of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol 56 : 581-592, 2021.
PubMed
P.267 掲載の参考文献
1) Shyr YM, Su CH, Tsay SH, et al : Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Ann Surg 223 : 141-146, 1996.
PubMed
2) Jablonska B : Pancreatic cysts : etiology, diagnosis and management. Cent Eur J Med 9 : 92-107, 2014.
 
3) Machado NO, Al Qadhi H, Al Wahibi K : Intraductal Papillary Mucinous Neoplasm of Pancreas. N Am J Med Sci 7 : 160-175, 2015.
PubMed
4) Mas L, Lupinacci RM, Cros J, et al : Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma : A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights. Int J Mol Sci 22 : 6756, 2021.
PubMed
5) Venkatesh PG, Navaneethan U, Vege SS : Intraductal papillary mucinous neoplasm and acute pancreatitis. J Clin Gastroenterol 45 : 755-758, 2011.
PubMed
6) Hata T, Sakata N, Okada T, et al : Dilated papilla with mucin extrusion is a potential predictor of acute pancreatitis associated with intraductal papillary mucinous neoplasms of pancreas. Pancreatology 13 : 615-620, 2013.
PubMed
7) Jang JW, Kim MH, Jeong SU, et al : Clinical characteristics of intraductal papillary mucinous neoplasm manifesting as acute pancreatitis or acute recurrent pancreatitis. J Gastroenterol Hepatol 28 : 731-738, 2013.
PubMed
8) Shin SH, Han DJ, Park KT, et al : Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg 34 : 776-783, 2010.
PubMed
9) Wiesenauer CA, Schmidt CM, Cummings OW, et al : Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms. Arch Surg 138 : 610-618, 2003.
PubMed
10) Oyama H, Tada M, Takagi K, et al : Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. Gastroenterology 158 : 226-237.e5, 2020.
 
11) European Study Group on Cystic Tumours of the Pancreas : European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67 : 789-804, 2018.
 
12) Jang JY, Park T, Lee S, et al : Proposed Nomogram Predicting the Individual Risk of Malignancy in the Patients With Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 266 : 1062-1068, 2017.
 
13) Fritz S, Hackert T, Hinz U, et al : Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 98 : 104-110, 2011.
PubMed
14) Ciprani D, Morales-Oyarvide V, Qadan M, et al : An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology 20 : 729-735, 2020.
PubMed
15) Yamanaka K, Masuda A, Toyama H, et al : Association between serum SPan-1 and lymph node metastasis in invasive intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 17 : 123-129, 2017.
PubMed
16) Roch AM, Parikh JA, Al-Haddad MA, et al : Abnormal serum pancreatic enzymes, but not pancreatitis, are associated with an increased risk of malignancy in patients with intraductal papillary mucinous neoplasms. Surgery 156 : 923-929, 2014.
 
17) Yagi Y, Masuda A, Zen Y, et al : Predictive value of low serum pancreatic enzymes in invasive intraductal papillary mucinous neoplasms. Pancreatology 16 : 893-899, 2016.
PubMed
18) Simpson RE, Yip-Schneider MT, Wu H, et al : Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. Am J Surg 217 : 425-428, 2019.
PubMed
19) Arima K, Okabe H, Hashimoto D, et al : The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms. J Gastrointest Surg 19 : 2171-2177, 2015.
 
20) Maker AV, Katabi N, Gonen M, et al : Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 18 : 199-206, 2011.
PubMed
21) Yang KS, Ciprani D, O'Shea A, et al : Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN. Gastroenterology 160 : 1345-1358.e11, 2021.
 
22) Permuth-Wey J, Chen DT, Fulp WJ, et al : Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Prev Res (Phila) 8 : 826-834, 2015.
PubMed
23) Furukawa T, Kuboki Y, Tanji E, et al : Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 1 : 161, 2011.
PubMed
24) Omori Y, Ono Y, Kobayashi T, et al : How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression. Virchows Arch 477 : 21-31, 2020.
 
25) Hata T, Mizuma M, Motoi F, et al : GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype. Sci Rep 10 : 17761, 2020.
PubMed
P.275 掲載の参考文献
1) 国際膵臓学会ワーキンググループ : IPMN国際診療ガイドライン [2017年版] 日本語版, 医学書院, 2018.
 
2) Kang KM, Lee JM, Shin CI, et al : Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas. J Magn Reson Imaging 38 : 555-563, 2013.
PubMed
3) Kamata K, Kitano M, Omoto S, et al : Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts. Endoscopy 48 : 35-41, 2016.
PubMed
4) Kobayashi G, Fujita N, Noda Y, et al : Lateral spread along the main pancreatic duct in branch-duct intraductal papillary-mucinous neoplasms of the pancreas : usefulness of intraductal ultrasonography for its evaluation. Dig Endosc 23 : 62-68, 2011.
PubMed
5) Tyberg A, Raijman I, Siddiqui A, et al : Digital Pancreaticocholangioscopy for Mapping of Pancreaticobiliary Neoplasia : Can We Alter the Surgical Resection Margin? J Clin Gastroenterol 53 : 71-75, 2019.
PubMed
6) Majumder S, Philip NA, Singh Nagpal SJ, et al : High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer. Am J Gastroenterol 114 : 524-529, 2019.
PubMed
7) Watanabe Y, Endo S, Nishihara K, et al : The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines. Surg Today 48 : 1011-1019, 2018.
PubMed
8) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
9) Shimizu Y, Hijioka S, Hirono S, et al : New Model for Predicting Malignancy in Patients With Intraductal Papillary Mucinous Neoplasm. Ann Surg 272 : 155-162, 2020.
PubMed
10) Kim TH, Song TJ, Lee SO, et al : Main duct and mixed type intraductal papillary mucinous neoplasms without enhancing mural nodules : Duct diameter of less than 10 mm and segmental dilatation of main pancreatic duct are findings support surveillance rather than immediate surgery. Pancreatology 19 : 1054-1060, 2019.
 
11) Ideno N, Ohtsuka T, Kono H, et al : Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258 : 141-151, 2013.
PubMed
12) 喜多絵美里, 橋本佳苗, 辻本彰子, ほか : 主膵管型と分枝型IPMNの術前画像診断分類. 胆と膵 41 : 19-25, 2020.
Medical*Online
13) Kobayashi G, Fujita N, Noda Y, et al : Intraductal papillary mucinous neoplasms of the pancreas showing fistula formation into other organs. J Gastroenterol 45 : 1080-1089, 2010.
PubMed
14) Fritz S, Schirren M, Klauss M, et al : Clinicopathologic characteristics of patients with resected multifocal intraductal papillary mucinous neoplasm of the pancreas. Surgery 152 : S74-S80, 2012.
PubMed
P.285 掲載の参考文献
1) Patra KC, Bardeesy N, Mizukami Y : Diversity of Precursor Lesions For Pancreatic Cancer : The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol 8 : e86, 2017.
PubMed
2) van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, et al : Diagnosis and management of pancreatic cystic neoplasms : current evidence and guidelines. Nat Rev Gastroenterol Hepatol 16 : 676-689, 2019.
PubMed
3) 山口浩, 永田耕治, 清水道生 : 膵粘液産生性腫瘍の病理診断. 病理と臨床 27 : 539-545, 2009.
Medical*Online
4) Wu J, Matthaei H, Maitra A, et al : Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3 : 92ra66, 2011.
PubMed
5) Furukawa T, Kuboki Y, Tanji E, et al : Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 1 : 161, 2011.
PubMed
6) Fischer CG, Wood LD : From somatic mutation to early detection : insights from molecular characterization of pancreatic cancer precursor lesions. J Pathol 246 : 395-404, 2018.
PubMed
7) Miyasaka Y, Ohtsuka T, Tamura K, et al : Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm. Ann Surg 263 : 1180-1187, 2016.
PubMed
8) Hashimoto D, Chikamoto A, Masuda T, et al : Pancreatic Cancer Arising From the Remnant Pancreas : Is It a Local Recurrence or New Primary Lesion? Pancreas 46 : 1083-1090, 2017.
PubMed
9) Izawa T, Obara T, Tanno S, et al : Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas. Cancer 92 : 1807-1817, 2001.
PubMed
10) Soto AM, Sonnenschein C : The tissue organization field theory of cancer : a testable replacement for the somatic mutation theory. Bioessays 33 : 332-340, 2011.
 
11) Parsons BL : Multiclonal tumor origin : Evidence and implications. Mutat Res Rev Mutat Res 777 : 1-18, 2018.
PubMed
12) Yokoyama A, Kakiuchi N, Yoshizato T, et al : Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565 : 312-317, 2019.
PubMed
13) Ushijima T, Clark SJ, Tan P : Mapping genomic and epigenomic evolution in cancer ecosystems. Science 373 : 1474-1479, 2021.
PubMed
14) Felsenstein M, Noe M, Masica DL, et al : IPMNs with co-occurring invasive cancers : neighbours but not always relatives. Gut 67 : 1652-1662, 2018.
 
15) Fischer CG, Beleva Guthrie V, Braxton AM, et al : Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations. Gastroenterology 157 : 1123-1137.e22, 2019.
 
16) Noe M, Niknafs N, Fischer CG, et al : Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun 11 : 4085, 2020.
PubMed
17) Tachibana S, Mizukami Y, Ono Y, et al : Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma : A Case Report and Multi-Region Sequencing Analysis. Front Oncol 10 : 728, 2020.
PubMed
18) Kanda M, Matthaei H, Wu J, et al : Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142 : 730-733.e9, 2012.
 
19) Bournet B, Muscari F, Buscail C, et al : KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol 7 : e157, 2016.
PubMed
20) Storz P : Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 14 : 296-304, 2017.
PubMed
21) Tsuda M, Fukuda A, Roy N, et al : The BRG1/SOX9 axis is critical for acinar cell-derived pancreatic tumorigenesis. J Clin Invest 128 : 3475-3489, 2018.
PubMed
22) Taki K, Ohmuraya M, Tanji E, et al : GNAS (R201H) and Kras (G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm. Oncogene 35 : 2407-2412, 2016.
PubMed
23) Patra KC, Kato Y, Mizukami Y, et al : Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20 : 811-822, 2018.
PubMed
24) Watanabe K, Nakamura T, Onodera S, et al : A novel GNAS-mutated human induced pluripotent stem cell model for understanding GNAS-mutated tumors. Tumour Biol 42 : 1010428320962588, 2020.
PubMed
25) Omori Y, Ono Y, Kobayashi T, et al : How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression. Virchows Arch 477 : 21-31, 2020.
 
26) He X, Zhang L, Chen Y, et al : The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehogdriven medulloblastoma. Nat Med 20 : 1035-1042, 2014.
 
27) Iglesias-Bartolome R, Torres D, Marone R, et al : Inactivation of a Gα (s) -PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. Nat Cell Biol 17 : 793-803, 2015.
 
28) Kawabata H, Ono Y, Tamamura N, et al : Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. J Gastroenterol 57 : 208-220, 2022.
PubMed
29) Wu J, Jiao Y, Dal Molin M, et al : Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 108 : 21188-21193, 2011.
PubMed
30) Amato E, Molin MD, Mafficini A, et al : Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233 : 217-227, 2014.
PubMed
31) Tan MC, Basturk O, Brannon AR, et al : GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. J Am Coll Surg 220 : 845-854.e1, 2015.
 
32) Gala MK, Mizukami Y, Le LP, et al : Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology 146 : 520-529, 2014.
PubMed
33) Fujikura K, Hosoda W, Felsenstein M, et al : Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. Gut 70 : 928-939, 2021.
 
34) Omori Y, Ono Y, Morikawa T, et al : Serine/Threonine Kinase 11 Plays a Canonical Role in Malignant Progression of KRAS-mutant and GNAS-wild-type Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 277 : e384-e395, 2023.
 
35) WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), IARC, Lyon, 2019.
 
36) Singhi AD, Wood LD, Parks E, et al : Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct. Gastroenterology 158 : 573-582.e2, 2020.
 
37) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
38) Yamaguchi K, Kanemitsu S, Hatori T, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 : 571-580, 2011.
PubMed
39) Omori Y, Ono Y, Tanino M, et al : Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Gastroenterology 156 : 647-661.e2, 2019.
 
40) Makohon-Moore AP, Matsukuma K, Zhang M, et al : Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561 : 201-205, 2018.
PubMed
41) 大森優子, 水上裕輔, 古川徹 : IPMNの分子生物学IPMN と併存膵癌のクローン進化. 胆と膵 41 (臨時増刊特大号) : 1245-1252, 2020.
 
42) European Study Group on Cystic Tumours of the Pancreas : European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67 : 789-804, 2018.
 
43) Elta GH, Enestvedt BK, Sauer BG, et al : ACG Clinical Guideline : Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol 113 : 464-479, 2018.
PubMed
44) Mukewar S, de Pretis N, Aryal-Khanal A, et al : Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms. Gut 66 : 1811-1817, 2017.
PubMed
45) Crippa S, Bassi C, Salvia R, et al : Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management : a mid-term follow-up analysis. Gut 66 : 495-506, 2017.
PubMed
46) Sakai A, Masuda A, Eguchi T, et al : Clinical outcome of conservatively managed pancreatic intraductal papillary mucinous neoplasms with mural nodules and main duct dilation. J Gastroenterol 56 : 285-292, 2021.
PubMed
47) Goh BKP, Tan DMY, Ho MMF, et al : Utility of the Sendai Consensus Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasms : A Systematic Review. J Gastrointest Surg 18 : 1350-1357, 2014.
PubMed
48) Fritz S, Klauss M, Bergmann F, et al : Pancreatic Main-Duct Involvement in Branch-Duct IPMNs An Underestimated Risk. Ann Surg 260 : 848-855, 2014.
PubMed
49) Aso T, Ohtsuka T, Matsunaga T, et al : "High-Risk Stigmata" of the 2012 International Consensus Guidelines Correlate With the Malignant Grade of Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreas 43 : 1239-1243, 2014.
PubMed
50) Sahora K, Mino-Kenudson M, Brugge W, et al : Branch Duct Intraductal Papillary Mucinous Neoplasms : Does Cyst Size Change the Tip of the Scale? A Critical Analysis of the Revised International Consensus Guidelines in a Large Single-Institutional Series. Ann Surg 258 : 466-475, 2013.
 
51) Kang JS, Park T, Han Y, et al : Clinical validation of the 2017 international consensus guidelines on intraductal papillary mucinous neoplasm of the pancreas. Ann Surg Treat Res 97 : 58-64, 2019.
PubMed
52) Sharib JM, Fonseca AL, Swords DS, et al : Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms : Do the 2017 International Consensus Guidelines improve clinical decision making? Surgery 164 : 1178-1184, 2018.
PubMed
53) Shimizu Y, Hijioka S, Hirono S, et al : New Model for Predicting Malignancy in Patients With Intraductal Papillary Mucinous Neoplasm. Ann Surg 272 : 155-162, 2020.
PubMed
54) Karasaki H, Mizukami Y, Tokusashi Y, et al : Localization of the most severely dysplastic/invasive lesions and mucin phenotypes in intraductal papillary mucinous neoplasm of the pancreas. Pancreas 40 : 588-594, 2011.
PubMed
55) Kawada N, Uehara H, Nagata S, et al : Mural nodule of 10 mm or larger as predictor of malignancy for intraductal papillary mucinous neoplasm of the pancreas : Pathological and radiological evaluations. Pancreatology 16 : 441-448, 2016.
 
56) 佐藤允洋, 唐崎秀則, 富永素矢, ほか : ゲノム解析により膵管内乳頭粘液性腫瘍併存癌の初期像と診断し得た1例. 日本消化器病学会雑誌 119 : 368-376, 2022.
Medical*Online
57) Vege SS, Ziring B, Jain R, et al : American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148 : 819-quize13, 2015.
PubMed
58) Pergolini I, Sahora K, Ferrone CR, et al : Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology 153 : 1284-1294.e1, 2017.
 
59) Oyama H, Tada M, Takagi K, et al : Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. Gastroenterology 158 : 226-237.e5, 2020.
 
60) Marchegiani G, Pollini T, Andrianello S, et al : Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery. JAMA Surg 156 : 654-661, 2021.
PubMed
61) Zelga P, Hernandez-Barco YG, Qadan M, et al : Number of Worrisome Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasm. J Am Coll Surg 234 : 1021-1030, 2022.
PubMed
62) Marchegiani G, Andrianello S, Pollini T, et al : " Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas : A Potential Target for Follow-Up Discontinuation? Am J Gastroenterol 114 : 1678-1684, 2019.
PubMed
63) Sahora K, Ferrone CR, Brugge WR, et al : Effects of Comorbidities on Outcomes of Patients With Intraductal Papillary Mucinous Neoplasms. Clin Gastroenterol Hepatol 13 : 1816-1823, 2015.
PubMed
64) Konings IC, Harinck F, Kuenen MA, et al : Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Fam Cancer 16 : 143-151, 2017.
PubMed
65) Dbouk M, Katona BW, Brand RE, et al : The Multicenter Cancer of Pancreas Screening Study : Impact on Stage and Survival. J Clin Oncol 40 : 3257-3266, 2022.
PubMed
66) Skaro M, Nanda N, Gauthier C, et al : Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology 156 : 1905-1913, 2019.
PubMed
67) Okada T, Mizukami Y, Ono Y, et al : Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance. J Gastroenterol 55 : 1183-1193, 2020.
PubMed
68) Takahashi K, Taniue K, Ono Y, et al : Long Non-Coding RNAs in Epithelial-Mesenchymal Transition of Pancreatic Cancer. Front Mol Biosci 8 : 717890, 2021.
PubMed
69) 高橋賢治, 大森優子, 小野裕介, ほか : IPMNの悪性度評価とliquid biopsy. 胆と膵 43 : 33-42, 2022.
Medical*Online
70) Springer S, Wang Y, Dal Molin M, et al : A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 149 : 1501-1510, 2015.
PubMed
71) Paniccia A, Polanco PM, Boone BA, et al : Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts. Gastroenterology 164 : 117-133.e7, 2023.
 
72) Suenaga M, Yu J, Shindo K, et al : Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. Clin Cancer Res 24 : 2963-2974, 2018.
PubMed
73) Takeda Y, Matsumoto K, Kurumi H, et al : Efficacy and safety of pancreatic juice cytology by using synthetic secretin in the diagnosis of pancreatic ductal adenocarcinoma. Dig Endosc 30 : 771-776, 2018.
PubMed
74) Collisson EA, Bailey P, Chang DK, et al : Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 16 : 207-220, 2019.
PubMed
75) Hwang WL, Jagadeesh KA, Guo JA, et al : Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat Genet 54 : 1178-1191, 2022.
PubMed
76) Yang KS, Ciprani D, O'Shea A, et al : Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN. Gastroenterology 160 : 1345-1358.e11, 2021.
 
P.297 掲載の参考文献
1) Zhang XP, Yu ZX, Zhao YP, et al : Current perspectives on pancreatic serous cystic neoplasms : Diagnosis, management and beyond. World J Gastrointest Surg 8 : 202-211, 2016.
PubMed
2) Jais B, Rebours V, Malleo G, et al : Serous cystic neoplasm of the pancreas : a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut 65 : 305-312, 2016.
 
3) Kimura W, Moriya T, Hirai I, et al : Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas 41 : 380-387, 2012.
PubMed
4) Fernandez-del Castillo C : Mucinous cystic neoplasms. J Gastrointest Surg 12 : 411-413, 2008.
PubMed
5) 南竜城, 真口宏介 : 膵管内乳頭粘液性腫瘍 (IPMN) 鑑別診断. 日本臨牀 73 (増刊 : 膵癌・胆道癌) : 240-243, 2015.
 
6) Yamao K, Yanagisawa A, Takahashi K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
7) 乾和郎, 服部昌志, 中澤三郎 : 膵仮性嚢胞の内視鏡治療ガイドライン ; 膵臓疾患の診断基準・診療ガイドライン. 別冊日本臨牀領域別症候群シリーズ No.16 膵臓症候群 (第3版), p401-404, 日本臨牀社, 2021.
 
8) Yamaguchi H, Shimizu M, Ban S, et al : Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 33 : 1164-1172, 2009.
PubMed
P.303 掲載の参考文献
1) Vege SS, Ziring B, Jain R, et al : American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148 : 819-quize13, 2015.
PubMed
2) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
3) European Study Group on Cystic Tumours of the Pancreas : European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67 : 789-804, 2018.
 
4) Elta GH, Enestvedt BK, Sauer BG, et al : ACG Clinical Guideline : Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol 113 : 464-479, 2018.
PubMed
5) Tanaka M, Chari S, Adsay V, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
6) Tanaka M, Fernandez-del Castillo C, Adsay V, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
7) Hirono S, Tani M, Kawai M, et al : Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors. Arch Surg 144 : 345-350, 2009.
PubMed
8) Hirono S, Shimizu Y, Ohtsuka T, et al : Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas ; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol 55 : 86-99, 2020.
PubMed
9) Yoon WJ, Daglilar ES, Fernandez-del Castillo C, et al : Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration : the PIPE Study. Endoscopy 46 : 382-387, 2014.
PubMed
10) Hirono S, Tani M, Kawai M, et al : The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 255 : 517-522, 2012.
PubMed
11) Fujita Y, Hirono S, Kawai M, et al : Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm. Eur J Surg Oncol 48 : 1054-1061, 2022.
PubMed
12) Hayakawa H, Fukasawa M, Sato T, et al : Carcinoembryonic antigen level in the pancreatic juice is effective in malignancy diagnosis and prediction of future malignant transformation of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol 54 : 1029-1037, 2019.
PubMed
13) Hirono S, Kawai M, Okada KI, et al : Factors associated with invasive intraductal papillary mucinous carcinoma of the pancreas. JAMA Surg 152 : e165054, 2017.
PubMed
14) Tsumura A, Hirono S, Kawai M, et al : Surgical indication for intraductal papillary mucinous neoplasm without mural nodule ≧5 mm. Surgery 169 : 388-395, 2021.
 
15) Tjaden C, Sandini M, Mihaljevic AL, et al : Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm. JAMA Surg 156 : 818-825, 2021.
PubMed
P.310 掲載の参考文献
1) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
2) European Study Group on Cystic Tumours of the Pancreas : European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67 : 789-804, 2018.
 
3) Hirono S, Kawai M, Okada K, et al : Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery 160 : 306-317, 2016.
PubMed
4) Hirono S, Shimizu Y, Ohtsuka T, et al : Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas ; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol 55 : 86-99, 2020.
PubMed
5) Nara S, Shimada K, Kosuge T, et al : Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas : clinicopathologic study of 104 intraductal papillary-mucinous neoplasms. Am J Surg Pathol 32 : 243-255, 2008.
PubMed
6) Izumo W, Higuchi R, Furukawa T, et al : Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma. Surgery 168 : 994-1002, 2020.
PubMed
7) Winter JM, Jiang W, Basturk O, et al : Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≦20-mm Invasive Component) : A Multiinstitutional Analysis. Ann Surg 263 : 793-801, 2016.
 
8) Hirono S, Tani M, Kawai M, et al : A central pancreatectomy for benign or low-grade malignant neoplasms. J Gastrointest Surg 13 : 1659-1665, 2009.
PubMed
9) Hirono S, Yamaue H : Middle pancreatectomy for pancreatic neoplasms. J Hepatobiliary Pancreat Sci 17 : 803-807, 2010.
PubMed
10) Hirono S, Kawai M, Okada KI, et al : Factors associated with invasive intraductal papillary mucinous carcinoma of the pancreas. JAMA Surg 152 : e165054, 2017.
PubMed
11) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
12) Hirono S, Kawai M, Okada KI, et al : Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 1 : 208-218, 2017.
PubMed
13) Hirono S, Yamaue H : Tips and tricks of the surgical technique for borderline resectable pancreatic cancer : mesenteric approach and modified distal pancreatectomy with en-bloc celiac axis resection. J Hepatobiliary Pancreat Sci 22 : E4-E7, 2015.
PubMed
14) Kawai M, Hirono S, Okada K, et al : Randomized Controlled Trial of Pancreaticojejunostomy versus Stapler Closure of the Pancreatic Stump During Distal Pancreatectomy to Reduce Pancreatic Fistula. Ann Surg 264 : 180-187, 2016.
PubMed
P.314 掲載の参考文献
1) Beger HG, Krautzberger W, Bittner R, et al : Duodenum-preserving resection of the head of the pancreas in patients with severe chronic pancreatitis. Surgery 97 : 467-473, 1985.
PubMed
2) Kato H, Asano Y, Ito M, et al : Significant positive impact of duodenum-preserving pancreatic head resection on the prevention of postoperative nonalcoholic fatty liver disease and acute cholangitis. Ann Gastroenterol Surg 6 : 851-861, 2022.
PubMed
3) Horiguchi A, Miyakawa S, Ishihara S, et al : Surgical design and outcome of duodenum-preserving pancreatic head resection for benign or low-grade malignant tumors. J Hepatobiliary Pancreat Sci 17 : 792-797, 2010.
PubMed
4) Miura F, Takada T, Asano T, et al : Hemodynamic changes of splenogastric circulation after spleen-preserving pancreatectomy with excision of splenic artery and vein. Surgery 138 : 518-522, 2005.
PubMed
5) Asano Y, Kato H, Arakawa S, et al : Clinical outcomes of organ-preserving pancreatectomy for benign or low-grade malignant pancreatic tumors : A multicenter nationwide survey in Japan. J Hepatobiliary Pancreat Sci 29 : 898-910, 2022.
PubMed
P.321 掲載の参考文献
1) 宮坂義浩, 川元真 : IPMN切除後の長期予後. 膵臓 37 : 150-160, 2022.
Medical*Online
2) Pea A, Yu J, Rezaee N, et al : Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg 266 : 133-141, 2017.
PubMed
3) Miyasaka Y, Ohtsuka T, Tamura K, et al : Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm. Ann Surg 263 : 1180-1187, 2016.
PubMed
4) Hirono S, Shimizu Y, Ohtsuka T, et al : Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas ; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol 55 : 86-99, 2020.
PubMed
5) Pfluger MJ, Griffin JF, Hackeng WM, et al : The Impact of Clinical and Pathological Features on Intraductal Papillary Mucinous Neoplasm Recurrence After Surgical Resection : Long-Term Follow-Up Analysis. Ann Surg 275 : 1165-1174, 2022.
PubMed
6) Kim HS, Han Y, Kang JS, et al : Fate of Patients With Intraductal Papillary Mucinous Neoplasms of Pancreas After Resection According to the Pathology and Margin Status : Continuously Increasing Risk of Recurrence Even After Curative Resection Suggesting Necessity of Lifetime Surveillance. Ann Surg 276 : e231-e238, 2022.
 
7) Dhar VK, Merchant NB, Patel SH, et al : Does Surgical Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms? : A Multi-institutional Study. Ann Surg 268 : 469-478, 2018.
PubMed
8) 膵癌診療ガイドライン [2022年版] (日本膵臓学会・膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
9) 宮坂義浩, 大塚隆生, 森泰寿, ほか : 同時性・異時性重複がんの実態と診療戦略膵癌・IPMN. 臨床外科 70 : 1365-1368, 2015.
 
10) Vege SS, Ziring B, Jain R, et al : American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148 : 819-822 ; quize12-13, 2015.
 
11) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
12) European Study Group on Cystic Tumours of the Pancreas : European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67 : 789-804, 2018.
 
13) Elta GH, Enestvedt BK, Sauer BG, et al : ACG Clinical Guideline : Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol 113 : 464-479, 2018.
PubMed
14) Kamata K, Takenaka M, Minaga K, et al : Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. Dig Endosc 30 : 659-666, 2018.
PubMed
15) Simpson RE, Ceppa EP, Wu HH, et al : The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN. J Gastrointest Surg 23 : 1593-1603, 2019.
PubMed
P.326 掲載の参考文献
1) 膵癌取扱い規約 [第5版] (日本膵臓学会編), 金原出版, 2002.
 
2) Hruban RH, Pitman MB, Klimstra DS : Tumors of the Pancreas. AFIP Atlas of Tumor Pathology, 4th series, Fascicle 6, American Registry of Pathology, Washington DC, 2007.
 
3) Chetty R, Serra S : Intraductal tubular adenoma (pyloric gland-type) of the pancreas : a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology 55 : 270-276, 2009.
PubMed
4) Nakayama Y, Inoue H, Hamada Y, et al : Intraductal tubular adenoma of the pancreas, pyloric gland type : a clinicopathologic and immunohistochemical study of 6 cases. Am J Surg Pathol 29 : 607-616, 2005.
PubMed
5) Yamaguchi H, Kuboki Y, Hatori T, et al : The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. J Pathol 231 : 335-341, 2013.
PubMed
6) Yamaguchi H, Kuboki Y, Hatori T, et al : Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol 35 : 1812-1817, 2011.
PubMed
7) Yamaguchi H, Shimizu M, Ban S, et al : Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 33 : 1164-1172, 2009.
PubMed
8) 膵癌取扱い規約 [第7版増補版] (日本膵臓学会編), 金原出版, 2020.
 
9) Basturk O, Esposito I, Fukushima N, et al : Pancreatic intraductal papillary mucinous neoplasm. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p310-314, IARC, Lyon, 2019.
 
10) Basturk O, Esposito I, Fukushima N, et al : Pancreatic intraductal oncocytic papillary neoplasm. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p315-316, IARC, Lyon, 2019.
 
11) Basturk O, Esposito I, Fukushima N, et al : Pancreatic intraductal tubulopapillary neoplasm. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p317-318, IARC, Lyon, 2019.
 
12) Basturk O, Adsay V, Askan G, et al : Intraductal Tubulopapillary Neoplasm of the Pancreas : A Clinicopathologic and Immunohistochemical Analysis of 33 Cases. Am J Surg Pathol 41 : 313-325, 2017.
PubMed
13) Motosugi U, Yamaguchi H, Furukawa T, et al : Imaging studies of intraductal tubulopapillary neoplasms of the pancreas : 2-tone duct sign and cork-of-wine-bottle sign as indicators of intraductal tumor growth. J Comput Assist Tomogr 36 : 710-717, 2012.
PubMed
14) Basturk O, Berger MF, Yamaguchi H, et al : Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Mod Pathol 30 : 1760-1772, 2017.
PubMed
15) Basturk O, Zamboni G, Klimstra DS, et al : Intraductal and papillary variants of acinar cell carcinomas : a new addition to the challenging differential diagnosis of intraductal neoplasms. Am J Surg Pathol 31 : 363-370, 2007.
 
P.329 掲載の参考文献
1) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas With overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
2) Kloppel G, Solcia E, Longnecker DS, et al : Histological Typing of Tumours of the Exocrine Pancreas (World Health Organization. International Histological Classification of Tumours), 2nd ed, Springer, Berlin, New York, 1996.
 
3) Solcia E, Capella C, Kloppel G : Tumors of the Pancreas. Atlas of Tumor Pathology, 3rd Series, Fascicle 20, Armed Forces Institute of Pathology, Washington DC, 1997.
 
4) Suzuki Y, Atomi Y, Sugiyama M, et al : Cystic neoplasm of the pancreas : a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
5) Yamao K, Yanagisawa A, Takahashi K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
6) Park JW, Jang JY, Kang MJ, et al : Mucinous cystic neoplasm of the pancreas : is surgical resection recommended for all surgically fit patients? Pancreatology 14 : 131-136, 2014.
PubMed
7) Le Baleur Y, Couvelard A, Vullierme MP, et al : Mucinous cystic neoplasms of the pancreas : definition of preoperative imaging criteria for high-risk lesions. Pancreatology 11 : 495-499, 2011.
PubMed
8) Postlewait LM, Ethun CG, McInnis MR, et al : Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms : A Multicenter Study. JAMA Surg 152 : 19-25, 2017.
 
9) Ohtsuka T, Nakamura M, Hijioka S, et al : Prediction of the Probability of Malignancy in Mucinous Cystic Neoplasm of the Pancreas With Ovarian-Type Stroma : A Nationwide Multicenter Study in Japan. Pancreas 49 : 181-186, 2020.
PubMed
10) Goh BK, Tan YM, Chung YF, et al : A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma : clinicopathological features of 344 patients. World J Surg 30 : 2236-2245, 2006.
PubMed
P.334 掲載の参考文献
1) WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), IARC, Lyon, 2019.
 
2) 山雄健次, 柳澤昭夫, 高橋邦幸, ほか : 卵巣型間質を伴うMCNの臨床病理学的特徴と予後-日本膵臓学会多施設共同研究から-. 膵臓 27 : 9-16, 2012.
 
3) Fukumura Y, Kinowaki Y, Matsuda Y, et al : Intralobular distribution of ovarian-like stroma in pancreatic mucinous cystic neoplasms : a discussion on its tumorigenesis. Sci Rep 12 : 3326, 2022.
PubMed
4) 三橋智子 : MCNの発生機序. 日本臨牀 73 (増刊 : 膵癌・胆道癌) : 267-271, 2015.
 
5) Elias KM, Tsantoulis P, Tille JC, et al : Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. J Pathol 246 : 459-469, 2018.
PubMed
6) Morris JP, Wang SC, Hebrok M : KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10 : 683-695, 2010.
PubMed
7) An S, Kim MJ, Kim SJ, et al : Multiple KRAS mutations in the non-mucinous epithelial lining in the majority of mucinous cystic neoplasms of the pancreas. Histopathology 75 : 559-567, 2019.
PubMed
8) Sakihama K, Koga Y, Yamamoto T, et al : RNF43 as a predictor of malignant transformation of pancreatic mucinous cystic neoplasm. Virchows Arch 480 : 1189-1199, 2022.
PubMed
9) Jimenez RE, Warshaw AL, Z'graggen K, et al : Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 230 : 501-509 ; discussion 509-511, 1999.
 
10) Luttges J, Feyerabend B, Buchelt T, et al : The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 26 : 466-471, 2002.
PubMed
11) Kim SG, Wu TT, Lee JH, et al : Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol 16 : 1086-1094, 2003.
PubMed
12) Ueki T, Toyota M, Skinner H, et al : Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 61 : 8540-8546, 2001.
PubMed
13) Schofield HK, Tandon M, Park MJ, et al : Pancreatic HIF2α Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. Cell Mol Gastroenterol Hepatol 5 : 169-185.e2, 2018.
 
14) Sano M, Driscoll DR, De Jesus-Monge WE, et al : Activated wnt signaling in stroma contributes to development of pancreatic mucinous cystic neoplasms. Gastroenterology 146 : 257-267, 2014.
PubMed
15) Izeradjene K, Combs C, Best M, et al : Kras (G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11 : 229-243, 2007.
PubMed
P.342 掲載の参考文献
1) Basturk O, Hong SM, Esposito I, et al : Mucinous cystic neoplasm. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p319-321, IARC, Lyon, 2019.
 
2) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
3) Ohashi K, Murakami Y, Muruayama M, et al : Four cases of mucin-secreting pancreatic cancer. Progress of Digestive Endoscopy 20 : 348-351, 1982.
 
4) Zamboni G, Fukushima N, Hruban RH, et al : Tumors of the exocrine pancreas. In : WHO Classification of Tumours, 4th ed, Vol 3, WHO Classification of Tumours of the Digestive System (ed by Bosman FT, Carneiro F, Hruban RH, et al), p300-303, IARC, Lyon, 2010.
 
5) Yamao K, Yanagisawa A, Takahashi K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
6) Tajiri T, Tate G, Inagaki T, et al : Mucinous cystadenoma of the pancreas 17 years after excision of gallbladder because of a choledochal cyst. J Gastroenterol 39 : 181-187, 2004.
PubMed
7) 福嶋敬宜 : Mucinous Cystic Neoplasm悪性例の病理像および頻度. 肝胆膵 63 : 731-735, 2011.
Medical*Online
8) Lewis GH, Wang H, Bellizzi AM, et al : Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 37 : 601-605, 2013.
PubMed
9) Adsay NV : Cystic lesions of the pancreas. Mod Pathol 20 (Suppl 1) : S71-S93, 2007.
 
10) Tajiri T, Tate G, Ohike N, et al : Sequential progression and intraductal spread of invasive ductal adenocarcinoma of the pancreas arising from around the main pancreatic duct. Hepatogastroenterology 52 : 745-748, 2005.
PubMed
11) Nitta T, Mitsuhashi T, Hatanaka Y, et al : Pancreatic ductal adenocarcinomas with multiple large cystic structures : a clinicopathologic and immunohistochemical study of seven cases. Pancreatology 13 : 401-408, 2013.
PubMed
12) Schechter S, Shi J : Simple Mucinous Cyst of the Pancreas : Review and Update. Arch Pathol Lab Med 141 : 1330-1335, 2017.
PubMed
13) Zamboni G, Scarpa A, Bogina G, et al : Mucinous cystic tumors of the pancreas : clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 23 : 410-422, 1999.
PubMed
14) Shimizu Y, Yasui K, Yamao K, et al : Possible oncogenesis of mucinous cystic tumors of the pancreas lacking ovarian-like stroma. Pancreatology 2 : 413-420, 2002.
PubMed
15) Tanaka M, Chari S, Adsay V, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
P.348 掲載の参考文献
1) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
2) Crippa S, Salvia R, Warshaw AL, et al : Mucinous Cystic Neoplasm of the Pancreas is Not an Aggressive Entity : Lessons From 163 Resected Patients. Ann Surg 247 : 571-579, 2008.
PubMed
3) Griffin JF, Page AJ, Samaha GJ, et al : Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm : A large single institution series. Pancreatology 17 : 490-496, 2017.
PubMed
4) Postlewait LM, Ethun CG, McInnis MR, et al : Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms : A Multicenter Study. JAMA Surg 152 : 19-25, 2017.
 
5) Keane MG, Shamali A, Nilsson LN, et al : Risk of malignancy in resected pancreatic mucinous cystic neoplasms. Br J Surg 105 : 439-446, 2018.
PubMed
6) Marchegiani G, Andrianello S, Crippa S, et al : Actual malignancy risk of either operated or non-operated presumed mucinous cystic neoplasms of the pancreas under surveillance. Br J Surg 108 : 1097-1104, 2021.
PubMed
7) Tanaka M, Fernandez-del Castillo C, Adsay V, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
8) European Study Group on Cystic Tumours of the Pancreas : European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67 : 789-804, 2018.
 
9) Elta GH, Enestvedt BK, Sauer BG, et al : ACG Clinical Guideline : Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol 113 : 464-479, 2018.
PubMed
10) 山口幸二 : 膵粘液嚢胞性腫瘍 (MCN) は全例, 切除の適応か? : 3つのガイドラインと多数例の後ろ向き観察研究よりみた検討. 膵臓 32 : 795-805, 2017.
Medical*Online
11) van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, et al : Diagnosis and management of pancreatic cystic neoplasms : current evidence and guidelines. Nat Rev Gastroenterol Hepatol 16 : 676-689, 2019.
PubMed
12) 山雄健次, 柳澤昭夫, 高橋邦幸, ほか : 卵巣型間質を伴うMCNの臨床病理学的特徴と予後-日本膵臓学会多施設共同研究から-. 膵臓 27 : 9-16, 2012.
 
13) Adam JP, Jacquin A, Laurent C, et al : Laparoscopic spleen-preserving distal pancreatectomy : splenic vessel preservation compared with the Warshaw technique. JAMA Surg 148 : 246-252, 2013.
 
14) Fernandez-Cruz L, Martinez I, Gilabert R, et al : Laparoscopic distal pancreatectomy combined with preservation of the spleen for cystic neoplasms of the pancreas. J Gastrointest Surg 8 : 493-501, 2004.
PubMed
15) Waghorn DJ : Overwhelming infection in asplenic patients : current best practice preventive measures are not being followed. J Clin Pathol 54 : 214-218, 2001.
 
16) Sauvanet A, Gaujoux S, Blanc B, et al : Parenchyma-sparing pancreatectomy for presumed noninvasive intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 260 : 364-371, 2014.
PubMed
17) Kuroki T, Eguchi S : Laparoscopic parenchyma-sparing pancreatectomy. J Hepatobiliary Pancreat Sci 21 : 323-327, 2014.
PubMed
18) Song KB, Kim SC, Park KM, et al : Laparoscopic central pancreatectomy for benign or low-grade malignant lesions in the pancreatic neck and proximal body. Surg Endosc 29 : 937-946, 2015.
PubMed
19) Crippa S, Bassi C, Warshaw AL, et al : Middle pancreatectomy : indications, short- and long-term operative outcomes. Ann Surg 246 : 69-76, 2007.
 
20) Iacono C, Verlato G, Ruzzenente A, et al : Systematic review of central pancreatectomy and meta-analysis of central versus distal pancreatectomy. Br J Surg 100 : 873-885, 2013.
PubMed
21) Faitot F, Gaujoux S, Barbier L, et al : Reappraisal of pancreatic enucleations : A single-center experience of 126 procedures. Surgery 158 : 201-210, 2015.
PubMed
22) Hughes DL, Hughes I, Silva MA : Determining the role of adjuvant therapy in Invasive Intraductal Papillary Mucinous Neoplasms ; a systematic review and meta-analysis. Eur J Surg Oncol 48 : 1567-1575, 2022.
PubMed
23) Kaiser J, Scheifele C, Hinz U, et al : IPMN-associated pancreatic cancer : Survival, prognostic staging and impact of adjuvant chemotherapy. Eur J Surg Oncol 48 : 1309-1320, 2022.
PubMed
24) Marchegiani G, Andrianello S, Dal Borgo C, et al : Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas : it is time for randomized controlled data. HPB (Oxford) 21 : 596-603, 2019.
PubMed
P.353 掲載の参考文献
1) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
2) Kloppel G, Solcia E, Longnecker DS, et al : Histological Typing of Tumours of the Exocrine Pancreas (World Health Organization. International Histological Classification of Tumours), 2nd ed, Springer, Berlin, New York, 1996.
 
3) Solcia E, Capella C, Kloppel G : Tumors of the Pancreas. Atlas of Tumor Pathology, 3rd Series, Fascicle 20, Armed Forces Institute of Pathology, Washington DC, 1997.
 
4) Tanaka M, Chari S, Adsay V, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
5) WHO Classification of Tumours, 4th ed, Vol 3, WHO Classification of Tumours of the Digestive System (ed by Bosman FT, Carneiro F, Hruban RH, et al), IARC, Lyon, 2010.
 
6) 膵癌取扱い規約 [第7版] (日本膵臓学会編), 金原出版, 2016.
 
7) Suzuki Y, Atomi Y, Sugiyama M, et al : Cystic neoplasm of the pancreas : a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
8) Yamao K, Yanagisawa A, Takahashi K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
9) Jang KT, Park SM, Basturk O, et al : Clinicopathologic characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma : implications for management and prognosis. Am J Surg Pathol 39 : 179-187, 2015.
PubMed
10) Park JW, Jang JY, Kang MJ, et al : Mucinous cystic neoplasm of the pancreas : is surgical resection recommended for all surgically fit patients? Pancreatology 14 : 131-136, 2014.
PubMed
11) Postlewait LM, Ethun CG, McInnis MR, et al : Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms : A Multicenter Study. JAMA Surg 152 : 19-25, 2017.
 
12) Tanaka M, Fernandez-del Castillo C, Adsay V, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
P.359 掲載の参考文献
1) Compagno J, Oertel JE : Microcystic adenomas of the pancreas (glycogen-rich cystadenomas) : a clinicopathologic study of 34 cases. Am J Clin Pathol 69 : 289-298, 1978.
PubMed
2) Hodgkinson DJ, ReMine WH, Weiland LH : Pancreatic cystadenoma. A clinicopathologic study of 45 cases. Arch Surg 113 : 512-519, 1978.
PubMed
3) Le Borgne J, de Calan L, Partensky C : Cystadenomas and cystadenocarcinomas of the pancreas : a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 230 : 152-161, 1999.
PubMed
4) Bassi C, Salvia R, Molinari E, et al : Management of 100 consecutive cases of pancreatic serous cystadenoma : wait for symptoms and see at imaging or vice versa? World J Surg 27 : 319-323, 2003.
PubMed
5) Tseng JF, Warshaw AL, Sahani DV, et al : Serous cystadenoma of the pancreas : tumor growth rates and recommendations for treatment. Ann Surg 242 : 413-419 ; discussion 419-421, 2005.
 
6) Galanis C, Zamani A, Cameron JL, et al : Resected serous cystic neoplasms of the pancreas : a review of 158 patients with recommendations for treatment. J Gastrointest Surg 11 : 820-826, 2007.
PubMed
7) Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al : 851 resected cystic tumors of the pancreas : a 33-year experience at the Massachusetts General Hospital. Surgery 152 (3 Suppl 1) : S4-12, 2012.
 
8) Kimura W, Moriya T, Hirai I, et al : Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas 41 : 380-387, 2012.
PubMed
9) Marchegiani G, Caravati A, Andrianello S, et al : Serous Cystic Neoplasms of the Pancreas Management in the Real-world : Still Operating on a Benign Entity. Ann Surg 276 : e868-e875, 2022.
PubMed
10) Kang JS, Kim HJ, Choi YJ, et al : Clinicoradiological features of resected serous cystic neoplasms according to morphological subtype and preoperative tentative diagnosis : can radiological characteristics distinguish serous cystic neoplasms from other lesions? Ann Surg Treat Res 98 : 247-253, 2020.
PubMed
11) Chen HY, Deng XY, Pan Y, et al : Pancreatic Serous Cystic Neoplasms and Mucinous Cystic Neoplasms : Differential Diagnosis by Combining Imaging Features and Enhanced CT Texture Analysis. Front Oncol 11 : 745001, 2021.
PubMed
12) 木村理, 森谷敏幸, 花田敬士, ほか : 膵漿液性嚢胞腫瘍 (Serous cystic neoplasm) の全国症例調査-日本膵臓学会膵嚢胞性腫瘍委員会-. 膵臓 27 : 572-583, 2012.
Medical*Online
13) Testini M, Gurrado A, Lissidini G, et al : Management of mucinous cystic neoplasms of the pancreas. World J Gastroenterol 16 : 5682-5692, 2010.
PubMed
14) Charlesworth M, Verbeke CS, Falk GA, et al : Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg 16 : 1422-1428, 2012.
PubMed
15) Choi JY, Kim MJ, Lee JY, et al : Typical and atypical manifestations of serous cystadenoma of the pancreas : imaging findings with pathologic correlation. AJR Am J Roentgenol 193 : 136-142, 2009.
PubMed
16) Hu F, Hu Y, Wang D, et al : Cystic Neoplasms of the Pancreas : Differential Diagnosis and Radiology Correlation. Front Oncol 12 : 860740, 2022.
 
17) Lee SE, Kwon Y, Jang JY, et al : The morphological classification of a serous cystic tumor (SCT) of the pancreas and evaluation of the preoperative diagnostic accuracy of computed tomography. Ann Surg Oncol 15 : 2089-2095, 2008.
PubMed
18) 青木豪, 元井冬彦, 江川新一, ほか : 膵漿液性嚢胞腫瘍に対する治療選択. 胆と膵 33 : 679-684, 2012.
Medical*Online
19) Huh J, Byun JH, Hong SM, et al : Malignant pancreatic serous cystic neoplasms : systematic review with a new case. BMC Gastroenterol 16 : 97, 2016.
PubMed
20) Kakeji Y, Takahashi A, Hasegawa H, et al : Surgical outcomes in gastroenterological surgery in Japan : Report of the National Clinical Database 2011-2018. Ann Gastroenterol Surg 4 : 250-274, 2020.
PubMed
P.364 掲載の参考文献
1) Frantz VK : Tumors of the pancreas. Atlas of Tumor Pathology, 1st Series, Fascicles 27 and 28, p32-33, Armed Forces Institute of Pathology, Washington DC, 1959.
 
2) Hanada K, Kurihara K, Itoi T, et al : Clinical and pathological features of solid pseudopapillary neoplasms of the pancreas. A nationwide multicenter study in Japan. Pancreas 47 : 1019-1026, 2018.
PubMed
3) Liu M, Liu J, Hu Q, et al : Management of solid pseudopapillary neoplasms of pancreas : A single center experience of 243 consecutive patients. Pancreatology 19 : 681-685, 2019.
 
4) Estrella JS, Li L, Rashid A, et al : Solid pseudopapillary neoplasm of the pancreas : Clinicopathologic and survival analyses of 64 cases from a single institution. Am J Surg Pathol 38 : 147-157, 2014.
PubMed
5) Song H, Dong M, Zhou J, et al : Solid pseudopapillary neoplasm of the pancreas : Clinicopathologic feature, risk factors of malignancy, and survival analysis of 53 cases from a single center. Biomed Res Int 2017 : 5465261, 2017.
 
6) 蒲田敏文, 松井修, 太田哲生, ほか : SPNの画像-CT, MRI所見を中心に. 肝胆膵画像 11 : 381-385, 2009.
 
7) Romics L Jr, Olah A, Belagyi T, et al : Solid pseudopapillary neoplasm of the pancreas-proposed algorithms for diagnosis and surgical treatment. Langenbecks Arch Surg 395 : 747-755, 2010.
PubMed
8) 柳澤昭夫, 安川覚, 佐々木恵子 : SPNの病理. 肝胆膵画像 11 : 373-379, 2009.
 
9) Lee JH, Yu JS, Kim H, et al : Solid pseudopapillary carcinoma of the pancreas : differentiation from benign solid pseudopapillary tumour using CT and MRI. Clin Radiol 63 : 1006-1014, 2008.
PubMed
10) Chung YE, Kim MJ, Choi JY, et al : Differentiation of benign and malignant solid pseudopapillary neoplasms of the pancreas. J Comput Assist Tomogr 33 : 689-694, 2009.
PubMed
11) Wang DB, Wang QB, Chai WM, et al : Imaging features of solid pseudopapillary tumor of the pancreas on multi-detector row computed tomography. World J Gastroenterol 15 : 829-835, 2009.
PubMed
12) Yu PF, Hu ZH, Wang XB, et al : Solid pseudopapillary tumor of the pancreas : a review of 553 cases in Chinese literature. World J Gastroenterol 16 : 1209-1214, 2010.
PubMed
13) Kang CM, Choi SH, Kim SC, et al : Predicting recurrence of pancreatic solid pseudopapillary tumors after surgical resection : a multicenter analysis in Korea. Ann Surg 260 : 348-355, 2014.
PubMed
14) Yang F, Jin C, Long J, et al : Solid pseudopapillary tumor of the pancreas : a case series of 26 consecutive patients. Am J Surg 198 : 210-215, 2009.
 
15) Lee SE, Jang JY, Hwang DW, et al : Clinical features and outcome of solid pseudopapillary neoplasm : differences between adults and children. Arch Surg 143 : 1218-1221, 2008.
PubMed
16) Reddy S, Cameron JL, Scudiere J, et al : Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors) : a large single-institutional series. J Am Coll Surg 208 : 950-957, 2009.
PubMed
17) Morikawa T, Onogawa T, Maeda S, et al : Solid pseudopapillary neoplasms of the pancreas : an 18-year experience at a single Japanese Institution. Surg Today 43 : 26-32, 2013.
 
18) 間下直樹, 越川克己, 谷口健次, ほか : 20年の経過で局所再発を来した膵solid-pseudopapillary neoplasmの1切除例. 日本消化器外科学会雑誌 43 : 948-952, 2010.
 
P.369 掲載の参考文献
1) Kerr AA : Cysts and pseudocysts of the pancreas. Surg Gynecol Obstet 27 : 40-44, 1918.
 
2) 井上匡央, 奥村文浩, 水島隆史, ほか : 膵尾部dermoid cystの1例. 膵臓 29 : 756-762, 2014.
Medical*Online
3) 浦田孝広, 泉良寛, 竹熊与志, ほか : 膵dermoid cystの1例. 日本消化器病学会雑誌 109 : 1791-1798, 2012.
Medical*Online
4) 熊野正士, 津田孝治, 田中宏明, ほか : 膵の嚢胞性腫瘍. 臨床画像 22 : 1010-1018, 2006.
Medical*Online
5) 井村仁郎, 宮田完志, 湯浅典博, ほか : 膵内副脾に発生した類上皮嚢胞の1例. 胆と膵 34 : 257-262, 2013.
Medical*Online
6) 篠原芙美, 古川善也, 斎宏, ほか : 粘液性嚢胞腫瘍と鑑別困難であった膵内副脾に発生したepidermoid cystの1例-本邦既報54例との比較検討-. 日本消化器病学会雑誌 111 : 566-575, 2014.
Medical*Online
7) Omer WH, Narita A, Hosomichi K, et al : Genome-wide linkage and exome analyses identify variants of HMCN1 for splenic epidermoid cyst. BMC Med Genet 15 : 115, 2014.
PubMed
8) 白石治, 亀井敬子, 石川原, ほか : 膵内副脾epidermoid cystの1症例. 日本外科系連合学会誌 33 : 213-217, 2008.
 
9) Luchtrath H, Schriefers KH : [A pancreatic cyst with features of a so-called branchiogenic cyst]. Pathologe 6 : 217-219, 1985.
PubMed
10) Truong LD, Rangdaeng S, Jordan PH Jr : Lymphoepithelial cyst of the pancreas. Am J Surg Pathol 11 : 899-903, 1987.
PubMed
11) 松本祐介, 甲斐恭平, 山田隆年, ほか : 慢性膵炎にみられた膵リンパ上皮嚢胞 (Lymphoepithelial cyst) の1例. 日本臨床外科学会雑誌 69 : 1786-1790, 2008.
 
12) 加茂田泰久, 藤野泰宏, 上田隆, ほか : 術前診断しえた膵lymphoepithelial cyst の1例. 膵臓 22 : 123-129, 2007.
Medical*Online
13) 佐々木翔, 末吉伸行, 山岡優子, ほか : 4年2カ月の経過で増大した膵リンパ上皮嚢胞の1例. 日本消化器病学会雑誌 111 : 326-333, 2014.
 
14) Ahlawat SK : Lymphoepithelial cyst of pancreas. Role of endoscopic ultrasound guided fine needle aspiration. JOP 9 : 230-234, 2008.
PubMed
15) Hirooka Y, Goto H, Itoh A, et al : Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. J Gastroenterol Hepatol 18 : 1323-1324, 2003.
PubMed
P.372 掲載の参考文献
1) Metz DC, Jensen RT : Gastrointestinal neuroendocrine tumors : pancreatic endocrine tumors. Gastroenterology 135 : 1469-1492, 2008.
PubMed
2) Yao JC, Hassan M, Phan A, et al : One hundred years after "carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 : 3063-3072, 2008.
PubMed
3) Modlin IM, Oberg K, Chung DC, et al : Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9 : 61-72, 2008.
PubMed
4) Ito T, Igarashi H, Jensen RT : Therapy of metastatic pancreatic neuroendocrine tumors (pNETs) : recent insights and advances. J Gastroenterol 47 : 941-960, 2012.
PubMed
5) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
6) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
7) Masui T, Ito T, Komoto I, et al : Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan. Int J Clin Oncol 27 : 840-849, 2022.
PubMed
8) 増井俊彦 : 膵神経内分泌腫瘍の疫学. 肝胆膵 84 : 717-724, 2022.
Medical*Online
P.379 掲載の参考文献
1) Williams ED, Siebenmann RE, Sobin LH, et al : WHO International Histological Classification of Tumours ; Histological Typing of Endocrine Tumours, World Health Organization, Geneva, 1980.
 
2) Jass JR, Sobin LH : WHO International Histological Classification of Tumours ; Histological Typing of Intestinal Tumours, 2nd ed, Springer-Verlag, Tokyo, 1976.
 
3) WHO Classification of Tumours, 3rd ed, Vol 2, Pathology and Genetics of Tumours of the Digestive System (ed by Hamilton SR, Aaltonen LA), IARC, Lyon, 2000.
 
4) WHO Classification of Tumours, 3rd ed, Vol 8, Pathology and Genetics of Tumours of Endocrine Organs (ed by DeLellis RA, Lloyd RV, Heitz PU, et al), IARC, Lyon, 2004.
 
5) TNM Classification of Malignant Tumours, 7th ed (ed by Sobin LH, Gospodarowicz MK, Wittekind Ch), Wiley-Blackwell, Oxford, 2009.
 
6) Rindi G, Kloppel G, Couvelard A, et al : TNM staging of midgut and hindgut (neuro) endocrine tumors : a consensus proposal including a grading system. Virchows Arch 451 : 757-762, 2007.
PubMed
7) WHO Classification of Tumours, 4th ed, Vol 3, WHO Classification of Tumours of the Digestive System (ed by Bosman FT, Carneiro F, Hruban RH, et al), IARC, Lyon, 2010.
 
8) Yachida S, Vakiani E, White CM, et al : Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36 : 173-184, 2012.
PubMed
9) Tang LH, Untch BR, Reidy DL, et al : Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component : A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res 22 : 1011-1017, 2016.
PubMed
10) WHO Classification of Tumours, 4th ed, Vol 10, WHO Classification of Tumours of Endocrine Organs (ed by Lloyd RV, Osamura RY, Kloppel G, et al), IARC, Lyon, 2017.
 
11) WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), IARC, Lyon, 2019.
 
12) 膵・消化管神経内分泌腫瘍 (NEN) 診療ガイドライン 2019年 [第2版] (日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン第2版作成委員会編), 金原出版, 2019.
 
13) Kloppel G, La Rosa S : Ki67 labeling index : assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 472 : 341-349, 2018.
PubMed
14) Konukiewitz B, Schlitter AM, Jesinghaus M, et al : Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol 30 : 587-598, 2017.
PubMed
P.387 掲載の参考文献
1) 土井隆一郎, 上本伸二, 塚田俊彦 : 多発性内分泌腺腫症1型に発生する膵島腫瘍の診断と手術法に関する新たな展開. 外科 68 : 808-814, 2006.
 
2) Alrezk R, Hannah-Shmouni F, Stratakis CA : MEN4 and CDKN1B mutations : the latest of the MEN syndromes. Endocr Relat Cancer 24 : T195-T208, 2017.
PubMed
3) Wohllk N, Schweizer H, Erlic Z, et al : Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab 24 : 371-387, 2010.
PubMed
4) McDonnell JE, Gild ML, Clifton-Bligh RJ, et al : Multiple endocrine neoplasia : an update. Intern Med J 49 : 954-961, 2019.
PubMed
5) Moline J, Eng C : Multiple endocrine neoplasia type 2 : an overview. Genet Med 13 : 755-764, 2011.
PubMed
6) Geslot A, Vialon M, Caron P, et al : New therapies for patients with multiple endocrine neoplasia type 1. Ann Endocrinol (Paris) 82 : 112-120, 2021.
PubMed
7) Machens A, Schaaf L, Karges W, et al : Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1) : a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67 : 613-622, 2007.
PubMed
8) Niederle B, Selberherr A, Bartsch DK, et al : Multiple Endocrine Neoplasia Type 1 and the Pancreas : Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology 111 : 609-630, 2021.
PubMed
9) Brandi ML, Gagel RF, Angeli A, et al : Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 : 5658-5671, 2001.
PubMed
10) Vialon M, Desailloud R, Caron P : La neoplasie endocrinienne multiple de type 1 : mise au point apres le congres de l'ENETS 2019 : Multiple Endocrine Neoplasia Type 1 : Development after the ENETS 2019 Congress. Ann Endocrinol (Paris) 80 (Suppl 1) : S19-S28, 2019.
 
11) Oberg K, Eriksson B : Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 : 753-781, 2005.
 
12) Plockinger U, Rindi G, Arnold R, et al : Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 : 394-424, 2004.
 
13) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
14) Gibril F, Schumann M, Pace A, et al : Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome : a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 83 : 43-83, 2004.
PubMed
15) Trump D, Farren B, Wooding C, et al : Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89 : 653-669, 1996.
PubMed
16) Sakurai A, Yamazaki M, Suzuki S, et al : Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1 : analysis of the database of the MEN Consortium of Japan. Endocr J 59 : 859-866, 2012.
PubMed
17) Goudet P, Murat A, Binquet C, et al : Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34 : 249-255, 2010.
 
18) 土井隆一郎 : 膵内分泌腫瘍. 消化器外科 31 : 1141-1152, 2008.
 
19) 土井隆一郎 : 神経内分泌腫瘍. 消化器外科 34 : 1239-1246, 2011.
 
20) Sakurai A, Suzuki S, Kosugi S, et al : Multiple endocrine neoplasia type 1 in Japan : establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 76 : 533-539, 2012.
PubMed
21) Plockinger U, Wiedenmann B, de Herder WW : ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. Neuroendocrinology 90 : 159-161, 2009.
PubMed
22) Schaefer S, Shipotko M, Meyer S, et al : Natural course of small adrenal lesions in multiple endocrine neoplasia type 1 : an endoscopic ultrasound imaging study. Eur J Endocrinol 158 : 699-704, 2008.
PubMed
23) Bartsch DK, Fendrich V, Langer P, et al : Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242 : 757-766, 2005.
PubMed
24) Fraker DL, Norton JA, Alexander HR, et al : Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 220 : 320-330, 1994.
PubMed
25) Norton JA, Fraker DL, Alexander HR, et al : Surgery increases survival in patients with gastrinoma. Ann Surg 244 : 410-419, 2006.
PubMed
26) Imamura M, Komoto I, Ota S, et al : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 17 : 1343-1353, 2011.
PubMed
27) Gibril F, Venzon DJ, Ojeaburu JV, et al : Prospective study of the natural history of gastrinoma in patients with MEN1 : definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86 : 5282-5293, 2001.
 
28) Jethwa P, Sodergren M, Lala A, et al : Diabetic control after total pancreatectomy. Dig Liver Dis 38 : 415-419, 2006.
PubMed
29) Steinmuller T, Kianmanesh R, Falconi M, et al : Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors : foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 : 47-62, 2008.
PubMed
30) Tham E, Grandell U, Lindgren E, et al : Clinical testing for mutations in the MEN1 gene in Sweden : a report on 200 unrelated cases. J Clin Endocrinol Metab 92 : 3389-3395, 2007.
 
P.395 掲載の参考文献
1) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
2) de Herder WW, Niederle B, Scoazec JY, et al : Well-differentiated pancreatic tumor/carcinoma : insulinoma. Neuroendocrinology 84 : 183-188, 2006.
PubMed
3) Kurakawa KI, Okada A, Manaka K, et al : Clinical characteristics and incidences of benign and malignant insulinoma using a national inpatient database in Japan. J Clin Endocrinol Metab 106 : 3477-3486, 2021.
PubMed
4) Falconi M, Eriksson B, Kaltsas G, et al : ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 103 : 153-171, 2016.
PubMed
5) Sakurai A, Yamazaki M, Suzuki S, et al : Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1 : analysis of the database of the MEN Consortium of Japan. Endocr J 59 : 859-866, 2012.
PubMed
6) 都築義和, 石井裕正 : インスリノーマ-本邦の1991-2000年における358例の臨床統計的観察-. 日本臨牀59 (本邦臨床統計集 (2)) : 121-131, 2001.
 
7) 膵・消化管神経内分泌腫瘍 (NEN) 診療ガイドライン 2019年 [第2版] (日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン第2版作成委員会編), 金原出版, 2019.
 
8) Placzkowski KA, Vella A, Thompson GB, et al : Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 94 : 1069-1073, 2009.
 
9) Torimoto K, Okada Y, Tanaka Y, et al : Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. Endocr J 67 : 509-513, 2020.
PubMed
10) Service FJ : Hypoglycemic disorders. N Engl J Med 332 : 1144-1152, 1995.
PubMed
11) Ueda K, Kawabe K, Lee L, et al : Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma. Pancreas 46 : 476-481, 2017.
PubMed
12) Gouya H, Vignaux O, Augui J, et al : CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181 : 987-992, 2003.
 
13) Grant CS, van Heerden J, Charboneau JW, et al : Insulinoma. The value of intraoperative ultrasonography. Arch Surg 123 : 843-848, 1988.
PubMed
14) Noone TC, Hosey J, Firat Z, et al : Imaging and localization of islet-cell tumors of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 19 : 195-211, 2005.
 
15) Imamura M : Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 16 : 4519-4525, 2010.
PubMed
16) Doppman JL, Miller DL, Chang R, et al : Insulinomas : localization with selective intraarterial injection of calcium. Radiology 178 : 237-241, 1991.
PubMed
17) Oberg K, Kvols L, Caplin M, et al : Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 : 966-973, 2004.
PubMed
18) Christ E, Wild D, Ederer S, et al : Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas : a prospective multicentre imaging study. Lancet Diabetes Endocrinol 1 : 115-122, 2013.
PubMed
19) Service FJ, McMahon MM, O'Brien PC, et al : Functioning insulinoma--incidence, recurrence, and long-term survival of patients : a 60-year study. Mayo Clin Proc 66 : 711-719, 1991.
PubMed
20) Sada A, Glasgow AE, Vella A, et al : Malignant Insulinoma : A Rare Form of Neuroendocrine Tumor. World J Surg 44 : 2288-2294, 2020.
PubMed
P.403 掲載の参考文献
1) Becker SW, Kahn D, Rothman S : Cutaneous Manifestations of internal malignant tumors. Arch Dermatol Syphilol 45 : 1069-1080, 1942.
 
2) McGavran MH, Unger RH, Recant L, et al : A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med 274 : 1408-1413, 1966.
PubMed
3) Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, et al : The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med 10 : 1141-1151, 2016.
PubMed
4) Ito T, Igarashi H, Jensen RT : Pancreatic neuroendocrine tumors : clinical features, diagnosis and medical treatment : advances. Best Pract Res Clin Gastroenterol 26 : 737-753, 2012.
PubMed
5) Croughs RJ, Hulsmans HA, Israel DE, et al : Glucagonoma as part of the polyglandular adenoma syndrome. Am J Med 52 : 690-698, 1972.
PubMed
6) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
7) Doi R, Komoto I, Nakamura Y, et al : Pancreatic endocrine tumor in Japan. Pancreas 28 : 247-252, 2004.
PubMed
8) Jensen RT, Cadiot G, Brandi ML, et al : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95 : 98-119, 2012.
PubMed
9) Roggli VL, Judge DM, McGavran MH : Duodenal glucagonoma : a case report. Hum Pathol 10 : 350-353, 1979.
PubMed
10) Hunstein W, Trumper LH, Dummer R, et al : Glucagonoma syndrome and bronchial carcinoma. Ann Intern Med 109 : 920-921, 1988.
PubMed
11) Guillausseau PJ, Guillausseau C, Villet R, et al : [Glucagonomas. Clinical, biological, anatomopathological and therapeutic aspects (general review of 130 cases]. Gastroenterol Clin Biol 6 : 1029-1041, 1982.
PubMed
12) Zandee WT, Hofland J, de Herder WW : Glucagonoma Syndrome. In : Endotext [Internet] (ed by Feingold KR, Anawalt B, Boyce A, et al), MDText, South Dartmouth, Last Update : November 5, 2000.
 
13) Wilkinson DS : Necrolytic migratory erythema with pancreatic carcinoma. Proc R Soc Med 64 : 1197-1198, 1971.
PubMed
14) Kindmark H, Sundin A, Granberg D, et al : Endocrine pancreatic tumors with glucagon hypersecretion : a retrospective study of 23 cases during 20 years. Med Oncol 24 : 330-337, 2007.
PubMed
15) Ro C, Chai W, Yu VE, et al : Pancreatic neuroendocrine tumors : biology, diagnosis,and treatment. Chin J Cancer 32 : 312-324, 2013.
 
16) Li H, Zhao L, Singh R, et al : The first pediatric case of glucagon receptor defect due to biallelic mutations in GCGR is identified by newborn screening of elevated arginine. Mol Genet Metab Rep 17 : 46-52, 2018.
 
17) Grozinsky-Glasberg S, Shimon I, Korbonits M, et al : Somatostatin analogues in the control of neuroendocrine tumours : efficacy and mechanisms. Endocr Relat Cancer 15 : 701-720, 2008.
PubMed
18) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 27 : 4656-4663, 2009.
 
19) Caplin ME, Pavel M, Ruszniewski P : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 : 1556-1557, 2014.
PubMed
20) Partelli S, Bartsch DK, Capdevila J, et al : ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours : Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology 105 : 255-265, 2017.
PubMed
21) McEntee GP, Nagorney DM, Kvols LK, et al : Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 : 1091-1096, 1990.
PubMed
22) King J, Quinn R, Glenn DM, et al : Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 : 921-929, 2008.
PubMed
23) Fjallskog ML, Granberg DP, Welin SL, et al : Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 : 1101-1107, 2001.
PubMed
24) Kulke MH, Wu B, Ryan DP, et al : A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51 : 1033-1038, 2006.
PubMed
25) Wynick D, Williams SJ, Bloom SR : Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319 : 605-607, 1988.
PubMed
P.407 掲載の参考文献
1) WHO Classification of Tumours, 4th ed, Vol 10, WHO Classification of Tumours of Endocrine Organs (ed by Lloyd RV, Osamura RY, Kloppel G, et al), IARC, Lyon, 2017.
 
2) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
3) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
4) 膵・消化管神経内分泌腫瘍 (NEN) 診療ガイドライン 2019年 [第2版] (日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン第2版作成委員会編), 金原出版, 2019.
 
5) Fraker DL, Norton JA, Alexander HR, et al : Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 220 : 320-330, 1994.
PubMed
6) Norton JA, Fraker DL, Alexander HR, et al : Surgery increases survival in patients with gastrinoma. Ann Surg 244 : 410-419, 2006.
PubMed
7) Bartsch DK, Fendrich V, Langer P, et al : Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242 : 757-766, 2005.
PubMed
8) Bartsch DK, Waldmann J, Fendrich V, et al : Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg 99 : 1234-1240, 2012.
PubMed
9) Giovinazzo F, Butturini G, Monsellato D, et al : Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg 65 : 19-24, 2013.
 
10) Norton JA, Alexander HR, Fraker DL, et al : Possible primary lymph node gastrinoma : occurrence, natural history, and predictive factors : a prospective study. Ann Surg 237 : 650-659, 2003.
PubMed
P.410 掲載の参考文献
1) Oberndorfer S : Karzinoide Tumoren des Dunndarmes. Frankfurt Z Pathol 1 : 426-429, 1907.
 
2) La Rosa S, Basturk O, Hong SM, et al : Serotonin-producing tumours with and without carcinoid syndrome. In : WHO Classification of Tumours online, Endcrine and Neuroendocrine Tumours (5th ed). //Neuroendocrine pancreas//Neuroendocrine neoplasms//Neuroendocrine tumours. [https://tumourclassification.iarc.who.int/chaptercontent/53/82] (2022年12月閲覧)
 
3) Modlin IM, Lye KD, Kidd M : A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 : 934-959, 2003.
PubMed
4) La Rosa S, Franzi F, Albarello L, et al : Serotonin-producing enterochromaffin cell tumors of the pancreas : clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors. Pancreas 40 : 883-895, 2011.
PubMed
5) Zavras N, Schizas D, Machairas N, et al : Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases : A case report and literature review. Oncol Lett 13 : 2373-2376, 2017.
PubMed
6) Mao C, El Attar A, Domenico DR, et al : Carcinoid tumors of the pancreas. Status report based on two cases and review of the world's literature. Int J Pancreatol 23 : 153-164, 1998.
PubMed
7) Puli SR, Kalva N, Bechtold ML, et al : Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors : a systematic review and meta analysis. World J Gastroenterol 19 : 3678-3684, 2013.
 
8) Falconi M, Eriksson B, Kaltsas G, et al : ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 103 : 153-171, 2016.
PubMed
9) Rubin J, Ajani J, Schirmer W, et al : Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17 : 600-606, 1999.
PubMed
10) Vinik AI, Wolin EM, Liyanage N, et al : Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect) : A Randomized, Double-Blind, Placebo-Controlled Trial. Endocr Pract 22 : 1068-1080, 2016.
PubMed
P.415 掲載の参考文献
1) WHO Classification of Tumours, 4th ed, Vol 10, WHO Classification of Tumours of Endocrine Organs (ed by Lloyd RV, Osamura RY, Kloppel G, et al), IARC, Lyon, 2017.
 
2) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
3) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
4) Masui T, Ito T, Komoto I, et al : JNETS Project Study Group : Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan : a population-based study. BMC Cancer 20 : 1104, 2020.
 
5) Jutric Z, Grendar J, Hoen HM, et al : Regional Metastatic Behavior of Nonfunctional Pancreatic Neuroendocrine Tumors : Impact of Lymph Node Positivity on Survival. Pancreas 46 : 898-903, 2017.
PubMed
6) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 : 224-233, 2014.
PubMed
7) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 501-513, 2011.
PubMed
8) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 : 514-523, 2011.
PubMed
9) Xu J, Shen L, Bai C, et al : Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p) : a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21 : 1489-1499, 2020.
 
P.421 掲載の参考文献
1) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
2) Maekawa A, Kudo A, Kishino M, et al : Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms : a novel therapeutic strategy. J Cancer Res Clin Oncol 148 : 697-706, 2022.
PubMed
3) Blansfield JA, Choyke L, Morita SY, et al : Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142 : 814-818 ; discussion 818.e1-2, 2007.
 
4) Mizuno Y, Kudo A, Akashi T, et al : Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 144 : 1155-1163, 2018.
 
5) Liu B, Kudo A, Kinowaki Y, et al : A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. J Gastroenterol 54 : 819-828, 2019.
 
6) Katsuta E, Kudo A, Akashi T, et al : Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. J Cancer Res Clin Oncol 142 : 1299-1306, 2016.
PubMed
7) Oba A, Kudo A, Akahoshi K, et al : A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors. J Gastroenterol 52 : 1140-1146, 2017.
PubMed
8) Kato T, Kudo A, Kinowaki Y, et al : A novel classification of portal venous tumor invasion to predict residual tumor status after surgery in patients with pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 148 : 931-941, 2022.
PubMed
9) Kudo A, Akahoshi K, Ito S, et al : Downregulated Pancreatic Beta Cell Genes Indicate Poor Prognosis in Patients With Pancreatic Neuroendocrine Neoplasms. Ann Surg 271 : 732-739, 2020.
PubMed
10) Fairweather M, Swanson R, Wang J, et al : Management of Neuroendocrine Tumor Liver Metastases : Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol 24 : 2319-2325, 2017.
PubMed
11) Asano D, Kudo A, Akahoshi K, et al : Curative Surgery and Ki-67 Value Rather than Tumor Differentiation Predict the Survival of Patients with High-grade Neuroendocrine Neoplasms. Ann Surg 276 : e108-e113, 2022.
PubMed
12) Murase Y, Kudo A, Akahoshi K, et al : Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms. Ann Gastroenterol Surg 5 : 692-700, 2021.
PubMed
13) Matsui S, Kudo A, Ogura T, et al : Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms? J Cancer Res Clin Oncol 145 : 2097-2104, 2019.
PubMed
14) Ono H, Kudo A, Akahoshi K, et al : Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 146 : 793-799, 2020.
PubMed
15) Kudo A, Tateishi U, Yoshimura R, et al : Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci 29 : 487-499, 2022.
 
P.429 掲載の参考文献
1) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 : 224-233, 2014.
PubMed
2) Ito T, Honma Y, Hijioka S, et al : Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 35 : 499-508, 2017.
PubMed
3) Caplin ME, Pavel M, Phan AT, et al : Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours : final results of the CLARINET open-label extension study. Endocrin 71 : 502-513, 2021.
 
4) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 501-513, 2011.
PubMed
5) Faivre S, Niccoli P, Castellano D, et al : Sunitinib in pancreatic neuroendocrine tumors : updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 28 : 339-343, 2017.
PubMed
6) Hijioka S, Hosoda W, Morizane C, et al : The diagnosis and treatment of pancreatic NEN-G3-a focus on clinicopathological difference of NET-G3 and NEC G3. JOP S 3 : 346-353, 2018.
 
7) Mizuno Y, Kudo A, Akashi T, et al : Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 144 : 1155-1163, 2018.
 
8) Kulke MH, Siu LL, Tepper JE, et al : Future directions in the treatment of neuroendocrine tumors : consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 : 934-943, 2011.
PubMed
9) Prakash L, Bhosale P, Cloyd J, et al : Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 21 : 155-163, 2017.
PubMed
10) Xu J, Shen L, Bai C, et al : Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p) : a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21 : 1489-1499, 2020.
 
11) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 : 519-523, 1992.
PubMed
12) Komoto I, Kokudo N, Aoki T, et al : Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Jpn J Clin Oncol 52 : 708-716, 2022.
PubMed
13) Shibuya H, Hijioka S, Sakamoto Y, et al : Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan : focus on weekly regimens and monotherapy. Cancer Chemother Pharmacol 82 : 661-668, 2018.
PubMed
14) Kunz PL, Catalano PJ, Nimeiri H, et al : A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors : a trial of the ECOGACRIN Cancer Research Group (E2211). J Clin Oncol 36 (15 Suppl) : Abstract 4004, 2018.
PubMed
15) Raj N, Valentino E, Capanu M, et al : Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology : Well Differentiated Versus Poorly Differentiated. Pancreas 46 : 296-301, 2017.
PubMed
16) Ikeda M, Okuyama H, Takahashi H, et al : Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. J Hepatobiliary Pancreat Sci 22 : 623-627, 2015.
PubMed
17) Morizane C, Machida N, Honma Y, et al : Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System : The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol 8 : 1447-1455, 2022.
PubMed
18) Hijioka S, Hosoda W, Matsuo K, et al : Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3 : A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res 23 : 4625-4632, 2017.
 
19) Tanaka H, Hijioka S, Hosoda W, et al : Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology 20 : 1421-1427, 2020.
 
20) Yachida S, Totoki Y, Noe M, et al : Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. Cancer Discov 12 : 692-711, 2022.
PubMed
21) Kim ST, Ha SY, Lee S, et al : The Impact of PD-L1 Expression in Patients with Metastatic GEPNETs. J Cancer 7 : 484-489, 2016.
PubMed
22) Puccini A, Poorman K, Salem ME, et al : Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clin Cancer Res 26 : 5943-5951, 2020.
PubMed
23) Cavalcanti E, Armentano R, Valentini AM, et al : Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis 8 : e3004, 2017.
PubMed
24) da Silva A, Bowden M, Zhang S, et al : Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas 47 : 1123-1129, 2018.
PubMed
25) Halperin DM, Liu S, Dasari A, et al : A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). J Clin Oncol 38 (4 Suppl) : Abstract 619, 2020.
 
26) Marabelle A, Fakih M, Lopez J, et al : Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21 : 1353-1365, 2020.
PubMed
27) Borga C, Businello G, Murgioni S, et al : Treatment personalization in gastrointestinal neuroendocrine tumors. Curr Treat Options Oncol 22 : 29, 2021.
PubMed
28) Hijioka S, Morizane C, Ikeda M, et al : Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 51 : 1185-1196, 2021.
PubMed
29) Shimoyama R, Hijioka S, Mizuno N, et al : Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors ; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology 20 : 1183-1188, 2020.
PubMed
P.437 掲載の参考文献
1) Imhof A, Brunner P, Marincek N, et al : Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA] -TOC in metastasized neuroendocrine cancers. J Clin Oncol 29 : 2416-2423, 2011.
PubMed
2) van der Zwan WA, Bodei L, Mueller-Brand J, et al : GEPNETs update : Radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol 172 : R1-R8, 2015.
PubMed
3) Kwekkeboom DJ, Krenning EP : Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 30 : 179-191, 2016.
PubMed
4) Esser JP, Krenning EP, Teunissen JJ, et al : Comparison of [177Lu-DOTA0,Tyr3] octreotate and [177Lu-DOTA0,Tyr3] octreotide : which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 33 : 1346-1351, 2006.
PubMed
5) Strosberg J, El-Haddad G, Wolin E, et al : Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376 : 125-135, 2017.
PubMed
6) Strosberg JR, Caplin ME, Kunz PL, et al : 177Lu-Dotatate plus long-acting octreotide versus high dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1) : final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22 : 1752-1763, 2021.
PubMed
7) Satapathy S, Mittal BR : 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors : a systematic review and meta-analysis. Nucl Med Commun 40 : 1195-1203, 2019.
PubMed
8) Camus B, Cottereau AS, Palmieri LJ, et al : Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors : An Updated Review. J Clin Med 10 : 1267, 2021.
PubMed
9) Pavel M, Oberg K, Falconi M, et al : Gastroenteropancreatic neuroendocrine neoplasms : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31 : 844-860, 2020.
PubMed
10) Zhang J, Kulkarni HR, Singh A, et al : Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms : Safety and Survival Analysis in 69 Patients. J Nucl Med 60 : 377-385, 2019.
PubMed
11) Kobayashi N, Takano S, Ito K, et al : Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0,Tyr3 -octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Ann Nucl Med 35 : 1332-1341, 2021.
PubMed
12) Kudo A, Tateishi U, Yoshimura R, et al : Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci 29 : 487-499, 2022.
 
13) Bodei L, Schoder H, Baum RP, et al : Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol 21 : e431-e443, 2020.
PubMed
14) Mittra ES : Neuroendocrine Tumor Therapy : 177Lu-DOTATATE. AJR Am J Roentgenol 211 : 278-285, 2018.
PubMed
15) Cremonesi M, Ferrari ME, Bodei L, et al : Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 45 : 2426-2441, 2018.
PubMed
16) van Vliet EI, van Eijck CH, de Krijger RR, et al : Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3] Octreotate. J Nucl Med 56 : 1647-1653, 2015.
PubMed
17) Carlsen EA, Fazio N, Granberg D, et al : Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3 : a multicenter cohort study. Endocr Relat Cancer 26 : 227-239, 2019.
 
18) Sorbye H, Kong G, Grozinsky-Glasberg S : PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer 27 : R67-R77, 2020.
 
19) Ostwal V, Basu S, Bhargava P, et al : Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms : Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake. Neuroendocrinology 111 : 998-1004, 2021.
PubMed
20) Chan HS, Konijnenberg MW, Daniels T, et al : Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pretreated with L-lysine. EJNMMI Res 6 : 83, 2016.
 
21) Chan HS, de Blois E, Konijnenberg MW, et al : Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy. EJNMMI Radiopharm Chem 1 : 9, 2017.
PubMed
22) Navalkissoor S, Grossman A : Targeted Alpha Particle Therapy for Neuroendocrine Tumours : The Next Generation of Peptide Receptor Radionuclide Therapy. Neuroendocrinology 108 : 256-264, 2019.
PubMed
23) Yordanova A, Ahmadzadehfar H : Combination Therapies with PRRT. Pharmaceuticals (Basel) 14 : 1005, 2021.
PubMed
P.443 掲載の参考文献
1) Nakamura E, Shimizu M, Itoh T, et al : Secondary tumors of the pancreas : clinicopathological study of 103 autopsy cases of Japanese patients. Pathol Int 51 : 686-690, 2001.
PubMed
2) Adsay NV, Andea A, Basturk O, et al : Secondary tumors of the pancreas : an analysis of a surgical and autopsy database and review of the literature. Virchows Arch 444 : 527-535, 2004.
PubMed
3) Cubilla AL, Fitzgerald PJ : Cancer of the exocrine pancreas : the pathologic aspects. CA Cancer J Clin 35 : 2-18, 1985.
PubMed
4) Adler H, Redmond CE, Heneghan HM, et al : Pancreatectomy for metastatic disease : a systematic review. Eur J Surg Oncol 40 : 379-386, 2014.
PubMed
5) Reddy S, Wolfgang CL : The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 10 : 287-293, 2009.
 
6) Ahmed S, Johnson PT, Hruban R, et al : Metastatic disease to the pancreas : pathologic spectrum and CT patterns. Abdom Imaging 38 : 144-153, 2013.
 
7) Iwasa H, Murata Y, Nishimori M, et al : Pancreatic FDG uptake on follow-up PET/CT in patients with cancer. Oncol Lett 21 : 270, 2021.
PubMed
8) DeWitt J, Jowell P, Leblanc J, et al : EUS-guided FNA of pancreatic metastases : a multicenter experience. Gastrointest Endosc 61 : 689-696, 2005.
PubMed
9) Ardengh JC, Lopes CV, Kemp R, et al : Accuracy of endoscopic ultrasound-guided fine-needle aspiration in the suspicion of pancreatic metastases. BMC Gastroenterol 13 : 63, 2013.
PubMed
10) Bianchi M, Sun M, Jeldres C, et al : Distribution of metastatic sites in renal cell carcinoma : a population-based analysis. Ann Oncol 23 : 973-980, 2012.
PubMed
11) Shin TJ, Song C, Jeong CW, et al : Metastatic renal cell carcinoma to the pancreas : Clinical features and treatment outcome. J Surg Oncol 123 : 204-213, 2021.
 
12) Hoshino Y, Shinozaki H, Kimura Y, et al : Pancreatic metastases from renal cell carcinoma : a case report and literature review of the clinical and radiological characteristics. World J Surg Oncol 11 : 289, 2013.
PubMed
13) 腎癌診療ガイドライン [2017年版] (日本泌尿器科学会編), メディカルレビュー社, 2017.
 
14) Tanis PJ, van der Gaag NA, Busch OR, et al : Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96 : 579-592, 2009.
PubMed
15) 大腸癌治療ガイドライン医師用 [2019年版] (大腸癌研究会編), 金原出版, 2019.
 
16) Sperti C, Pasquali C, Berselli M, et al : Metastasis to the pancreas from colorectal cancer : is there a place for pancreatic resection? Dis Colon Rectum 52 : 1154-1159, 2009.
 
17) Lee CW, Wu RC, Hsu JT, et al : Isolated pancreatic metastasis from rectal cancer : a case report and review of literature. World J Surg Oncol 8 : 26, 2010.
PubMed
18) Tani R, Hori T, Yamada M, et al : Metachronous Pancreatic Metastasis from Rectal Cancer that Masqueraded as a Primary Pancreatic Cancer : A Rare and Difficult-to-Diagnose Metastatic Tumor in the Pancreas. Am J Case Rep 20 : 1781-1787, 2019.
PubMed
19) Sano I, Katanuma A, Yane K, et al : Pancreatic Metastasis from Rectal Cancer that was Diagnosed by Endoscopic Ultrasonography-guided Fine Needle Aspiration (EUS-FNA). Intern Med 56 : 301-305, 2017.
PubMed
20) Niu FY, Zhou Q, Yang JJ, et al : Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer 16 : 149, 2016.
PubMed
21) Maeno T, Satoh H, Ishikawa H, et al : Patterns of pancreatic metastasis from lung cancer. Anticancer Res 18 : 2881-2884, 1998.
PubMed
22) DeLuzio MR, Moores C, Dhamija A, et al : Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients-a systematic review. Pancreatology 15 : 456-462, 2015.
 
23) Jaen-Torrejimeno I, Lopez-Guerra D, Rojas-Holguin A, et al : Resection of isolated pancreatic metastases from pulmonary neoplasia : a systematic review. Updates Surg 74 : 1817-1825, 2022.
PubMed
24) 肺癌診療ガイドライン-悪性胸膜中皮腫・胸腺腫瘍含む- [2020年版] (日本肺癌学会編), 金原出版, 2021.
 
P.449 掲載の参考文献
1) Horie A, Yano Y, Kotoo Y, et al : Morphogenesis of pancreatoblastoma, infantile carcinoma of the pancreas : report of two cases. Cancer 39 : 247-254, 1977.
PubMed
2) WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), IARC, Lyon, 2019.
 
3) Morohoshi T, Sagawa F, Mitsuya T : Pancreatoblastoma with marked elevation of serum alphafetoprotein. An autopsy case report with immunocytochemical study. Virchows Arch A Pathol Anat Histopathol 416 : 265-270, 1990.
PubMed
4) Cingolani N, Shaco-Levy R, Farruggio A, et al : Alpha-fetoprotein production by pancreatic tumors exhibiting acinar cell differentiation : study of five cases, one arising in a mediastinal teratoma. Hum Pathol 31 : 938-944, 2000.
 
5) Cavallini A, Falconi M, Bortesi L, et al : Pancreatoblastoma in adults : a review of the literature. Pancreatology 9 : 73-80, 2009.
PubMed
6) Reggiani G, Affinita MC, Dall' Igna P, et al : Treatment Strategies for Children With Relapsed Pancreatoblastoma : A Literature Review. J Pediatr Hematol Oncol 43 : 288-293, 2021.
PubMed
7) Nakatani Y, Masudo K, Nozawa A, et al : Biotin-rich, optically clear nuclei express estrogen receptor-β : tumors with morules may develop under the influence of estrogen and aberrant β-catenin expression. Hum Pathol 35 : 869-874, 2004.
 
8) Thompson ED, Wood LD : Pancreatic Neoplasms With Acinar Differentiation : A Review of Pathologic and Molecular Features. Arch Pathol Lab Med 144 : 808-815, 2020.
PubMed
9) Abraham SC, Wu TT, Klimstra DS, et al : Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/β-catenin pathway and chromosome 11p. Am J Pathol 159 : 1619-1627, 2001.
 
10) Kerr NJ, Chun YH, Yun K, et al : Pancreatoblastoma is associated with chromosome 11p loss of heterozygosity and IGF2 overexpression. Med Pediatr Oncol 39 : 52-54, 2002.
PubMed
11) Isobe T, Seki M, Yoshida K, et al : Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. Cancer Res 78 : 865-876, 2018.
PubMed
12) Abraham SC, Wu TT, Hruban RH, et al : Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma : frequent allelic loss on chromosome 11p and alterations in the APC/β-catenin pathway. Am J Pathol 160 : 953-962, 2002.
 
13) Jiao Y, Yonescu R, Offerhaus GJ, et al : Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 232 : 428-435, 2014.
PubMed
14) Marchegiani G, Gareer H, Parisi A, et al : Pancreatic hepatoid carcinoma : a review of the literature. Dig Surg 30 : 425-433, 2013.
PubMed
15) Matsueda K, Yamamoto H, Yoshida Y, et al : Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP). J Gastroenterol 41 : 1011-1019, 2006.
PubMed
16) Hameed O, Xu H, Saddeghi S, et al : Hepatoid carcinoma of the pancreas : a case report and literature review of a heterogeneous group of tumors. Am J Surg Pathol 31 : 146-152, 2007.
PubMed
17) Askan G, Deshpande V, Klimstra DS, et al : Expression of Markers of Hepatocellular Differentiation in Pancreatic Acinar Cell Neoplasms : A Potential Diagnostic Pitfall. Am J Clin Pathol 146 : 163-169, 2016.
PubMed
18) Notohara K, Hamazaki S, Tsukayama C, et al : Solid-pseudopapillary tumor of the pancreas : immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol 24 : 1361-1371, 2000.
PubMed
19) Yang C, Sun L, Lai JZ, et al : Primary Hepatoid Carcinoma of the Pancreas : A Clinicopathological Study of 3 Cases With Review of Additional 31 Cases in the Literature. Int J Surg Pathol 27 : 28-42, 2019.
PubMed
20) Mattiolo P, Mafficini A, Lawlor RT, et al : "Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations : a new entity among solid pseudopapillary neoplasms. Virchows Arch 481 : 41-47, 2022.
PubMed
21) Wilentz RE, Goggins M, Redston M, et al : Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas : A newly described and characterized entity. Am J Pathol 156 : 1641-1651, 2000.
PubMed
22) Goggins M, Offerhaus GJ, Hilgers W, et al : Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 152 : 1501-1507, 1998.
PubMed
23) Banville N, Geraghty R, Fox E, et al : Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol 37 : 1498-1502, 2006.
 
24) Hu ZI, Shia J, Stadler ZK, et al : Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma : Challenges and Recommendations. Clin Cancer Res 24 : 1326-1336, 2018.
PubMed
P.453 掲載の参考文献
1) Liakakos T, Misiakos EP, Tsapralis D, et al : A role for surgery in primary pancreatic B-cell lymphoma : a case report. J Med Case Rep 2 : 167, 2008.
PubMed
2) Dawson IM, Cornes JS, Morson BC : Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 49 : 80-89, 1961.
PubMed
3) Nayer H, Weir EG, Sheth S, et al : Primary pancreatic lymphomas : a cytopathologic analysis of a rare malignancy. Cancer 102 : 315-321, 2004.
PubMed
4) Koca T, Aslan N, Dereci S, et al : Burkitt lymphoma with unusual presentation : Acute pancreatitis. Pediatr Int 57 : 775-777, 2015.
PubMed
5) Saif MW : Primary pancreatic lymphomas. JOP 7 : 262-273, 2006.
PubMed
6) 田中浩敬, 廣岡芳樹 : 画像診断における超音波診断技術と将来展望. 新医療 49 : 82-84, 2022.
 
7) Ishikawa T, Kawashima H, Ohno E, et al : Clinical Impact of EUS-Guided Fine Needle Biopsy Using a Novel Franseen Needle for Histological Assessment of Pancreatic Diseases. Can J Gastroenterol Hepatol 2019 : 8581743, 2019.
PubMed
8) 日本超音波医学会医用超音波診断基準に関する委員会 : 膵癌超音波診断基準. 超音波医学 19 : 553-557, 1992.
 
9) Kawa S, Kamisawa T, Notohara K, et al : Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018 : Revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011. Pancreas 49 : e13-e14, 2020.
PubMed
10) Grimison PS, Chin MT, Harrison ML, et al : Primary pancreatic lymphoma-pancreatic tumours that are potentially curable without resection, a retrospective review of four cases. BMC Cancer 6 : 117, 2006.
PubMed

III 特論

P.462 掲載の参考文献
1) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
2) 膵癌診療ガイドライン [2019年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2019.
 
3) Minds診療ガイドライン作成マニュアル 2020 (Minds診療ガイドライン作成マニュアル編集委員会編), 日本医療機能評価機構, 2021.
 
P.467 掲載の参考文献
1) Tanaka M, Chari S, Adsay V, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
2) Tanaka M, Fernandez-del Castillo C, Adsay V, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
3) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al : Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17 : 738-753, 2017.
PubMed
4) Park WG, Mascarenhas R, Palaez-Luna M, et al : Diagnostic performance of cyst fluid carcinoembryonic antigen and amylase in histologically confirmed pancreatic cysts. Pancreas 40 : 42-45, 2011.
PubMed
5) Cizginer S, Turner BG, Turner B, et al : Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas 40 : 1024-1028, 2011.
PubMed
6) Wu J, Matthaei H, Maitra A, et al : Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3 : 92ra66, 2011.
PubMed
7) Yoon WJ, Daglilar ES, Fernandez-del Castillo C, et al : Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration : the PIPE Study. Endoscopy 46 : 382-387, 2014.
PubMed
8) 渡邉雄介, 大塚隆生, 森泰寿, ほか : 分枝型IPMN の診療方針. 胆と膵 41 : 41-45, 2020.
Medical*Online
9) Kang JS, Park T, Han Y, et al : Clinical validation of the 2017 international consensus guidelines on intraductal papillary mucinous neoplasm of the pancreas. Ann Surg Treat Res 97 : 58-64, 2019.
PubMed
10) Hackert T, Fritz S, Klauss M, et al : Main-duct Intraductal Papillary Mucinous Neoplasm : High Cancer Risk in Duct Diameter of 5 to 9 mm. Ann Surg 262 : 875-880 ; discussion 880-881, 2015.
 
11) Kim TH, Song TJ, Lee SO, et al : Main duct and mixed type intraductal papillary mucinous neoplasms without enhancing mural nodules : Duct diameter of less than 10 mm and segmental dilatation of main pancreatic duct are findings support surveillance rather than immediate surgery. Pancreatology 19 : 1054-1060, 2019.
 
12) Basturk O, Chung SM, Hruban RH, et al : Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch 469 : 523-532, 2016.
PubMed
13) Omori Y, Ono Y, Tanino M, et al : Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Gastroenterology 156 : 647-661.e2, 2019.
 
14) Tamura K, Ohtsuka T, Date K, et al : Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers. Pancreas 45 : 826-835, 2016.
PubMed
15) European Study Group on Cystic Tumours of the Pancreas : European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67 : 789-804, 2018.
 
P.472 掲載の参考文献
1) Ito T, Tanaka M, Sasano H, et al : Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 42 : 497-500, 2007.
PubMed
2) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
3) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
4) 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン 2015年 [第1版] (日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編), 金原出版, 2015.
 
5) 膵・消化管神経内分泌腫瘍 (NEN) 診療ガイドライン 2019年 [第2版] (日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン第2版作成委員会編), 金原出版, 2019.
 
6) Ito T, Jensen RT : Molecular imaging in neuroendocrine tumors : recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes 24 : 15-24, 2017.
PubMed
7) WHO Classification of Tumours, 4th ed, Vol 10, WHO Classification of Tumours of Endocrine Organs (ed by Lloyd RV, Osamura RY, Kloppel G, et al), IARC Press, Lyon, 2017.
 
8) Gill AJ, Klimstra DS, Lam AK, et al : Tumours of the pancreas. In : WHO Classification of Tumours, 5th ed, Vol 1, Digestive System Tumours (ed by the WHO Classification of Tumours Editorial Board), p295-370, IARC, Lyon, 2019.
 
9) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 387 : 968-977, 2016.
 
10) Ito T, Honma Y, Hijioka S, et al : Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 35 : 499-508, 2017.
PubMed
11) Ito T, Fujimori N, Honma Y, et al : Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors : Final results of a phase II open-label extension study. Asia Pac J Clin Oncol 17 : e153-e161, 2021.
PubMed
12) Hijioka S, Hosoda W, Matsuo K, et al : Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3 : A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res 23 : 4625-4632, 2017.
 
13) Shibuya H, Hijioka S, Sakamoto Y, et al : Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan : focus on weekly regimens and monotherapy. Cancer Chemother Pharmacol 82 : 661-668, 2018.
PubMed
14) Ito T, Masui T, Ikeda M, et al : Statements for peptide receptor radionuclide therapy from JNETS. Japanese Journal of Gastroenterology Research 2 : 1070-1071, 2021.
 
15) Ito T, Masui T, Komoto I, et al : JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms : diagnosis, treatment, and follow-up : a synopsis. J Gastroenterol 56 : 1033-1044, 2021.
 
P.482 掲載の参考文献
1) Hosein AN, Dougan SK, Aguirre AJ, et al : Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer 3 : 272-286, 2022.
PubMed
2) Gourley C, Balmana J, Ledermann JA, et al : Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J Clin Oncol 37 : 2257-2269, 2019.
PubMed
3) Crowley F, Park W, O'Reilly EM : Targeting DNA damage repair pathways in pancreas cancer. Cancer Metastasis Rev 40 : 891-908, 2021.
PubMed
4) Golan T, Hammel P, Reni M, et al : Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381 : 317-327, 2019.
PubMed
5) Reiss KA, Mick R, O'Hara MH, et al : Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 39 : 2497-2505, 2021.
 
6) Seeber A, Zimmer K, Kocher F, et al : Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open 5 : e000942, 2020.
PubMed
7) Gout J, Perkhofer L, Morawe M, et al : Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut 70 : 743-760, 2021.
 
8) Strickler JH, Satake H, George TJ, et al : Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med 388 : 33-43, 2023.
 
9) Canon J, Rex K, Saiki AY, et al : The clinical KRAS (G12C) inhibitor AMG510 drives anti-tumour immunity. Nature 575 : 217-223, 2019.
PubMed
10) Ou SI, Janne PA, Leal TA, et al : First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1). J Clin Oncol 40 : 2530-2538, 2022.
PubMed
11) Hayashi H, Kohno T, Ueno H, et al : Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas 46 : 335-340, 2017.
PubMed
12) Hallin J, Bowcut V, Calinisan A, et al : Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 28 : 2171-2182, 2022.
PubMed
13) Hofmann MH, Gmachl M, Ramharter J, et al : BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov 11 : 142-157, 2021.
PubMed
15) Singhi AD, George B, Greenbowe JR, et al : Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology 156 : 2242-2253.e4, 2019.
PubMed
16) Nywening TM, Wang-Gillam A, Sanford DE, et al : Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer : a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17 : 651-662, 2016.
PubMed
17) Hegde S, Krisnawan VE, Herzog BH, et al : Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell 37 : 289-307.e9, 2020.
 
18) Feng M, Jiang W, Kim BYS, et al : Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19 : 568-586, 2019.
 
19) Mariathasan S, Turley SJ, Nickles D, et al : TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554 : 544-548, 2018.
 
20) Murphy JE, Wo JY, Ryan DP, et al : Total Neoadjuvant Therapy with FOLFIRINOX in Combination with Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer : A Phase 2 Clinical Trial. JAMA Oncol 5 : 1020-1027, 2019.
PubMed
21) Sherman MH, Yu RT, Engle DD, et al : Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159 : 80-93, 2014.
PubMed
22) Das S, Shapiro B, Vucic EA, et al : Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. Cancer Res 80 : 1088-1101, 2020.
 
23) Kocher HM, Basu B, Froeling FEM, et al : Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun 11 : 4841, 2020.
PubMed
24) Tran E, Robbins PF, Lu YC, et al : T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 375 : 2255-2262, 2016.
PubMed
25) Leidner R, Sanjuan Silva N, Huang H, et al : Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med 386 : 2112-2119, 2022.
PubMed
P.489 掲載の参考文献
1) Siegel RL, Miller KD, Fuchs HE, et al : Cancer statistics, 2022. CA Cancer J Clin 72 : 7-33, 2022.
PubMed
2) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
3) Frese KK, Neesse A, Cook N, et al : nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2 : 260-269, 2012.
 
4) Nomi T, Sho M, Akahori T, et al : Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13 : 2151-2157, 2007.
PubMed
5) 勝田将裕, 山上裕機 : 膵癌に対する樹状細胞ワクチンの開発と治験. ファルマシア 53 : 979-983, 2017.
 
6) Chen DS, Mellman I : Oncology meets immunology : the cancer-immunity cycle. Immunity 39 : 1-10, 2013.
PubMed
7) 唐崎隆弘, 垣見和宏 : がん免疫療法の個別化とバイオマーカー. Pharma Medica 34 : 53-57, 2016.
Medical*Online
8) Schreiber RD, Old LJ, Smyth MJ : Cancer immunoediting : integrating immunity's roles in cancer suppression and promotion. Science 331 : 1565-1570, 2011.
PubMed
9) 中山健太郎, 山下瞳, 京哲 : 免疫チェックポイント阻害薬 : ペムブロリズマブ, アテゾリズマブ, ニボルマブ, イピリムマブ. 産婦人科の実際 70 : 1300-1307, 2021.
 
10) Fujiwara J, Sowa Y, Horinaka M, et al : The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. Int J Oncol 48 : 854, 2016.
PubMed
11) 谷口智憲, 河上裕 : 複合がん免疫療法. Pharma Medica 34 : 59-63, 2016.
Medical*Online
12) 宮澤基樹, 山上裕機 : 膵癌治療用ワクチンの現状と未来. 日本耳鼻咽喉科学会会報 116 : 573-580, 2013.
Medical*Online
13) Iwahashi M, Katsuda M, Nakamori M, et al : Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 101 : 2510-2517, 2010.
PubMed
14) 小澤敬也 : がんに対する遺伝子改変免疫細胞療法-CAR-T細胞療法を中心に-. Pharma Medica 39 : 53-57, 2021.
Medical*Online
15) Leidner R, Sanjuan Silva N, Huang H, et al : Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med 386 : 2112-2119, 2022.
PubMed
16) Sasaki T, Nishiwada S, Nakagawa K, et al : Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Int J Clin Oncol 27 : 948-957, 2022.
PubMed
17) Pitt JM, Marabelle A, Eggermont A, et al : Targeting the tumor microenvironment : removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol 27 : 1482-1492, 2016.
PubMed
18) Yasuda S, Sho M, Yamato I, et al : Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 172 : 500-506, 2013.
PubMed
P.495 掲載の参考文献
1) 国立がん研究センター : がん情報サービス「がん統計」. [https://ganjoho.jp/reg_stat/statistics/stat/cancer/10_pancreas.html] (2022年11月閲覧)
 
2) がんゲノム医療推進コンソーシアム懇談会報告書. [https://www.mhlw.go.jp/stf/shingi2/0000169238.html] (2022年11月閲覧)
 
3) National Comprehensive Cancer Network : Clinical practice guidelines in oncology : NCCN guidelines for pancreatic adenocarcinoma V.2.2021.
 
4) Yang Y, Li L, Qu C, et al : Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions : a systematic review and Meta-Analysis. Sci Rep 6 : 22978, 2016.
 
5) Hisada Y, Hijioka S, Ikeda G, et al : Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuideTM NCC Oncopanel System analysis suitability criteria : a single-arm, phase II clinical trial. J Gastroenterol 57 : 990-998, 2022.
 
6) Nakamura Y, Taniguchi H, Ikeda M, et al : Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer : SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26 : 1859-1864, 2020.
PubMed
7) Kohno T, Kato M, Kohsaka S, et al : C-CAT : The National Datacenter for Cancer Genomic Medicine in Japan. Cancer Discov 12 : 2509-2515, 2022.
PubMed
8) Singhi AD, George B, Greenbowe JR, et al : Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology 156 : 2242-2253.e4, 2019.
PubMed
9) Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer. Cancer Discov 12 : 878-879, 2022.
PubMed
10) Schram AM, Odintsov I, Espinosa-Cotton M, et al : Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov 12 : 1233-1247, 2022.
PubMed
11) Momozawa Y, Sasai R, Usui Y, et al : Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol 8 : 871-878, 2022.
PubMed
12) Klein AP, Brune KA, Petersen GM, et al : Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64 : 2634-2638, 2004.
PubMed
13) Hijioka S, Morizane C, Takaori K, et al : Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreatic cancer syndrome : The Diamond Study. Pancreatology 22 : 534-538, 2022.
PubMed
P.500 掲載の参考文献
1) Crane CH, Varadhachary GR, Yordy JS, et al : Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma : correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29 : 3037-3043, 2011.
PubMed
2) Koong AC, Le QT, Ho A, et al : Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58 : 1017-1021, 2004.
PubMed
3) Schellenberg D, Goodman KA, Lee F, et al : Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72 : 678-686, 2008.
PubMed
4) Chang DT, Schellenberg D, Shen J, et al : Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115 : 665-672, 2009.
PubMed
5) Schellenberg D, Kim J, Christman-Skieller C, et al : Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 81 : 181-188, 2011.
PubMed
6) Herman JM, Chang DT, Goodman KA, et al : Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121 : 1128-1137, 2015.
PubMed
7) Hassanzadeh C, Rudra S, Bommireddy A, et al : Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Adv Radiat Oncol 6 : 100506, 2020.
PubMed
8) Ioka T, Furuse J, Fukutomi A, et al : Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer : Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol 51 : 235-243, 2021.
PubMed
9) Reyngold M, O'Reilly EM, Varghese AM, et al : Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol 7 : 735-738, 2021.
PubMed
10) Oonishi K, Cui X, Hirakawa H, et al : Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol 105 : 258-265, 2012.
 
11) Shinoto M, Yamada S, Terashima K, et al : Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 95 : 498-504, 2016.
PubMed
12) Kawashiro S, Yamada S, Okamoto M, et al : Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer : Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas. Int J Radiat Oncol Biol Phys 101 : 1212-1221, 2018.
 
13) Shinoto M, Terashima K, Suefuji H, et al : A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. Radiother Oncol 129 : 333-339, 2018.
PubMed
14) Ueno H, Ikeda M, Ueno M, et al : Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77 : 595-603, 2016.
PubMed
15) Kawashiro S, Mori S, Yamada S, et al : Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer : simulation with four-dimensional computed tomography. Br J Radiol 90 : 20160790, 2017.
PubMed
16) Hagiwara Y, Bhattacharyya T, Matsufuji N, et al : Influence of dose-averaged linear energy transfer on tumour control after carbon-ion radiation therapy for pancreatic cancer. Clin Transl Radiat Oncol 21 : 19-24, 2019.
 
17) Maemura K, Mataki Y, Kurahara H, et al : Comparison of proton beam radiotherapy and hyperfractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology 17 : 833-838, 2017.
PubMed
P.507 掲載の参考文献
1) Kamisawa T, Wood LD, Itoi T, et al : Pancreatic cancer. Lancet 388 : 73-85, 2016.
PubMed
2) Matsubayashi H, Takaori K, Morizane C, et al : Familial pancreatic cancer : Concept, management and issues. World J Gastroenterol 23 : 935-948, 2017.
PubMed
3) Lu C, Xu CF, Wan XY, et al : Screening for pancreatic cancer in familial high-risk individuals : A systematic review. World J Gastroenterol 21 : 8678-8686, 2015.
 
4) Canto MI, Almario JA, Schulick RD, et al : Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155 : 740-751.e2, 2018.
 
5) Matsubayashi H, Maeda A, Kanemoto H, et al : Risk factors of familial pancreatic cancer in Japan : current smoking and recent onset of diabetes. Pancreas 40 : 974-978, 2011.
PubMed
6) Klein AP, Brune KA, Petersen GM, et al : Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64 : 2634-2638, 2004.
PubMed
7) Giardiello FM, Brensinger JD, Tersmette AC, et al : Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119 : 1447-1453, 2000.
PubMed
8) Roberts NJ, Jiao Y, Yu J, et al : ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2 : 41-46, 2012.
PubMed
9) Hall MJ, Bernhisel R, Hughes E, et al : Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers. Cancer Prev Res (Phila) 14 : 433-440, 2021.
PubMed
10) Kondo T, Kanai M, Kou T, et al : Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget 9 : 19817-19825, 2018.
PubMed
11) Canto MI, Goggins M, Hruban RH, et al : Screening for early pancreatic neoplasia in high-risk individuals : a prospective controlled study. Clin Gastroenterol Hepatol 4 : 766-781, 2006.
PubMed
12) Wada K, Takaori K, Traverso LW, et al : Clinical importance of Familial Pancreatic Cancer Registry in Japan : a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. J Hepatobiliary Pancreat Sci 20 : 557-566, 2013.
PubMed
13) 森実千種, 北野雅之, 肱岡範, ほか : 膵癌早期発見に向けた家族性膵癌登録. 膵臓 32 : 23-29, 2017.
Medical*Online
14) 松田文彦 : ながはま0次予防コホート事業-地域に根ざした未来型健康づくりの試み-. 環境と健康 25 : 106-115, 2012.
Medical*Online
15) Canto MI, Harinck F, Hruban RH, et al : International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62 : 339-347, 2013.
 
16) 北野雅之, 森実千種, 肱岡範, ほか : 家族性膵癌高危険群のサーベイランス法 (エキスパート・コンセンサス) -日本膵臓学会家族性膵癌レジストリ委員会・家族性膵癌に関する小班会議-. 膵臓 35 : 322-330, 2020.
Medical*Online
17) Hijioka S, Morizane C, Takaori K, et al : Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreatic cancer syndrome : The Diamond Study. Pancreatology 22 : 534-538, 2022.
PubMed
P.512 掲載の参考文献
1) 膵癌診療ガイドライン [2019年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2019.
 
2) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e1-94, 2007.
 
3) 厚生労働省 : 国民健康・栄養調査 (令和元年). [https://www.mhlw.go.jp/bunya/kenkou/kenkou_eiyou_chousa.html]
 
4) Song S, Wang B, Zhang X, et al : Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer : A Meta-Analysis. PLoS One 10 : e0134321, 2015.
 
5) 舩越顕博 : 2型糖尿病に発症する膵癌-その機序と特徴. 胆と膵 35 : 373-377, 2014.
Medical*Online
6) Li D, Yeung SC, Hassan MM, et al : Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137 : 482-488, 2009.
PubMed
7) Ito T, Otsuki M, Igarashi H, et al : Epidemiological study of pancreatic diabetes in Japan in 2005 : a nationwide study. Pancreas 39 : 829-835, 2010.
PubMed
8) Risch HA : Diabetes and Pancreatic Cancer : Both Cause and Effect. J Natl Cancer Inst 111 : 1-2, 2019.
PubMed
9) Pannala R, Leibson CL, Rabe KG, et al : Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 104 : 2318-2325, 2009.
PubMed
10) Aune D, Greenwood DC, Chan DS, et al : Body mass index, abdominal fatness and pancreatic cancer risk : a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 23 : 843-852, 2012.
 
11) 林櫻松, 菊地正悟, 江川直人 : 肥満と膵癌, 胆道癌の関連. 胆と膵 33 : 1221-1226, 2012.
Medical*Online
12) Lin Y, Kikuchi S, Tamakoshi A, et al : Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer 120 : 2665-2671, 2007.
 
13) Koyanagi YN, Ito H, Matsuo K, et al : Smoking and Pancreatic Cancer Incidence : A Pooled Analysis of 10 Population-Based Cohort Studies in Japan. Cancer Epidemiol Biomarkers Prev 28 : 1370-1378, 2019.
PubMed
14) Pericleous M, Rossi RE, Mandair D, et al : Nutrition and pancreatic cancer. Anticancer Res 34 : 9-21, 2014.
PubMed
P.517 掲載の参考文献
1) 膵癌診療ガイドライン [2016年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2016.
 
2) 国立がん研究センター : がん情報サービス「がん統計」 (全国がん登録). [https://ganjoho.jp/reg_stat/statistics/stat/cancer/10_pancreas.html] (2022年12月閲覧)
 
3) 日本人間ドック学会 : 2017年度・2018年度会員施設実態調査報告. [https://www.ningen-dock.jp/other/release] (2022年12月閲覧)
 
4) 三原修一, 大竹宏治, 川口哲 : 腹部超音波によるがん検診の現状と課題-25年間の成績をもとに-. 日本がん検診・診断学会誌 18 : 201-209, 2011.
Medical*Online
5) 古川正幸, 杉本理恵, 久野晃聖, ほか : がん専門病院における膵がんドックの試みと受診者の臨床的特徴. 膵臓 34 : 206-213, 2019.
Medical*Online
6) US Preventive Services Task Force ; Owens DK, Davidson KW, Krist AH, et al : Screening for Pancreatic Cancer : US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 322 : 438-444, 2019.
PubMed
7) 花田敬士, 清水晃典, 南智之 : 膵癌早期発見への取り組み-地域医療連携システムの構築-. 日本消化器病学会雑誌 115 : 327-333, 2018.
Medical*Online
8) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
9) 花田敬士, 栗原啓介, 清水晃典, ほか : 膵癌早期診断における地域医療連携システム構築の課題と役割 : 地方型. 胆と膵 41 : 375-379, 2020.
Medical*Online
10) Kurihara K, Hanada K, Shimizu A : Endoscopic Ultrasonography Diagnosis of Early Pancreatic Cancer. Diagnostics (Basel) 10 : 1086, 2020.
PubMed
11) Sakamoto H, Harada S, Nishioka N, et al : A Social Program for the Early Detection of Pancreatic Cancer : The Kishiwada Katsuragi Project. Oncology 93 (Suppl 1) : 89-97, 2017.
 
12) 八隅秀二郎 : 10 mm以下膵癌診断における地域医療連携システム構築の課題と役割 : 都市型システム構築. 胆と膵 41 : 381-385, 2020.
Medical*Online
13) 深澤光晴, 依田芳起, 高山一郎, ほか : 膵癌早期発見を目指した地域連携. 消化器内科 57 : 63-67, 2013.. 島根医学
 
14) 松本和也, 串山義則, 泉明夫, ほか : 松江市膵がんプロジェクト. 島根医学 39 : 109, 2019.
Medical*Online
15) 北野雅之, 吉田岳市, 川路祐輝, ほか : 膵癌早期診断を目的とした地域医療連携システムの構築 (きのくにプロジェクト). 膵臓 35 : A110, 2020.
Medical*Online
P.524 掲載の参考文献
1) Sohal DPS, Kennedy EB, Khorana A, et al : Metastatic Pancreatic Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 36 : 2545-2556, 2018.
PubMed
2) Sohal DPS, Kennedy EB, Cinar P, et al : Metastatic pancreatic cancer : ASCO Guideline update. J Clin Oncol 38 : 3217-3230, 2020.
 
3) Rietjens JAC, Sudore RL, Connolly M, et al : Definition and recommendations for advance care planning : an international consensus supported by the European Association for Palliative Care. Lancet Oncol 18 : e543-e551, 2017.
PubMed
4) 膵癌診療ガイドライン [2022年版] (日本膵臓学会膵癌診療ガイドライン改訂委員会編), 金原出版, 2022.
 
5) Murai M, Higashiguchi T, Futamura A, et al : Interleukin-8 and clinical symptoms can be prognostic indicators for advanced cancer patients with cachexia. Fujita Med J 6 : 117-121, 2020.
PubMed
6) 伊藤彰博 : 緩和ケアにおける輸液・栄養管理. 消化器外科 40 : 1343-1351, 2017.
 
7) がん緩和ケアにおける胸水・腹水管理 (太田惠一朗編), 真興交易医書出版部, 2010.
 
8) 終末期がん患者の輸液療法に関するガイドライン [2013年版] (日本緩和医療学会緩和医療ガイドライン委員会編), 金原出版, 2013.
 
9) 伊藤彰博, 臼井正信, 都築則正, ほか : 腹膜播種患者の栄養管理. 三重医報 40 : 1343-1351, 2021.
 
10) Radbruch L, Elsner F, Trottenberg P, et al : Clinical practice guidelines on cancer cachexia in advanced cancer patients with a focus on refractory cachexia. European Palliative Care Research Collaborative, 2011.
 
11) Fearon K, Strasser F, Anker SD, et al : Definition and classification of cancer cachexia : an international consensus. Lancet Oncol 12 : 489-495, 2011.
PubMed
12) Bozzetti F, Arends J, Lundholm K, et al : ESPEN Guidelines on Parenteral Nutrition : non-surgical oncology. Clin Nutr 28 : 445-454, 2009.
PubMed
13) Naito T, Uchino J, Kojima T, et al : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer 128 : 2025-2035, 2022.
 
14) 伊藤彰博, 臼井正信, 二村昭彦, ほか : 終末期における栄養管理. 臨床栄養 141 : 590-596, 2022.
Medical*Online

書評

最近チェックした商品履歴

Loading...